U.S. patent application number 14/705248 was filed with the patent office on 2016-01-21 for phosphatidylinositol 3-kinase inhibitors.
The applicant listed for this patent is Gilead Calistoga LLC. Invention is credited to Jerry Evarts, Joshua Kaplan, Leena Patel, Stephane Perreault, Gary Phillips, Jennifer A. Treiberg.
Application Number | 20160016915 14/705248 |
Document ID | / |
Family ID | 49943596 |
Filed Date | 2016-01-21 |
United States Patent
Application |
20160016915 |
Kind Code |
A1 |
Evarts; Jerry ; et
al. |
January 21, 2016 |
PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS
Abstract
The present disclosure provides phosphatidylinositol 3-kinase
(PI3K) inhibitors of formula (I), ##STR00001## or pharmaceutically
acceptable salts thereof, in which n, m, R.sup.1, R.sup.2, and
R.sup.3 are as defined herein. These compounds are useful for
treatment of conditions mediated by one or more PI3K isoforms, such
as PI3K.delta.. The present disclosure further provides
pharmaceutical compositions that include a compound of formula (I),
or pharmaceutically acceptable salts thereof, and methods of using
these compounds and compositions to treat conditions mediated by
one or more PI3K isoforms, such as PI3K.delta..
Inventors: |
Evarts; Jerry; (Seattle,
WA) ; Patel; Leena; (Mercer Island, WA) ;
Kaplan; Joshua; (Foster City, CA) ; Treiberg;
Jennifer A.; (Redmond, WA) ; Perreault; Stephane;
(Brier, WA) ; Phillips; Gary; (Issaquah,
WA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Gilead Calistoga LLC |
Foster City |
CA |
US |
|
|
Family ID: |
49943596 |
Appl. No.: |
14/705248 |
Filed: |
May 6, 2015 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
14137979 |
Dec 20, 2013 |
9029384 |
|
|
14705248 |
|
|
|
|
61745437 |
Dec 21, 2012 |
|
|
|
Current U.S.
Class: |
514/266.2 ;
544/284 |
Current CPC
Class: |
A61P 7/00 20180101; A61P
37/00 20180101; A61P 43/00 20180101; A61P 7/06 20180101; C07D
403/12 20130101; A61P 9/00 20180101; A61P 17/00 20180101; A61P
19/02 20180101; A61P 21/04 20180101; A61P 29/00 20180101; C07D
473/34 20130101; A61P 25/00 20180101; A61P 37/02 20180101; A61P
35/02 20180101; A61P 37/06 20180101; C07D 239/90 20130101; A61P
7/04 20180101; A61P 11/06 20180101; A61P 17/02 20180101; C07D
239/91 20130101; A61P 35/00 20180101 |
International
Class: |
C07D 239/91 20060101
C07D239/91 |
Claims
1. A compound having the structure of formula (I): ##STR00242## or
a pharmaceutically acceptable salt thereof, wherein: n is 0, 1, 2,
or 3; each R.sup.1 is independently halo, cyano, unsubstituted or
substituted alkyl, unsubstituted or substituted haloalkyl,
unsubstituted or substituted alkoxy, hydroxy, unsubstituted or
substituted cycloalkyl, SO.sub.2R.sup.1r, or C(O)NR.sup.1sR.sup.1t,
wherein each R.sup.1r, R.sup.1s and R.sup.1t is independently
hydrogen or unsubstituted or substituted alkyl; m is 0, 1, 2, or 3;
each R.sup.2 is independently halo, cyano, unsubstituted or
substituted alkyl, unsubstituted or substituted haloalkyl, or
unsubstituted or substituted alkoxy; and R.sup.3 is hydrogen or
unsubstituted or substituted alkyl.
2. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein each R.sup.1 is independently fluoro, chloro,
cyano, methyl, CHF.sub.2, CF.sub.3, methoxy, or hydroxy.
3. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein n is 1 or 2.
4. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein each R.sup.2 is independently fluoro, chloro,
iodo, cyano, methoxy, CHF.sub.2, or CF.sub.3.
5. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein m is 1 or 2.
6. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein R.sup.3 is methyl or ethyl.
7. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein: n is 1, 2, or 3; each R.sup.1 is independently
halo, cyano or unsubstituted or substituted alkyl; m is 1, 2, or 3;
each R.sup.2 is independently halo or cyano; and R.sup.3 is
unsubstituted or substituted alkyl.
8. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein: n is 1; R.sup.1 is halo; m is 2; each R.sup.2 is
independently halo; R.sup.3 is unsubstituted or substituted
alkyl.
9. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein the compound is the (S)-enantiomer.
10. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein n is 2 and m is 2, and the compound is of formula
(IA-1): ##STR00243## or a pharmaceutically acceptable salt thereof,
wherein: each R.sup.1a, R.sup.1b is independently halo, cyano,
unsubstituted or substituted alkyl, unsubstituted or substituted
haloalkyl, unsubstituted or substituted alkoxy, hydroxy, or
unsubstituted or substituted cycloalkyl; each R.sup.2a and R.sup.2b
is independently halo, cyano, unsubstituted or substituted alkyl,
unsubstituted or substituted haloalkyl, or unsubstituted or
substituted alkoxy; and R.sup.3 is unsubstituted or substituted
alkyl.
11. The compound of claim 10, or a pharmaceutically acceptable salt
thereof, wherein: each R.sup.1a and R.sup.1b is independently
hydrogen, halo, cyano, or unsubstituted or substituted alkyl; and
each R.sup.2a and R.sup.2b is independently hydrogen, halo, or
cyano.
12. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein n is 1 and m is 2, and the compound is of formula
(IB-1): ##STR00244## or a pharmaceutically acceptable salt thereof,
wherein: R.sup.1a is halo, cyano, unsubstituted or substituted
alkyl, or haloalkyl; each R.sup.2a and R.sup.2b is independently
hydrogen, halo or cyano; and R.sup.3 is unsubstituted or
substituted alkyl.
13. The compound of claim 1, or a pharmaceutically acceptable salt
thereof, wherein n is 1 and m is 2, and the compound is of formula
(IB-4): ##STR00245## or a pharmaceutically acceptable salt thereof,
wherein: R.sup.1a is halo, cyano, unsubstituted or substituted
alkyl, or haloalkyl; each R.sup.2a and R.sup.2b is independently
hydrogen, halo or cyano; and R.sup.3 is unsubstituted alkyl.
14. A pharmaceutical composition comprising: a compound of claim 1
or a pharmaceutically acceptable salt thereof; and at least one
pharmaceutically acceptable vehicle.
15. A compound selected from the group consisting of:
(S)-2,4-diamino-6-((1-(5-chloro-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroq-
uinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-hydroxy-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-y-
l)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(8-methyl-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl-
)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-chloro-8-methyl-4-oxo-3-phenyl-3,4-dihydroquinaz-
olin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-chlorophenyl)-8-methyl-4-oxo-3,4-dih-
ydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3-chlorophenyl)-8-methyl-4-oxo-3,4-dihydroquina-
zolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2-(1-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-phenyl--
3,4-dihydroquinazoline-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-chlorophenyl)-4-oxo-3,4-dihydroquina-
zolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(6-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl-
)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-5-fluoro-4-oxo-3,4-dihydroq-
uinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-6-fluoro-4-oxo-3,4-dihydroq-
uinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-cyanophenyl)-4-oxo-3,4-dihydroquinaz-
olin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3-cyanophenyl)-6-fluoro-4-oxo-3,4-dihydroquinaz-
olin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3-chlorophenyl)-6-fluoro-4-oxo-3,4-dihydroquina-
zolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-chloro-3-(3,5-difluorophenyl)-8-fluoro-4-oxo-3,4-
-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-8-fluoro-4-oxo-3,4-dihydroq-
uinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-8-fluoro-4-oxo-3,4-dihydroq-
uinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-5-methyl-4-oxo-3,4-dihydroq-
uinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-5-methyl-4-oxo-3,4-dihydroq-
uinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-cyano-5-fluorophenyl)-4-oxo-3,4-dihy-
droquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-5,8-difluoro-4-oxo-3,4-dihy-
droquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(8-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl-
)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-methyl-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl-
)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3-cyano-5-fluorophenyl)-5-methyl-4-oxo-3,4-dihy-
droquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-8-fluoro-5-methyl-4-oxo-3,4-
-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-6-fluoro-4-oxo-3,4-dihydroq-
uinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-5,8-difluoro-4-oxo-3,4-dihy-
droquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquinazolin-
-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-5,6-difluoro-4-oxo-3,4-dihy-
droquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-5,6-difluoro-4-oxo-3,4-dihy-
droquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3-cyano-5-fluorophenyl)-8-fluoro-5-methyl-4-oxo-
-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3-cyano-5-fluorophenyl)-5-fluoro-4-oxo-3,4-dihy-
droquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-fluoro-3-(3-fluoro-5-(trifluoromethyl)phenyl)-4--
oxo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-4-oxo-8-(trifluoromethyl)-3-
,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-5-fluoro-8-methyl-4-oxo-3,4-
-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquinazolin-
-2-yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-5-fluoro-8-methyl-4-oxo-3,4-
-dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3-cyanophenyl)-5-fluoro-4-oxo-3,4-dihydroquinaz-
olin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(8-methyl-4-oxo-3-(3-(trifluoromethyl)phenyl)-3,4-d-
ihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-fluoro-4-oxo-3-(3-(trifluoromethyl)phenyl)-3,4-d-
ihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-chloro-3-(3,5-dichlorophenyl)-4-oxo-3,4-dihydroq-
uinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-dichlorophenyl)-5-fluoro-4-oxo-3,4-dihydroq-
uinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-chloro-5-fluorophenyl)-4-oxo-3,4-dih-
ydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3-chloro-5-fluorophenyl)-5-fluoro-4-oxo-3,4-dih-
ydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-fluoro-5-(trifluoromethyl)phenyl)-4--
oxo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-fluoro-4-oxo-3-(3-(trifluoromethyl)phenyl)-3,4-d-
ihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-(3-(trifluoromethyl)phenyl)-3,4-d-
ihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-cyano-5-fluorophenyl)-8-fluoro-4-oxo-
-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl-
)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5,8-dichloro-4-oxo-3-phenyl-3,4-dihydroquinazolin--
2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-chloro-3-(3,5-dimethoxyphenyl)-4-oxo-3,4-dihydro-
quinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-(difluoromethyl)-3-(3,5-difluorophenyl)-4-oxo-3,-
4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-(difluoromethyl)-3-(3,5-difluorophenyl)-4-oxo-3,-
4-dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3-(difluoromethyl)-5-fluorophenyl)-5-fluoro-4-o-
xo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-(difluoromethyl)-5-fluorophenyl)-4-o-
xo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(8-(difluoromethyl)-4-oxo-3-phenyl-3,4-dihydroquina-
zolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(8-(difluoromethyl)-3-(3,5-difluorophenyl)-4-oxo-3,-
4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(8-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl-
)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5,8-difluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin--
2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(8-fluoro-5-methyl-4-oxo-3-phenyl-3,4-dihydroquinaz-
olin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-fluoro-8-methyl-4-oxo-3-phenyl-3,4-dihydroquinaz-
olin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-(difluoromethyl)-4-oxo-3-phenyl-3,4-dihydroquina-
zolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3-cyanophenyl)-5-(difluoromethyl)-4-oxo-3,4-dih-
ydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3-cyanophenyl)-8-fluoro-5-methyl-4-oxo-3,4-dihy-
droquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3-(difluoromethyl)-5-fluorophenyl)-5-fluoro-4-o-
xo-3,4-dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-(difluoromethyl)-5-fluorophenyl)-4-o-
xo-3,4-dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(8-chloro-3-(3,5-difluorophenyl)-5-fluoro-4-oxo-3,4-
-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-8-methoxy-4-oxo-3,4-dihydro-
quinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-6,8-difluoro-4-oxo-3,4-dihy-
droquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-6,8-difluoro-4-oxo-3,4-dihy-
droquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(8-chloro-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroq-
uinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(8-chloro-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroq-
uinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-chloro-3-(3,5-difluorophenyl)-8-methyl-4-oxo-3,4-
-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5,8-dichloro-3-(3,5-difluorophenyl)-4-oxo-3,4-dihy-
droquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-8-methyl-4-oxo-3,4-dihydroq-
uinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-8-methyl-4-oxo-3,4-dihydroq-
uinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-5-fluoro-4-oxo-3,4-dihydroq-
uinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-chloro-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroq-
uinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-6,7-difluoro-4-oxo-3,4-dihy-
droquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
2,4-diamino-6-(((3-(3,5-difluorophenyl)-6,7-difluoro-4-oxo-3,4-dihydroqui-
nazolin-2-yl)methyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl-
)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3-cyanophenyl)-5-fluoro-8-methyl-4-oxo-3,4-dihy-
droquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3-cyano-5-fluorophenyl)-5-fluoro-8-methyl-4-oxo-
-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
2,4-diamino-6-(((8-chloro-3-(3-cyanophenyl)-4-oxo-3,4-dihydroquinazolin-2-
-yl)methyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(6-chloro-3-(3,5-difluorophenyl)-5-fluoro-4-oxo-3,4-
-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(6-chloro-3-(3,5-difluorophenyl)-5-fluoro-4-oxo-3,4-
-dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-5-(5-chloro-2-(1-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-o-
xoquinazolin-3(4H)-yl)isophthalonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-bis(trifluoromethyl)phenyl)-5-fluoro-4-oxo--
3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(8-chloro-3-(3,5-difluorophenyl)-6-fluoro-4-oxo-3,4-
-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(1-(5-chloro-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroqu-
inazolin-2-yl)ethylamino)pyrimidine-5-carboxamide;
(S)-5-chloro-2-(1-(2,6-diamino-5-chloropyrimidin-4-ylamino)ethyl)-3-pheny-
lquinazolin-4(3H)-one;
(S)-2-(1-(2,6-diamino-5-chloropyrimidin-4-ylamino)propyl)-3-(3,5-difluoro-
phenyl)-5-fluoroquinazolin-4(3H)-one;
(S)-2,4-diamino-6-(1-(5-chloro-3-(3-(difluoromethyl)-5-fluorophenyl)-4-ox-
o-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carboxamide;
(S)-5-chloro-2-(1-(2,6-diamino-5-(methylsulfonyl)pyrimidin-4-ylamino)ethy-
l)-3-(3,5-difluorophenyl)quinazolin-4(3H)-one;
(S)-2,4-diamino-6-(1-(5-(methylsulfonyl)-4-oxo-3-phenyl-3,4-dihydroquinaz-
olin-2-yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(1-(3-(3,5-difluorophenyl)-5-(methylsulfonyl)-4-oxo-3,4-
-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(1-(3-(3-(difluoromethyl)phenyl)-5-fluoro-4-oxo-3,4-dih-
ydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(1-(3-(3-(difluoromethyl)-5-fluorophenyl)-5-(methylsulf-
onyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitril-
e;
(S)-2,4-diamino-6-(1-(5-(difluoromethyl)-3-(3-(difluoromethyl)-5-fluoro-
phenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitr-
ile;
(S)-2,4-diamino-6-(1-(5-chloro-3-(3-(difluoromethyl)phenyl)-4-oxo-3,4-
-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carboxamide;
(S)-2-(1-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-3-(3,5-difluoro-
phenyl)-4-oxo-3,4-dihydroquinazoline-8-carbonitrile;
(S)-2,4-diamino-6-((1-(8-chloro-3-(3,5-difluorophenyl)-5-fluoro-4-oxo-3,4-
-dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-8-ethyl-4-oxo-3,4-dihydroqu-
inazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-5-chloro-2-(1-((2,6-diamino-5-chloropyrimidin-4-yl)amino)ethyl)-3-phe-
nylquinazolin-4(3H)-one;
(S)-2-(1-((2,6-diamino-5-chloropyrimidin-4-yl)amino)propyl)-3-(3,5-difluo-
rophenyl)-5-fluoroquinazolin-4(3H)-one;
(S)-2,4-diamino-6-(1-(5-chloro-3-(3-(difluoromethyl)phenyl)-4-oxo-3,4-dih-
ydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(1-(5-chloro-3-(3-isopropylphenyl)-4-oxo-3,4-dihydroqui-
nazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(1-(5-chloro-3-(3-fluorophenyl)-4-oxo-3,4-dihydroquinaz-
olin-2-yl)ethylamino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-(1-(5-chloro-3-(3-methoxy-2-methylphenyl)-4-oxo-3,4-dih-
ydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile; and
(S)-2,4-diamino-6-(1-(5-chloro-3-(5-fluoro-3-methoxy-2-methylphenyl)-4-ox-
o-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile,
or a pharmaceutically acceptable salt thereof.
16. A pharmaceutical composition comprising: a compound of claim 15
or a pharmaceutically acceptable salt thereof; and at least one
pharmaceutically acceptable vehicle.
17. A method for treating a human, who has or is suspected of
having a disease or condition responsive or believed to be
responsive to the inhibition of PI3K.delta. activity, comprising
administering to the human a compound of claim 1 or a
pharmaceutically acceptable salt thereof.
18. The method of claim 17, wherein the disease or condition is an
inflammatory disorder, an autoimmune disease, or a cancer.
19. The method of claim 17, wherein the disease or condition is
lymphoma, multiple myeloma, or leukemia.
20. The method of claim 17, wherein the disease or condition is
acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML),
chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma
(SLL), myelodysplastic syndrome (MDS), myeloproliferative disease
(MPD), chronic myeloid leukemia (CML), multiple myeloma (MM),
non-Hodgkin's lymphoma (NHL), mantle cell lymphoma (MCL),
follicular lymphoma, Waldestrom's macroglobulinemia (WM), T-cell
lymphoma, B-cell lymphoma, diffuse large B-cell lymphoma (DLBCL),
pancreatic cancer, bladder cancer, colorectal cancer, breast
cancer, prostate cancer, renal cancer, hepatocellular cancer, lung
cancer, ovarian cancer, cervical cancer, gastric cancer, esophageal
cancer, head and neck cancer, melanoma, neuroendocrine cancer, CNS
cancer, brain cancer, bone cancer, soft tissue sarcoma, non-small
cell lung cancer, small-cell lung cancer, colon cancer, systemic
lupus erythematosus (SLE), myestenia gravis, rheumatoid arthritis
(RA), acute disseminated encephalomyelitis, idiopathic
thrombocytopenic purpura, multiple sclerosis (MS), Sjoegren's
syndrome, autoimmune hemolytic anemia, asthma, rheumatoid
arthritis, multiple sclerosis, or lupus.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit of U.S. Provisional
Patent Application Ser. No. 61/745,437, filed Dec. 21, 2012, the
disclosure of which is hereby incorporated by reference in its
entirety.
FIELD
[0002] The present disclosure relates generally to inhibitors of
phosphatidylinositol 3-kinase (PI3K) activity and, more
specifically, to novel compounds that are selective inhibitors of
PI3K delta activity.
BACKGROUND
[0003] Cell signaling via 3'-phosphorylated phosphoinositides has
been implicated in a variety of cellular processes, e.g., malignant
transformation, growth factor signaling, inflammation, and
immunity. See generally Rameh et al., J. Biol. Chem., 274:8347-8350
(1999). The enzyme responsible for generating these phosphorylated
signaling products is phosphatidylinositol 3-kinase (PI 3-kinase;
PI3K). PI3K originally was identified as an activity associated
with viral oncoproteins and growth factor receptor tyrosine kinases
that phosphorylate phosphatidylinositol (PI) and its phosphorylated
derivatives at the 3'-hydroxyl of the inositol ring. See Panayotou
et al., Trends Cell Biol 2:358-60 (1992).
[0004] Presently, three classes of the PI 3-kinase (PI3K) enzymes
are distinguished, based on their substrate specificities. Class I
PI3Ks can phosphorylate phosphatidylinositol (PI),
phosphatidylinositol-4-phosphate, and
phosphatidylinositol-4,5-biphosphate (PIP.sub.2) to produce
phosphatidylinositol-3-phosphate (PIP),
phosphatidylinositol-3,4-biphosphate, and
phosphatidylinositol-3,4,5-triphosphate, respectively. Class II
PI3Ks phosphorylate PI and phosphatidylinositol-4-phosphate,
whereas Class III PI3Ks can only phosphorylate PI.
[0005] The initial purification and molecular cloning of PI
3-kinase revealed that it was a heterodimer consisting of p85 and
p110 subunits. See Otsu et al., Cell, 65:91-104 (1991); Hiles et
al., Cell, 70:419-29 (1992). Since then, four distinct Class I
PI3Ks have been identified, designated PI3K .alpha., .beta.,
.delta., and .gamma., each consisting of a distinct 110 kDa
catalytic subunit and a regulatory subunit. More specifically,
three of the catalytic subunits, i.e., p110.alpha., p110.beta., and
p110 .delta., each interact with the same regulatory subunit, i.e.,
p85, whereas p110.gamma. interacts with a distinct p101 regulatory
subunit. As described below, the patterns of expression of each of
these PI3Ks in human cells and tissues also are distinct.
[0006] Identification of the p110.delta. isoform of PI 3-kinase is
described in Chantry et al., J. Biol. Chem., 272:19236-41 (1997).
It was observed that the human p110.delta. isoform is expressed in
a tissue-restricted fashion. It is expressed at high levels in
lymphocytes and lymphoid tissues, suggesting that the protein might
play a role in PI 3-kinase-mediated signaling in the immune system.
Details concerning the p110.delta. isoform also can be found in
U.S. Pat. Nos. 5,858,753; 5,822,910; and 5,985,589, each of which
is incorporated herein by reference. See also Vanhaesebroeck et
al., Proc. Natl. Acad. Sci. USA, 94:4330-5 (1997); and WO
97/46688.
[0007] A need remains, however, for additional therapeutic agents
useful to treat proliferative disorders or diseases that are
mediated by PI3K. The present invention provides novel compounds
that are inhibitors of PI3K isoforms.
SUMMARY
[0008] Compounds and pharmaceutically acceptable salts thereof
useful for inhibiting PI3K isoforms, such as PI3K.delta., are
described herein. Compositions, including pharmaceutical
compositions, and kits that include the compounds are also
provided, as are methods of using and making the compounds. The
compounds provided herein may find use in treating diseases,
disorders, or conditions that are mediated by PI3K isoforms, such
as PI3K.delta..
[0009] In one aspect, provided is a compound of formula (J):
##STR00002##
or a pharmaceutically acceptable salt, prodrug, or solvate thereof,
wherein:
[0010] A is N or CH;
[0011] n is 0, 1, 2, or 3;
[0012] each R.sup.1 is independently unsubstituted or substituted
alkyl, unsubstituted or substituted haloalkyl, unsubstituted or
substituted aryl, unsubstituted or substituted heteroaryl, halo,
cyano, NHC(.dbd.O)alkylene-N(R.sup.1x).sub.2, NO.sub.2, OR.sup.1x,
OCF.sub.3, N(R.sup.1x).sub.2, OC(.dbd.O)R.sup.1x,
C(.dbd.O)R.sup.1x, C(.dbd.O)OR.sup.1x, aryl-OR.sup.1y, Het,
NR.sup.1xC(.dbd.O)alkylene-C(.dbd.O)OR.sup.1x,
aryl-O-alkylene-N(R.sup.1x).sub.2, aryl-O--C(.dbd.O)R.sup.1x,
alkylene-C(.dbd.O)OR.sup.1x, O-alkylene-C(.dbd.O)OR.sup.1x,
alkylene-O-alkylene-C(.dbd.O)OR.sup.1x,
C(.dbd.O)NR.sup.1xSO.sub.2R.sup.1x, alkylene-N(R.sup.1x).sub.2,
alkenylene-N(R.sup.1x).sub.2,
C(.dbd.O)NR.sup.1x-alkylene-OR.sup.1x,
C(.dbd.O)NR.sup.1xalkylene-Het, O-alkylene-N(R.sup.1x).sub.2,
O-alkylene-CH(OR.sup.1y)CH.sub.2N(R.sup.1x).sub.2, O-alkylene-Het,
O-alkylene-OR.sup.1x, O-alkylene-NR.sup.1x(.dbd.O)OR.sup.1x,
NR.sup.1x-alkylene-N(R.sup.1x).sub.2, NR.sup.1xC(.dbd.O)R.sup.1x,
NR.sup.1xC(.dbd.O)N(R.sup.1x).sub.2, N(SO.sub.2-alkyl).sub.2,
NR.sup.1x(SO.sub.2-alkyl), SO.sub.2R.sup.1x,
SO.sub.2N(R.sup.1x).sub.2, OSO.sub.2CF.sub.3, alkylenearyl,
alkylene-Het, alkylene-OR.sup.1y, alkylene-N(R.sup.1x).sub.2,
C(.dbd.O)N(R.sup.1x).sub.2, NHC(.dbd.O)alkylenearyl, unsubstituted
or substituted cycloalkyl, unsubstituted or substituted
heteocycloalkyl, aryl-O-alkylene-N(R.sup.1x).sub.2,
aryl-OC(.dbd.O)R.sup.1y, NHC(.dbd.O)alkylene-heterocycloalkyl,
NHC(.dbd.O)alkyelne-Het, O-alkylene-O-alkylene-C(.dbd.O)OR.sup.1y,
C(.dbd.O)alkylene-Het, or NHC(.dbd.O)haloalkyl,
[0013] wherein Het is a 5- or 6-membered heterocyclic ring
containing at least one heteroatom selected from the group
consisting of oxygen, nitrogen and sulfur, wherein the 5- or
6-membered heterocyclic ring is saturated, partially unsaturated or
fully unsaturated, and wherein Het is unsubstituted or substituted
with alkyl or C(.dbd.O)OR.sup.1x,
[0014] wherein R.sup.1x is independently hydrogen, unsubstituted or
substituted alkyl, unsubstituted or substituted cycloalkyl,
unsubstituted or substituted heterocycloalkyl,
alkylene-N(R.sup.1x).sub.2, unsubstituted or substituted aryl,
arylalkyl, alkylenearyl, unsubstituted or substituted heteroaryl,
unsubstituted or substituted heteroarylalkyl, or
alkyleneheteroaryl, or two R.sup.1a groups are taken together to
form a 5- or 6-membered ring, optionally containing at least one
heteroatom,
[0015] wherein R.sup.1y is hydrogen, unsubstituted or substituted
alkyl, unsubstituted or substituted aryl, unsubstituted or
substituted heteroaryl, arylalkyl, heteroarylalkyl, alkylenearyl,
and alkyleneheteroaryl;
[0016] m is 0, 1, 2, or 3;
[0017] each R.sup.2 is independently halo, cyano, unsubstituted or
substituted alkyl, unsubstituted or substituted haloalkyl,
unsubstituted or substituted alkoxy, or NR.sup.2xR.sup.2y, wherein
each R.sup.2x and R.sup.2y is independently hydrogen, C(O)R.sup.2s
or C(O)OR.sup.2s, wherein R.sup.2s is unsubstituted or substituted
alkyl;
[0018] R.sup.3 is hydrogen or unsubstituted or substituted alkyl;
and
[0019] R.sup.4 is cyano, CON(R.sup.4a).sub.2, SO.sub.2-alkyl, halo,
or haloalkyl, where each R.sup.4a is independently hydrogen, or
unsubstituted or substituted alkyl.
[0020] In some embodiments of formula (J) where A is N, the
compound is of formula (JA):
##STR00003##
or a pharmaceutically acceptable salt, prodrug, or solvate
thereof.
[0021] In other embodiments of formula (J) where A is CH, the
compound is of formula (JB):
##STR00004##
or a pharmaceutically acceptable salt, prodrug, or solvate
thereof.
[0022] In some embodiments of formula (JA) or (JB),
[0023] each R.sup.1 is independently halo, cyano, unsubstituted or
substituted alkyl, unsubstituted or substituted haloalkyl,
unsubstituted or substituted alkoxy, hydroxy, unsubstituted or
substituted cycloalkyl, --SO.sub.2R.sup.1x, or
--C(O)N(R.sup.1x).sub.2, wherein each R.sup.1' is independently
hydrogen or unsubstituted or substituted alkyl;
[0024] each R.sup.2 is independently halo, cyano, unsubstituted or
substituted alkyl, unsubstituted or substituted haloalkyl,
unsubstituted or substituted alkoxy, or N(R.sup.2x).sub.2, wherein
each R.sup.2x is independently hydrogen, C(O)R.sup.2s or
C(O)OR.sup.2s, wherein R.sup.2s is unsubstituted or substituted
alkyl; and
[0025] R.sup.3 and R.sup.4 are as defined for formula (J).
[0026] In another aspect, provided is a compound of formula
(I):
##STR00005##
or a pharmaceutically acceptable salt, prodrug, or solvate thereof,
wherein each of n, R.sup.1, m, R.sup.2, and R.sup.3 is as defined
for formula (J).
[0027] In some embodiments of formula (I):
[0028] n is 0, 1, 2, or 3;
[0029] each R.sup.1 is independently halo, cyano, unsubstituted or
substituted alkyl, unsubstituted or substituted haloalkyl,
unsubstituted or substituted alkoxy, hydroxy, unsubstituted or
substituted cycloalkyl, --SO.sub.2R.sup.1r, or
--C(O)NR.sup.1sR.sup.1t, wherein each R.sup.1r, R.sup.1s and
R.sup.1t is independently hydrogen or unsubstituted or substituted
alkyl;
[0030] m is 0, 1, 2, or 3;
[0031] each R.sup.2 is independently halo, cyano, unsubstituted or
substituted alkyl, unsubstituted or substituted haloalkyl, or
unsubstituted or substituted alkoxy; and
[0032] R.sup.3 is hydrogen, or unsubstituted or substituted
alkyl.
[0033] In some embodiments of formula (I), one or both of the
following properties apply:
[0034] (i) n is 1, 2 or 3; and
[0035] (ii) m is 1, 2 or 3.
[0036] In other embodiments of formula (I) where n is 2 and m is 2,
the compound is of formula (IA-1):
##STR00006##
or a pharmaceutically acceptable salt, prodrug, or solvate thereof,
wherein:
[0037] each R.sup.1a and R.sup.1b can be selected from the moieties
defined for R.sup.1 of formula (I);
[0038] each R.sup.2a and R.sup.2b can be selected from the moieties
defined for R.sup.2 of formula (I); and
[0039] R.sup.3 is as defined for formula (I).
[0040] In certain embodiments of formula (IA-1),
[0041] each R.sup.1a and R.sup.1b is independently halo, cyano,
unsubstituted or substituted alkyl, unsubstituted or substituted
haloalkyl, unsubstituted or substituted alkoxy, hydroxy, or
unsubstituted or substituted cycloalkyl;
[0042] each R.sup.2a and R.sup.2b is independently halo, cyano,
unsubstituted or substituted alkyl, unsubstituted or substituted
haloalkyl, or unsubstituted or substituted alkoxy; and
[0043] R.sup.3 is unsubstituted or substituted alkyl.
[0044] In other embodiments of formula (I) where n is 2 and m is 2,
the compound is of formula (IA-2):
##STR00007##
or a pharmaceutically acceptable salt, prodrug, or solvate thereof,
wherein each of R.sup.1a, R.sup.1b, R.sup.2a, R.sup.2b and R.sup.3
is as defined for formula (IA-1).
[0045] In other embodiments of formula (I) where n is 1 and m is 2,
the compound is of formula (IB-1):
##STR00008##
or a pharmaceutically acceptable salt, prodrug, or solvate thereof,
wherein:
[0046] R.sup.1a can be selected from the moieties defined for
R.sup.1 of formula (I);
[0047] each R.sup.2a and R.sup.2b can be selected from the moieties
defined for R.sup.2 of formula (I); and
[0048] R.sup.3 is as defined for formula (I).
[0049] In certain embodiments of formula (IB-1),
[0050] R.sup.1a is halo, cyano, unsubstituted or substituted alkyl,
or unsubstituted or substituted haloalkyl;
[0051] each R.sup.2a and R.sup.2b is independently hydrogen, halo
or cyano; and
[0052] R.sup.3 is unsubstituted or substituted alkyl.
[0053] In yet other embodiments of formula (I) where n is 1 and m
is 2, the compound is of formula (IB-2):
##STR00009##
or a pharmaceutically acceptable salt, prodrug, or solvate thereof,
wherein each of R.sup.1a, R.sup.2a, R.sup.2b and R.sup.3 is as
defined for formula (IB-1).
[0054] In yet other embodiments of formula (I) where n is 1 and m
is 2, the compound is of formula (IB-3):
##STR00010##
or a pharmaceutically acceptable salt, prodrug, or solvate thereof,
wherein each of R.sup.1a, R.sup.2a, R.sup.2b and R.sup.3 is as
defined for formula (IB-1).
[0055] In yet other embodiments of formula (I) where n is 1 and m
is 2, the compound is of formula (IB-4):
##STR00011##
or a pharmaceutically acceptable salt, prodrug, or solvate thereof,
wherein each of R.sup.1a, R.sup.2a, R.sup.2b and R.sup.3 is as
defined for formula (IB-1).
[0056] Provided are also compounds selected from Table 1, or a
pharmaceutically acceptable salt, prodrug, or solvate thereof. In
some embodiments, the compound is selected from Compound No. 1-89,
95-99, 101-103, and 106-110, or a pharmaceutically acceptable salt,
prodrug, or solvate thereof. In other embodiments, the compound is
selected from Compound No. 90-94, 100, 104, and 105, or a
pharmaceutically acceptable salt, prodrug, or solvate thereof. In
one embodiment, the compound is
(S)-2,4-diamino-6-((1-(5-chloro-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroq-
uinaltsazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl-
)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-5-fluoro-4-oxo-3,4-dihydroq-
uinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-5-fluoro-4-oxo-3,4-dihydroq-
uinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile, or a
pharmaceutically acceptable salt, prodrug, or solvate thereof. In
other embodiments, the compound is selected from Compound No.
111-122, 124, 125, 127, 129-133, 135-138, 140, 141, 145, 146,
148-156, 159-168, 175, 176, 178, 179, 181-186, 190, 192, 193, 194,
195-198, 205, 206, 142, 187-189, 191, 199, 200-204 and 207, or a
pharmaceutically acceptable salt, prodrug, or solvate thereof.
[0057] Also provided is a pharmaceutical composition that includes
a compound of formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2),
(IB-3), or (IB-4), or a pharmaceutically acceptable salt, prodrug,
or solvate thereof, together with at least one pharmaceutically
acceptable vehicle. Examples of pharmaceutically acceptable vehicle
may be selected from carriers, adjuvants, and excipients.
[0058] Also provided is a method of treating a subject, who has or
is suspected of having a disease or condition responsive or
believed to be responsive to the inhibition of PI3K.delta. activity
by administering to the subject a compound of formula (J), (I),
(IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or (IB-4), or a
pharmaceutically acceptable salt, prodrug, or solvate thereof. In
some embodiments, the subject is a human.
[0059] Also provided is a method of inhibiting kinase activity of a
phosphatidylinositol 3-kinase delta polypeptide by contacting the
polypeptide with a compound of formula (J), (I), (IA-1), (IA-2),
(IB-1), (IB-2), (IB-3), or (IB-4), or a pharmaceutically acceptable
salt, prodrug, or solvate thereof. Further provided is a method of
inhibiting excessive or destructive immune reactions, such as
asthma, rheumatoid arthritis, multiple sclerosis, and lupus.
[0060] Also provided is a method of disrupting leukocyte function
comprising contacting the leukocytes with an effective amount of a
compound of formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2),
(IB-3), or (IB-4), or a pharmaceutically acceptable salt, prodrug,
or solvate thereof.
[0061] Also provided is a method of inhibiting a growth or a
proliferation of cancer cells comprising contacting the cancer
cells with an effective amount of a compound of formula (J), (I),
(IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or (IB-4), or a
pharmaceutically acceptable salt, prodrug, or solvate thereof. Also
provided is a method for increasing sensitivity of cancer cells to
chemotherapy, comprising administering to a patient undergoing
chemotherapy with a chemotherapeutic agent an amount a compound of
formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or
(IB-4), or a pharmaceutically acceptable salt, prodrug, or solvate
thereof, sufficient to increase the sensitivity of cancer cells to
the chemotherapeutic agent. In some embodiments, the cancers cells
are of hematopoietic origin.
[0062] Also provided is a kit that includes a compound of formula
(J), (I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or (IB-4), or a
pharmaceutically acceptable salt, prodrug, or solvate thereof; and
a label and/or instructions for use of the compound in the
treatment of a disease or condition mediated by PI3K.delta.
activity.
[0063] Also provided are articles of manufacture that include a
compound of formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2),
(IB-3), or (IB-4), or a pharmaceutically acceptable salt, prodrug,
or solvate thereof; and a container. In one embodiment, the
container may be a vial, jar, ampoule, preloaded syringe, or an
intravenous bag.
DETAILED DESCRIPTION
[0064] The following description sets forth exemplary methods,
parameters and the like. It should be recognized, however, that
such description is not intended as a limitation on the scope of
the present disclosure but is instead provided as a description of
exemplary embodiments.
[0065] As used in the present specification, the following words,
phrases and symbols are generally intended to have the meanings as
set forth below, except to the extent that the context in which
they are used indicates otherwise.
[0066] A dash ("-") that is not between two letters or symbols is
used to indicate a point of attachment for a substituent. For
example, --CONH.sub.2 is attached through the carbon atom.
[0067] Reference to "about" a value or parameter herein includes
(and describes) embodiments that are directed to that value or
parameter per se. For example, description referring to "about X"
includes description of "X".
[0068] "Alkyl" refers to a monoradical unbranched or branched
saturated hydrocarbon chain. In some embodiments, alkyl as used
herein, such as in compounds of formula (J), (I), (IA-1), (IA-2),
(IB-1), (IB-2), (IB-3), or (IB-4), has 1 to 20 carbon atoms (i.e.,
C.sub.1-20 alkyl), 1 to 8 carbon atoms (i.e., C.sub.1-8 alkyl), 1
to 6 carbon atoms (i.e., C.sub.1-6 alkyl), or 1 to 4 carbon atoms
(i.e., C.sub.14 alkyl). Examples of alkyl groups include methyl,
ethyl, propyl, isopropyl, n-butyl, sec-butyl, tert-butyl, pentyl,
2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and
3-methylpentyl. When an alkyl residue having a specific number of
carbons is named, all geometric isomers having that number of
carbons may be encompassed; thus, for example, "butyl" can include
n-butyl, sec-butyl, isobutyl and t-butyl; "propyl" can include
n-propyl and isopropyl.
[0069] "Cycloalkyl." refers to a cyclic alkyl group. In some
embodiments, cycloalkyl as used herein, such as in compounds of
formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or
(IB-4), has from 3 to 20 ring carbon atoms (i.e., C.sub.3-20
cycloalkyl), or 3 to 12 ring carbon atoms (i.e., C.sub.3-12
cycloalkyl), or 3 to 8 ring carbon atoms (i.e., C.sub.3-8
cycloalkyl). Examples of cycloalkyl groups include cyclopropyl,
cyclobutyl, cyclopentyl, and cyclohexyl.
[0070] "Heterocycloalkyl" refers to a cyclic alkyl group, with one
or more ring heteroatoms independently selected from nitrogen,
oxygen and sulfur. In some embodiments, the heterocycloalkyl as
used herein, such as in compounds of formula (J), (I), (IA-1),
(IA-2), (IB-1), (IB-2), (IB-3), or (IB-4), has 2 to 20 ring carbon
atoms (i.e., C.sub.2-20 heterocycloalkyl), 2 to 12 ring carbon
atoms (i.e., C.sub.2-12 heterocycloalkyl), or 2 to 8 ring carbon
atoms (i.e., C.sub.2-8 heterocycloalkyl); and 1 to 5 ring
heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 or
2 ring heteroatoms, or 1 ring heteroatom independently selected
from nitrogen, sulfur or oxygen. In one example, a heterocycloalkyl
has 2 to 8 ring carbon atoms, with 1 to 3 ring heteroatoms
independently selected from nitrogen, oxygen and sulfur. Examples
of heterocycloalkyl groups may include pyrrolidinyl, piperidinyl,
piperazinyl, oxetanyl, dioxolanyl, azetidinyl, and morpholinyl.
[0071] "Alkoxy" refers to the group "alkyl-O--". Examples of alkoxy
groups may include methoxy, ethoxy, n-propoxy, iso-propoxy,
n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and
1,2-dimethylbutoxy.
[0072] "Aryl" refers to an aromatic carbocyclic group having a
single ring (e.g., phenyl), multiple rings (e.g., biphenyl), or
multiple fused rings (e.g., naphthyl, fluorenyl, and anthryl). In
certain embodiments, aryl as used herein, such as in compounds of
formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or
(IB-4), has 6 to 20 ring carbon atoms (i.e., C.sub.6-20 aryl), or 6
to 12 carbon ring atoms (i.e., C.sub.6-12 aryl). Aryl, however,
does not encompass or overlap in any way with heteroaryl,
separately defined below. In certain embodiments, if one or more
aryl groups are fused with a heteroaryl ring, the resulting ring
system is heteroaryl.
[0073] "Heteroaryl" refers to an aromatic group having a single
ring, multiple rings, or multiple fused rings, with one or more
ring heteroatoms independently selected from nitrogen, oxygen, and
sulfur. In some embodiments, heteroaryl is an aromatic, monocyclic
or bicyclic ring containing one or more heteroatoms independently
selected from nitrogen, oxygen and sulfur with the remaining ring
atoms being carbon. In certain embodiments, heteroaryl as used
herein, such as in compounds of formula (J), (I), (IA-1), (IA-2),
(IB-1), (IB-2), (IB-3), or (IB-4), has 3 to 20 ring carbon atoms
(i.e., C.sub.3-20 heteroaryl), 3 to 12 ring carbon atoms (i.e.,
C.sub.3-12) heteroaryl), or 3 to 8 carbon ring atoms (i.e.,
C.sub.3-8 heteroaryl); and 1 to 5 heteroatoms, 1 to 4 heteroatoms,
1 to 3 ring heteroatoms, 1 or 2 ring heteroatoms, or 1 ring
heteroatom independently selected from nitrogen, oxygen, and
sulfur. In one example, a heteroaryl has 3 to 8 ring carbon atoms,
with 1 to 3 ring heteroatoms independently selected from nitrogen,
oxygen and sulfur. Examples of heteroaryl groups include pyridyl,
pyridazinyl, pyrimidinyl, benzothiazolyl, and pyrazolyl. Heteroaryl
does not encompass or overlap with aryl as defined above.
[0074] The term "substituted", as used herein, means that any one
or more hydrogen atoms on the designated atom or group is replaced
with a moiety other than hydrogen, provided that the designated
atom's normal valence is not exceeded.
[0075] "Substituted alkyl" refers to an alkyl group having one or
more substituents including, for example, hydroxyl, haloalkyl,
cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cyano, halo,
carboxyl, and NR.sub.2, where each R is independently hydrogen,
alkyl, haloalkyl, alkylC(O)--, alkylOC(O)--, or H.sub.2NC(O)--. In
some embodiments, a substituted alkyl may have 1 to 5 substituents,
1 to 3 substituents, 1 to 2 substituents, or 1 substituent.
[0076] "Substituted cycloalkyl" refers to a cycloalkyl group having
one or more substituents including, for example, alkyl, haloalkyl,
heterocycloalkyl, aryl, heteroaryl, alkoxy, cyano, halo, carboxyl,
hydroxyl, and NR.sub.2, where each R is independently hydrogen,
haloalkyl, alkylC(O)--, alkylOC(O)--, or H.sub.2NC(O)--. In some
embodiments, a substituted cycloalkyl may have 1 to 5 substituents,
1 to 3 substituents, 1 to 2 substituents, or 1 substituent.
[0077] "Substituted heterocycloalkyl" refers to a heterocycloalkyl
group having one or more substituents including, for example,
alkyl, haloalkyl, cycloalkyl, aryl, heteroaryl, alkoxy, cyano,
halo, carboxyl, hydroxyl, and NR.sub.2, where each R is
independently hydrogen, alkyl, haloalkyl, alkylC(O)--,
alkylOC(O)--, or H.sub.2NC(O)--. In some embodiments, a substituted
heterocycloalkyl may have 1 to 5 substituents, 1 to 3 substituents,
1 to 2 substituents, or 1 substituent. In certain embodiments, a
substituted heterocycloalkyl may contain 1, 2 or 3 heteroatoms
independently selected from nitrogen, oxygen, and sulfur.
[0078] "Substituted aryl" refers to an aryl group having one or
more substituents including, for example, halo, OR, NR.sub.2,
C(O)NR'.sub.2, SO.sub.2NR'.sub.2, heterocycloalkyl, heteroaryl,
alkoxy, amino, cyano, and carboxyl, where each R is independently
hydrogen, alkyl, haloalkyl, alkylC(O)--, alkylOC(O)--, or
H.sub.2NC(O)-- and each R' is independently hydrogen, alkyl,
haloalkyl. In some embodiments, a substituted aryl may have 1 to 5
substituents, 1 to 3 substituents, 1 to 2 substituents, or 1
substituent.
[0079] "Substituted heteroaryl" refers to a heteroaryl group having
one or more substituents including, for example, alkyl, haloalkyl,
halo, NR.sub.2, OR, --C(O)OR, heterocycloalkyl, aryl, and cyano,
where each R is independently hydrogen, alkyl, haloalkyl,
alkylC(O)--, alkylOC(O)--, or H.sub.2NC(O)--. In some embodiments,
a substituted heteroaryl may have 1 to 5 substituents, 1 to 3
substituents, 1 to 2 substituents, or 1 substituent. In certain
embodiments, a substituted heteroaryl may contain 1, 2 or 3
heteroatoms independently selected from nitrogen, oxygen, and
sulfur.
[0080] The term "halogen" or "halo" includes fluoro, chloro, bromo,
and iodo, and the term "halogen" includes fluorine, chlorine,
bromine, and iodine. "Haloalkyl" refers to an unbranched or
branched alkyl group as defined above, wherein one or more hydrogen
atoms are replaced by a halogen. For example, where a residue is
substituted with more than one halogen, it may be referred to by
using a prefix corresponding to the number of halogen moieties
attached. For example, dihaloaryl, dihaloalkyl, and trihaloaryl
refer to aryl and alkyl substituted with two ("di") or three
("tri") halo groups, which may be, but are not necessarily, the
same halogen; thus, for example, 3,5-difluorophenyl,
3-chloro-5-fluorophenyl, 4-chloro-3-fluorophenyl, and
3,5-difluoro-4-chlorophenyl is within the scope of dihaloaryl.
Other examples of a haloalkyl group include difluoromethyl
(--CHF.sub.2) and trifluoromethyl (--CF.sub.3). It should be
understood that trifluoromethyl (--CF.sub.3) may also be referred
to as perfluoromethyl.
PI3K Inhibitor Compounds
[0081] Provided herein are compounds that function as inhibitors of
PI3K isoforms, such as PI3K.delta.. In one aspect, provided is a
compound of formula (J):
##STR00012##
or a pharmaceutically acceptable salt, prodrug, or solvate thereof,
wherein:
[0082] A is N or CH; [0083] n is 0, 1, 2, or 3; [0084] each R.sup.1
is independently unsubstituted or substituted alkyl, unsubstituted
or substituted haloalkyl, unsubstituted or substituted aryl,
unsubstituted or substituted heteroaryl, halo, cyano,
NHC(.dbd.O)alkylene-N(R.sup.1x).sub.2, NO.sub.2, .degree. R.sup.1x,
OCF.sub.3, N(R.sup.1x).sub.2, OC(.dbd.O)R.sup.1x,
C(.dbd.O)R.sup.1x, C(.dbd.O)OR.sup.1x, aryl-OR.sup.1y, Het,
NR.sup.1xC(.dbd.O)alkylene-C(.dbd.O)OR.sup.1x,
aryl-O-alkylene-N(R.sup.1x).sub.2, aryl-O--C(.dbd.O)R.sup.1x,
alkylene-C(.dbd.O)OR.sup.1x, O-alkylene-C(.dbd.O)OR.sup.1x,
alkylene-O-alkylene-C(.dbd.O)OR.sup.1x,
C(.dbd.O)NR.sup.1xSO.sub.2R.sup.1x, alkylene-N(R.sup.1x).sub.2,
alkenylene-N(R.sup.1x).sub.2,
C(.dbd.O)NR.sup.1x-alkylene-OR.sup.1x,
C(.dbd.O)NR.sup.1xalkylene-Het, O-alkylene-N(R.sup.1x).sub.2,
O-alkylene-CH(OR.sup.1y)CH.sub.2N(R.sup.1x).sub.2, O-alkylene-Het,
O-alkylene-OR.sup.1x, O-alkylene-NR.sup.1xC(.dbd.O)OR.sup.1x,
NR.sup.1x-alkylene-N(R.sup.1x).sub.2, NR.sup.1xC(.dbd.O)R.sup.1x,
NR.sup.1xC(.dbd.O)N(R.sup.1x).sub.2, N(SO.sub.2-alkyl).sub.2,
NR.sup.1x(SO.sub.2-alkyl), SO.sub.2R.sup.1x,
SO.sub.2N(R.sup.1x).sub.2, OSO.sub.2CF.sub.3, alkylenearyl,
alkylene-Het, alkylene-OR.sup.1y, alkylene-N(R.sup.1x).sub.2,
C(.dbd.O)N(R.sup.1x).sub.2, NHC(.dbd.O)alkylenearyl, unsubstituted
or substituted cycloalkyl, unsubstituted or substituted
heteocycloalkyl, aryl-O-alkylene-N(R.sup.1x).sub.2,
aryl-OC(.dbd.O)R.sup.1y, NHC(.dbd.O)alkylene-heterocycloalkyl,
NHC(.dbd.O)alkyelne-Het, O-alkylene-O-alkylene-C(.dbd.O)OR.sup.1Y,
C(.dbd.O)alkylene-Het, or NHC(.dbd.O)haloalkyl,
[0085] wherein Het is a 5- or 6-membered heterocyclic ring
containing at least one heteroatom selected from the group
consisting of oxygen, nitrogen and sulfur, wherein the 5- or
6-membered heterocyclic ring is saturated, partially unsaturated or
fully unsaturated, and wherein Het is unsubstituted or substituted
with alkyl or C(.dbd.O)OR.sup.1x,
[0086] wherein R.sup.1x is independently hydrogen, unsubstituted or
substituted alkyl, unsubstituted or substituted cycloalkyl,
unsubstituted or substituted heterocycloalkyl,
alkylene-N(R.sup.1x).sub.2, unsubstituted or substituted aryl,
arylalkyl, alkylenearyl, unsubstituted or substituted heteroaryl,
unsubstituted or substituted heteroarylalkyl, or
alkyleneheteroaryl, or two R.sup.1a groups are taken together to
form a 5- or 6-membered ring, optionally containing at least one
heteroatom,
[0087] wherein R.sup.1y is hydrogen, unsubstituted or substituted
alkyl, unsubstituted or substituted aryl, unsubstituted or
substituted heteroaryl, arylalkyl, heteroarylalkyl, alkylenearyl,
and alkyleneheteroaryl;
[0088] m is 0, 1, 2, or 3;
[0089] each R.sup.2 is independently halo, cyano, unsubstituted or
substituted alkyl, unsubstituted or substituted haloalkyl,
unsubstituted or substituted alkoxy, or NR.sup.2xR.sup.2y, wherein
each R.sup.2x and R.sup.2y is independently hydrogen, C(O)R.sup.2s
or C(O)OR.sup.2s, wherein R.sup.2s is unsubstituted or substituted
alkyl;
[0090] R.sup.3 is hydrogen, unsubstituted or substituted alkyl, or
unsubstituted or substituted haloalkyl; and
[0091] R.sup.4 is cyano, CON(R.sup.4a).sub.2, SO.sub.2-alkyl, halo,
or haloalkyl, where each R.sup.4a is independently hydrogen, or
unsubstituted or substituted alkyl.
[0092] In some embodiments of formula (J),
[0093] A is N or CH;
[0094] n is 0, 1, 2, or 3;
[0095] each R.sup.1 is independently halo, cyano, unsubstituted or
substituted alkyl, unsubstituted or substituted haloalkyl,
unsubstituted or substituted alkoxy, hydroxy, unsubstituted or
substituted cycloalkyl, SO.sub.2R.sup.1r, or C(O)NR.sup.1sR.sup.1t,
wherein each R.sup.1r, R.sup.1s and R.sup.1t is independently
hydrogen or unsubstituted or substituted alkyl;
[0096] m is 0, 1, 2, or 3;
[0097] each R.sup.2 is independently halo, cyano, unsubstituted or
substituted alkyl, unsubstituted or substituted haloalkyl, or
unsubstituted or substituted alkoxy;
[0098] R.sup.3 is hydrogen or unsubstituted or substituted alkyl;
and
[0099] R.sup.4 is cyano, CON(R.sup.4a).sub.2, SO.sub.2-alkyl, halo,
or haloalkyl, where each R.sup.4a is independently hydrogen, or
unsubstituted or substituted alkyl.
[0100] In other embodiments of formula (J),
[0101] A is N or CH;
[0102] n is 0, 1, 2, or 3;
[0103] each R.sup.1 is independently halo, cyano, OR.sup.1x,
C(.dbd.O)OR.sup.1x, SO.sub.2R.sup.1x, or
C(.dbd.O)N(R.sup.1x).sub.2, wherein R.sup.1x is independently
hydrogen, or unsubstituted or substituted alkyl;
[0104] m is 0, 1, 2, or 3;
[0105] each R.sup.2 is independently halo, cyano, unsubstituted or
substituted alkyl, unsubstituted or substituted haloalkyl, or
unsubstituted or substituted alkoxy;
[0106] R.sup.3 is hydrogen, unsubstituted or substituted alkyl, or
unsubstituted or substituted haloalkyl; and
[0107] R.sup.4 is cyano, CON(R.sup.4a).sub.2, halo, or haloalkyl,
where each R.sup.4a is independently hydrogen, or unsubstituted or
substituted alkyl.
[0108] In some embodiments of formula (J), each R.sup.1 is
independently fluoro, chloro, cyano, methyl, CHF.sub.2, CF.sub.3,
methoxy, or hydroxy. In other embodiments of formula (J), each
R.sup.1 is independently halo, cyano, OR.sup.1x,
C(.dbd.O)OR.sup.1x, SO.sub.2R.sup.1x, or
C(.dbd.O)N(R.sup.1x).sub.2, wherein R.sup.1x is independently
hydrogen, or unsubstituted or substituted alkyl.
[0109] In certain embodiments of formula (J), n is 0, 1 or 2. In
certain embodiments of formula (J), n is 1 or 2.
[0110] In some embodiments of formula (J), each R.sup.2 is
independently fluoro, chloro, iodo, cyano, methoxy, CHF.sub.2, or
CF.sub.3. In other embodiments of formula (J), each R.sup.2 is
independently halo or substituted alkoxy. In one embodiment, each
R.sup.2 is independently fluoro or --OCF.sub.3.
[0111] In certain embodiments of formula (J), m is 1 or 2.
[0112] In some embodiments of formula (J), R.sup.3 is alkyl
substituted with halo or alkoxy. In one embodiment, R.sup.3 is
--CH.sub.2CF.sub.3 or --CH.sub.2OCH.sub.3. In other embodiments of
formula (J), R.sup.3 is unsubstituted alkyl. In one embodiment,
R.sup.3 is methyl, ethyl, propyl or butyl. In another embodiment,
R.sup.3 is methyl or ethyl.
[0113] In some embodiments of formula (J), R.sup.4 is halo. In one
embodiment, R.sup.4 is chloro.
[0114] In certain embodiments of formula (J),
[0115] n is 1, 2, or 3;
[0116] each R.sup.1 is independently halo, cyano or unsubstituted
or substituted alkyl;
[0117] m is 1, 2, or 3;
[0118] each R.sup.2 is independently halo or cyano; and
[0119] R.sup.3 is unsubstituted or substituted alkyl.
[0120] In certain embodiments of formula (J),
[0121] n is 1;
[0122] R.sup.1 is halo;
[0123] m is 2;
[0124] each R.sup.2 is independently halo;
[0125] R.sup.3 is unsubstituted or substituted alkyl.
[0126] In some embodiments of formula (J) where A is N, the
compound is of formula (JA):
##STR00013##
or a pharmaceutically acceptable salt, prodrug, or solvate
thereof.
[0127] In other embodiments of formula (J) where A is CH, the
compound is of formula (JB):
##STR00014##
or a pharmaceutically acceptable salt, prodrug, or solvate
thereof.
[0128] In some embodiments of formula (JA) or (JB),
[0129] each R.sup.1 is independently halo, cyano, unsubstituted or
substituted alkyl, unsubstituted or substituted haloalkyl,
unsubstituted or substituted alkoxy, hydroxy, unsubstituted or
substituted cycloalkyl, --SO.sub.2R.sup.1x, or
--C(O)N(R.sup.1x).sub.2, wherein each R.sup.1x is independently
hydrogen or unsubstituted or substituted alkyl;
[0130] each R.sup.2 is independently halo, cyano, unsubstituted or
substituted alkyl, unsubstituted or substituted haloalkyl,
unsubstituted or substituted alkoxy, or N(R.sup.2x).sub.2, wherein
each R.sup.2x is independently hydrogen, C(O)R.sup.2s or
C(O)OR.sup.2s, wherein R.sup.2s is unsubstituted or substituted
alkyl; and
[0131] R.sup.3 and R.sup.4 are as defined for formula (J).
It is intended and understood that each and every variation of
R.sup.1 and R.sup.2 may be combined with each and every variation
of n, m, R.sup.3 and R.sup.4 as described for formula (JA) or (JB),
as if each and every combination is individually described.
[0132] In some embodiments of formula (JA) or (JB), R.sup.3 is
hydrogen. In other embodiments, R.sup.3 is unsubstituted or
substituted alkyl. In certain embodiments, R.sup.3 is methyl or
ethyl. It is intended and understood that each and every variation
of R.sup.3 may be combined with each and every variation of n,
R.sup.1, m, R.sup.2 and R.sup.4 as described for formula (JA) or
(JB), as if each and every combination is individually
described.
[0133] In some embodiments of formula (JA) or (JB), R.sup.4 is
cyano, fluoro, chloro, CONH.sub.2, or SO.sub.2CH.sub.3. In one
embodiment, R.sup.4 is cyano. It is intended and understood that
each and every variation of R.sup.4 may be combined with each and
every variation of n, R.sup.1, m, R.sup.2 and R.sup.3 as described
for formula (JA) or (JB), as if each and every combination is
individually described.
[0134] In some embodiments of formula (J), (JA), or (JB), one or
both of the following properties apply:
[0135] (i) n is 1, 2 or 3; and
[0136] (ii) m is 1, 2 or 3.
It is intended and understood that each and every variation of n
and m may be combined with each and every variation of R.sup.1,
R.sup.2, R.sup.3 and R.sup.4 as described for formula (J), (JA),
and (JB), as if each and every combination is individually
described.
[0137] The embodiments and variations described herein are suitable
for compounds of any formulae detailed herein, where applicable.
For example, the embodiments and structures as described herein
with respect to formula (J) are suitable for compounds of any
formulae detailed herein, including (JA) and (JB) where
applicable.
[0138] In another aspect, provided is a compound of formula
(I):
##STR00015##
or a pharmaceutically acceptable salt thereof, wherein each of n,
R.sup.1, m, R.sup.2, and R.sup.3 are as defined for formula
(J).
[0139] In some embodiments of formula (I),
[0140] n is 0, 1, 2, or 3;
[0141] each R.sup.1 is independently halo, cyano, unsubstituted or
substituted alkyl, unsubstituted or substituted haloalkyl,
unsubstituted or substituted alkoxy, hydroxy, unsubstituted or
substituted cycloalkyl, --SO.sub.2R.sup.1r, or
--C(O)NR.sup.1sR.sup.1t, wherein each R.sup.1r, R.sup.1s and
R.sup.1t is independently hydrogen or unsubstituted or substituted
alkyl;
[0142] m is 0, 1, 2, or 3;
[0143] each R.sup.2 is independently halo, cyano, unsubstituted or
substituted alkyl, unsubstituted or substituted haloalkyl, or
unsubstituted or substituted alkoxy; and
[0144] R.sup.3 is hydrogen, or unsubstituted or substituted
alkyl.
[0145] In some embodiments of formula (I), one or both of the
following properties apply:
[0146] (i) n is 1, 2 or 3; and
[0147] (ii) m is 1, 2 or 3.
[0148] In one embodiment of formula (I), n is 0. In other
embodiments, n is 1, 2 or 3. In certain embodiments, n is 1 or 2.
In one embodiment, n is 1. The R.sup.1 moiety may be located on any
position of the quinazolinone ring, as depicted below.
##STR00016##
[0149] In another embodiment, n is 2. In embodiments where n is 2,
both R.sup.1 may be the same or different. Two R.sup.1 moieties may
be located of any two positions of the quinazolinone ring as
depicted below. For example, two R.sup.1 moieties may be in para-,
meta- or ortho-positions to each other.
##STR00017##
[0150] In yet another embodiment, n is 3. In embodiments where n is
3, all R.sup.1 may be the same or different, or two R.sup.1 may be
the same and different from the third R.sup.1. Three R.sup.1
moieties may be located on any three positions of the quinazolinone
ring as depicted below. For example, the first R.sup.1 may be ortho
to the second R.sup.1, and the first R.sup.1 may be para to the
third R.sup.1.
##STR00018##
[0151] In some embodiments of formula (I), each R.sup.1 is
independently halo, cyano, unsubstituted or substituted alkyl,
unsubstituted or substituted haloalkyl, unsubstituted or
substituted alkoxy, or hydroxy. In certain embodiments, each
R.sup.1 is independently halo, cyano, unsubstituted or substituted
alkyl, or unsubstituted or substituted haloalkyl.
[0152] In some embodiments of formula (I), each R.sup.1 is
independently halo, cyano, unsubstituted or substituted C.sub.1-6
alkyl, unsubstituted or substituted C.sub.1-6 haloalkyl,
unsubstituted or substituted C.sub.1-6 alkoxy, hydroxy, or
unsubstituted or substituted C.sub.3-6 cycloalkyl. In certain
embodiments, each R.sup.1 is independently halo or unsubstituted or
substituted C.sub.1-6 alkyl.
[0153] In certain embodiments of formula (I), each R.sup.1 is
independently fluoro, chloro, cyano, methyl, CHF.sub.2, CF.sub.3,
methoxy, hydroxy, CONH.sub.2, SO.sub.2CH.sub.3, or cyclopropyl. In
one embodiment, each R.sup.1 is independently fluoro, chloro,
cyano, methyl, CHF.sub.2, CF.sub.3, methoxy, or hydroxy. In another
embodiment, each R.sup.1 is independently fluoro, chloro, cyano or
methyl.
[0154] In some embodiments of formula (I) where n is 1, R.sup.1 is
halo, cyano, unsubstituted or substituted alkyl, unsubstituted or
substituted haloalkyl, unsubstituted or substituted alkoxy,
hydroxy, --SO.sub.2R.sup.1r, or --C(O)NR.sup.1sR.sup.1t, or
unsubstituted or substituted cycloalkyl. In certain embodiments
where n is 1, R.sup.1 is fluoro, chloro, cyano, methyl, ethyl,
CHF.sub.2, CF.sub.3, methoxy, hydroxy, CONH.sub.2,
SO.sub.2CH.sub.3, or cyclopropyl. In one embodiment where n is 1,
R.sup.1 is fluoro, chloro, hydroxy, methyl, cyano, CHF.sub.2,
CF.sub.3, or methoxy. In another embodiment where n is 1, R.sup.1
is fluoro, chloro, or cyano. It should be understood that the
R.sup.1 moiety may be located on any position of the quinazolinone
ring.
[0155] In other embodiments of formula (I) where n is 2, both
R.sup.1 are independently halo, which may the same (e.g., both
R.sup.1 are fluoro) or which may be different (e.g., one R.sup.1 is
fluoro and the other R.sup.1 is chloro). In other embodiments where
n is 2, one R.sup.1 is halo and the other R.sup.1 is unsubstituted
alkyl. In certain embodiments where n is 2, both R.sup.1 are chloro
or both R.sup.1 are fluoro. In yet other embodiments where n is 2,
one R.sup.1 is chloro and the other R.sup.1 is fluoro; one R.sup.1
is chloro and the other R.sup.1 is methyl; or one R.sup.1 is fluoro
and the other R.sup.1 is methyl. It should be understood that the
two R.sup.1 moieties may be located of any two positions of the
quinazolinone ring as depicted below.
[0156] In some embodiments, the moiety
##STR00019##
of formula (I) is:
##STR00020## ##STR00021##
[0157] In certain embodiments, the moiety
##STR00022##
of formula (I) is:
##STR00023## ##STR00024## ##STR00025## ##STR00026##
[0158] It is intended and understood that each and every variation
of n and R.sup.1 may be combined with each and every variation of
m, R.sup.2 and R.sup.3 as described for formula (I), as if each and
every combination is individually described.
[0159] In some embodiments of formula (I), m is 0. In other
embodiments, m is 1, 2 or 3. In yet other embodiments, m is 1 or 2.
In one embodiment, m is 1. The R.sup.2 moiety may be located on any
position of the phenyl ring, as depicted below.
##STR00027##
[0160] In another embodiment, m is 2. In embodiments where m is 2,
both R.sup.2 may be the same or different. The two R.sup.2 moieties
may be located on any two positions of the phenyl ring, as depicted
below.
##STR00028##
[0161] In yet another embodiment, m is 3. In embodiments where m is
3, all R.sup.2 may be the same or different, or two R.sup.2 may be
the same and different from the third R.sup.2. The three R.sup.2
moieties may be located on any three positions of the phenyl ring,
as depicted below.
##STR00029##
[0162] In some embodiments of formula (I), each R.sup.2 is
independently halo, cyano, unsubstituted or substituted C.sub.1-6
alkyl, unsubstituted or substituted C.sub.1-6 haloalkyl, or
unsubstituted or substituted C.sub.1-6 alkoxy. In certain
embodiments, each R.sup.2 is independently halo or cyano.
[0163] In certain embodiments of formula (I), each R.sup.2 is
independently fluoro, chloro, iodo, cyano,
--NHC(O)NHCH.sub.2CH.sub.3, methoxy, CHF.sub.2, or CF.sub.3. In one
embodiment, each R.sup.2 is independently fluoro, chloro, iodo,
cyano, methoxy, CHF.sub.2, or CF.sub.3. In another embodiment, each
R.sup.2 is independently fluoro, chloro, or cyano.
[0164] In some embodiments of formula (I), m is 1 or 2. In some
embodiments of formula (I) where m is 1, R.sup.2 is halo, cyano, or
haloalkyl. In certain embodiments where m is 1, R.sup.2 is fluoro,
chloro, cyano, CHF.sub.2, or CF.sub.3. In one embodiment where m is
1, R.sup.2 is fluoro, chloro, or cyano. It should be understood
that the R.sup.2 moiety may be located on any position of the
phenyl ring.
[0165] In some embodiments of formula (I) where m is 2, both
R.sup.2 are independently halo, which may the same (e.g., both
R.sup.2 are fluoro) or which may be different (e.g., one R.sup.2 is
fluoro and the other R.sup.2 is chloro). In other embodiments where
m is 2, both R.sup.2 are independently unsubstituted or substituted
alkyl, which may the same (e.g., both R.sup.2 are methyl) or which
may be different (e.g., one R.sup.2 is methyl and the other R.sup.2
is ethyl). In other embodiments where m is 2, both R.sup.2 are
independently unsubstituted or substituted haloalkyl, which may the
same (e.g., both R.sup.2 are CF.sub.3) or which may be different
(e.g., one R.sup.2 is CF.sub.3 and the other R.sup.2 is CHF.sub.2).
In yet other embodiments where m is 2, both R.sup.2 are
independently unsubstituted or substituted alkoxy, which may the
same (e.g., both R.sup.2 are methoxy) or which may be different
(e.g., one R.sup.2 is methoxy and the other R.sup.1 is ethoxy). In
other embodiments where m is 2, one R.sup.2 is halo and the other
R.sup.2 is cyano, one R.sup.2 is halo and the other R.sup.2 is
unsubstituted or substituted haloalkyl, one R.sup.2 is halo and the
other R.sup.2 is unsubstituted or substituted alkyl, one R.sup.2 is
halo and the other R.sup.2 is unsubstituted or substituted alkoxy,
or one R.sup.2 is cyano and the other R.sup.2 is unsubstituted or
substituted haloalkyl.
[0166] In certain embodiments of formula (I) where m is 2, both
R.sup.2 are fluoro, both R.sup.2 are chloro, or both R.sup.2 are
methoxy. In yet other embodiments where m is 2, one R.sup.2 is
fluoro and the other R.sup.2 is chloro, one R.sup.2 is fluoro and
the other R.sup.2 is cyano, one R.sup.2 is chloro and the other
R.sup.2 is cyano, one R.sup.2 is fluoro and the other R.sup.2 is
CF.sub.3, one R.sup.2 is fluoro and the other R.sup.2 is CHF.sub.2,
one R.sup.2 is chloro and the other R.sup.2 is CF.sub.3, one
R.sup.2 is chloro and the other R.sup.2 is CHF.sub.2, one R.sup.2
is cyano and the other R.sup.2 is CF.sub.3, or one R.sup.2 is cyano
and the other R.sup.2 is CHF.sub.2. It should be understood that
the two R.sup.2 moieties may be located on any two positions of the
phenyl ring.
[0167] In yet other embodiments of formula (I) where m is 3, one or
two of R.sup.2 are independently halo, which may the same (e.g.,
two R.sup.2 are fluoro) or which may be different (e.g., one
R.sup.2 is fluoro and another R.sup.2 is chloro), the third R.sup.2
is unsubstituted or substituted alkoxy (e.g., third R.sup.2 is
methoxy). In another embodiment where m is 3, one R.sup.2 is alkyl,
another R.sup.2 is alkoxy, and the third R.sup.2 is halo. It should
be understood that the three R.sup.2 moieties may be located on any
three positions of the phenyl ring.
[0168] In some embodiments, the moiety
##STR00030##
of formula (I) is:
##STR00031##
[0169] In some embodiments, the moiety
##STR00032##
of formula (I) is:
##STR00033## ##STR00034##
[0170] It is intended and understood that each and every variation
of m and R.sup.2 may be combined with each and every variation of
n, R.sup.1 and R.sup.3 as described for formula (I), as if each and
every combination is individually described.
[0171] In some embodiments of formula (I), R.sup.3 is hydrogen, or
unsubstituted or substituted C.sub.1-6 alkyl. In one embodiment,
R.sup.3 is hydrogen. In another embodiment, R.sup.3 is methyl or
ethyl. It is intended and understood that each and every variation
of R.sup.3 may be combined with each and every variation of n,
R.sup.1, m and R.sup.2 as described for formula (I), as if each and
every combination is individually described.
[0172] In some embodiments of formula (I),
[0173] n is 1, 2, or 3;
[0174] each R.sup.1 is independently halo, cyano, or unsubstituted
or substituted alkyl;
[0175] m is 1, 2, or 3;
[0176] each R.sup.2 is independently halo or cyano; and
[0177] R.sup.3 is unsubstituted alkyl.
[0178] In one embodiment of formula (I),
[0179] n is 1;
[0180] R.sup.1 is halo;
[0181] m is 2;
[0182] each R.sup.2 is independently halo; and
[0183] R.sup.3 is unsubstituted alkyl.
[0184] In some embodiments of formula (I) where n is 2 and m is 2,
the compound is of formula (IA-1):
##STR00035##
or a pharmaceutically acceptable salt, prodrug, or solvate thereof,
wherein:
[0185] each R.sup.1a and R.sup.1b can be selected from the moieties
defined for R.sup.1 of formula (I);
[0186] each R.sup.2a and R.sup.2b can be selected from the moieties
defined for R.sup.2 of formula (I); and
[0187] R.sup.3 is as defined for formula (I).
[0188] In certain embodiments of formula (IA-1),
[0189] each R.sup.1a, R.sup.1b is independently halo, cyano,
unsubstituted or substituted alkyl, unsubstituted or substituted
haloalkyl, unsubstituted or substituted alkoxy, hydroxy, or
unsubstituted or substituted cycloalkyl;
[0190] each R.sup.2a and R.sup.2b is independently halo, cyano,
unsubstituted or substituted alkyl, unsubstituted or substituted
haloalkyl, or unsubstituted or substituted alkoxy; and
[0191] R.sup.3 is unsubstituted or substituted alkyl.
[0192] In one embodiment of formula (IA-1),
[0193] each R.sup.1a and R.sup.1b is independently hydrogen, halo,
cyano, or unsubstituted or substituted alkyl; and
[0194] each R.sup.2a and R.sup.2b is independently hydrogen, halo,
or cyano.
[0195] In other embodiments of formula (I) where n is 2 and m is 2,
the compound is of formula (IA-2):
##STR00036##
or a pharmaceutically acceptable salt, prodrug, or solvate thereof,
wherein:
[0196] each R.sup.1a and R.sup.1b can be selected from the moieties
defined for R.sup.1 of formula (I);
[0197] each R.sup.2a and R.sup.2b can be selected from the moieties
defined for R.sup.2 of formula (I); and
[0198] R.sup.3 is as defined for formula (I).
[0199] In certain embodiments of formula (IA-1) or (IA-2),
[0200] each R.sup.1a and R.sup.1b is independently halo, cyano,
unsubstituted or substituted alkyl, unsubstituted or substituted
haloalkyl, unsubstituted or substituted alkoxy, hydroxy, or
unsubstituted or substituted cycloalkyl;
[0201] each R.sup.2a and R.sup.2b is independently halo, cyano,
unsubstituted or substituted alkyl, unsubstituted or substituted
haloalkyl, or unsubstituted or substituted alkoxy; and
[0202] R.sup.3 is unsubstituted or substituted alkyl.
[0203] In some embodiments of formula (IA-1) or (IA-2), each
R.sup.1a and R.sup.1b is independently halo, cyano, unsubstituted
or substituted C.sub.1-6 alkyl, unsubstituted or substituted
C.sub.1-6 haloalkyl, unsubstituted or substituted C.sub.1-6 alkoxy,
hydroxy, unsubstituted or substituted C.sub.3-6 cycloalkyl,
--SO.sub.2R.sup.1r, or --C(O)NR.sup.1sR.sup.1t, wherein each
R.sup.1r, R.sup.1s and R.sup.1t is independently hydrogen or
unsubstituted or substituted C.sub.1-6 alkyl. In certain
embodiments, each R.sup.1a and R.sup.1b is independently halo,
cyano, or unsubstituted alkyl. In one embodiment, each R.sup.1a and
R.sup.1b is independently fluoro, chloro, cyano, methyl, CF.sub.3,
or CHF.sub.2. In another embodiment, each R.sup.1a and R.sup.1b is
independently fluoro, chloro, cyano, or methyl. It is intended and
understood that each and every variation of R.sup.1a and R.sup.1b
may be combined with each and every variation of R.sup.2a,
R.sup.2b, and R.sup.3 as described for formula (IA-1) or (IA-2), as
if each and every combination is individually described.
[0204] In some embodiments of formula (IA-1) or (IA-2), each
R.sup.2a and R.sup.2b is independently halo, cyano, unsubstituted
or substituted C.sub.1-6 alkyl, unsubstituted or substituted
C.sub.1-6 haloalkyl, or unsubstituted or substituted C.sub.1-6
alkoxy. In certain embodiments, each R.sup.2a and R.sup.2b is
independently halo, cyano, or unsubstituted C.sub.1-6 alkyl. In one
embodiment, each R.sup.2a and R.sup.2b is independently fluoro,
chloro, cyano, methyl, CF.sub.3, or CHF.sub.2. In another
embodiment, each R.sup.2a and R.sup.2b is independently fluoro,
chloro, or cyano. It is intended and understood that each and every
variation of R.sup.2a and R.sup.2b may be combined with each and
every variation of R.sup.1a, R.sup.1b, and R.sup.3 as described for
formula (IA-1) or (IA-2), as if each and every combination is
individually described.
[0205] In some embodiments, R.sup.3 is unsubstituted C.sub.1-6
alkyl. In one embodiment, R.sup.3 is methyl. In another embodiment,
R.sup.3 is ethyl. It is intended and understood that each and every
variation of R.sup.3 may be combined with each and every variation
of R.sup.1a, R.sup.1b, R.sup.2a and R.sup.2b as described for
formula (IA-1) or (IA-2), as if each and every combination is
individually described.
[0206] In other embodiments of formula (I) where n is 1 and m is 2,
the compound is of formula (IB-1):
##STR00037##
or a pharmaceutically acceptable salt, prodrug, or solvate thereof,
wherein:
[0207] R.sup.1a can be selected from the moieties defined for
R.sup.1 of formula (I);
[0208] each R.sup.2a and R.sup.2b can be selected from the moieties
defined for R.sup.2 of formula (I); and
[0209] R.sup.3 is as defined for formula (I).
[0210] In some embodiments of formula (IB-1),
[0211] R.sup.1a is halo, cyano, unsubstituted or substituted alkyl,
or haloalkyl;
[0212] each R.sup.2a and R.sup.2b is independently hydrogen, halo
or cyano; and
[0213] R.sup.3 is unsubstituted or substituted alkyl.
[0214] In yet other embodiments of formula (I) where n is 1 and m
is 2, the compound is of formula (IB-2):
##STR00038##
or a pharmaceutically acceptable salt, prodrug, or solvate thereof,
wherein each of R.sup.1a, R.sup.2a, R.sup.2b and R.sup.3 is as
defined for formula (IB-1).
[0215] In yet other embodiments of formula (I) where n is 1 and m
is 2, the compound is of formula (IB-3):
##STR00039##
or a pharmaceutically acceptable salt, prodrug, or solvate thereof,
wherein each of R.sup.1a, R.sup.2a, R.sup.2b and R.sup.3 is as
defined for formula (IB-1).
[0216] In yet other embodiments of formula (I) where n is 1 and m
is 2, the compound is of formula (IB-4):
##STR00040##
or a pharmaceutically acceptable salt, prodrug, or solvate thereof,
wherein each of R.sup.1a, R.sup.2a, R.sup.2b and R.sup.3 is as
defined for formula (IB-1).
[0217] In certain embodiments of formula (IB-4),
[0218] R.sup.1a is halo, cyano, unsubstituted or substituted alkyl,
or haloalkyl;
[0219] each R.sup.2a and R.sup.2b is independently hydrogen, halo
or cyano; and
[0220] In certain embodiments of formula (IB-1), (IB-2), (IB-3),
and (IB-4),
[0221] R.sup.1a is halo, cyano, unsubstituted or substituted alkyl,
or unsubstituted or substituted haloalkyl;
[0222] each R.sup.2a and R.sup.2b is independently hydrogen, halo
or cyano; and
[0223] R.sup.3 is unsubstituted or substituted alkyl.
[0224] In some embodiments of formula (IB-1), (IB-2), (IB-3), and
(IB-4), R.sup.1a is fluoro or chloro. In one embodiment, R.sup.1a
is fluoro. In another embodiment, R.sup.1a is chloro.
[0225] In other embodiments formula (IB-1), (IB-2), (IB-3), and
(IB-4), each R.sup.2a and R.sup.2b is independently fluoro, chloro,
or cyano. In one embodiment, both R.sup.2a and R.sup.2b are fluoro.
In another embodiment, both R.sup.2a and R.sup.2b are chloro. In
another embodiment, R.sup.2a is chloro and R.sup.2b is fluoro. In
yet another embodiment, R.sup.2a is fluoro and R.sup.2b is
chloro.
[0226] In yet other embodiments formula (IB-1), (IB-2), (IB-3), and
(IB-4), R.sup.3 is methyl or ethyl. In one embodiment, R.sup.3 is
methyl. In another embodiment, R.sup.3 is ethyl.
[0227] It should be understood that the embodiments and structures
as described herein with respect to formula (I) are suitable for
compounds of any formulae detailed herein, including (IA-1),
(IA-2), (IB-1), (IB-2), (IB-3), and (IB-4) where applicable.
[0228] For compounds of the invention, including the compounds of
formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or
(IB-4), or a pharmaceutically acceptable salt thereof, bearing one
or more chiral centers, each unique stereoisomer has a compound
number bearing a suffix "a", "b", etc. As an example, Compound 1
bearing one chiral center can be resolved into its individual
enantiomers 1a and 1b.
##STR00041##
[0229] In any one of the foregoing embodiments, the compound of
formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or
(IB-4), or a pharmaceutically acceptable salt thereof, is the
(S)-enantiomer. In other aspects, in any one of the foregoing
embodiments, the compound of formula (J), (I), (IA-1), (IA-2),
(IB-1), (IB-2), (IB-3), or (IB-4), or a pharmaceutically acceptable
salt thereof, is the (R)-enantiomer.
[0230] A composition containing a mixture of enantiomers of the
compound of formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2),
(IB-3), or (IB-4), or a pharmaceutically acceptable salt thereof,
is also provided herein. In some embodiments, the composition
contains the (S)-enantiomer of the compound and is substantially
free of its corresponding (R)-enantiomer. In certain embodiments, a
composition substantially free of the (R)-enantiomer has less than
or about 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 1%, 0.05%, or 0.01%
of the (R)-enantiomer. In other embodiments, the composition
containing the (S)-enantiomer of a compound of formula (J), (I),
(IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or (IB-4), or a
pharmaceutically acceptable salt thereof, predominates over its
corresponding (R)-enantiomer by a molar ratio of at least or about
9:1, at least or about 19:1, at least or about 40:1, at least or
about 80:1, at least or about 160:1, or at least or about
320:1.
[0231] The composition containing a compound of formula (J), (I),
(IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or (IB-4), or a
pharmaceutically acceptable salt thereof, may also contain the
compound in enantiomeric excess (e.e.). For instance, a compound
with 95% (S)-isomer and 5% (R)-isomer will have an e.e. of 90%. In
some embodiments, the compound has an e.e. of at least or about
60%, 75%, 80%, 85%, 90%, 95%, 98% or 99%. In some of the foregoing
embodiments, the compound is enantiomerically-enriched in the
(S)-isomer of compound of formula (J), (I), (IA-1), (IA-2), (IB-1),
(IB-2), (IB-3), or (IB-4).
[0232] Provided is also a composition comprising a mixture of the
(S)-enantiomer and the (R)-enantiomer of a compound of formula (J),
(I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or (IB-4), or a
pharmaceutically acceptable salt thereof. In one embodiment, the
mixture is a racemic mixture. In other embodiments, the composition
comprises the (S)-enantiomer of a compound of formula (J), (I),
(IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or (IB-4), or a
pharmaceutically acceptable salt thereof, wherein the
(S)-enantiomer of the compound is present in excess of over the
corresponding the (R)-enantiomer of the compound, or a
pharmaceutically acceptable salt thereof.
[0233] In certain embodiments, the compound of formula (J), (I),
(IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or (IB-4), or a
pharmaceutically acceptable salt thereof, is a diastereomer. As an
example, Compound 164 is a diastereomer that can be resolved into
its individual stereoisomers as depicted below.
##STR00042##
[0234] In any one of the foregoing embodiments, the compound of
formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or
(IB-4), or a pharmaceutically acceptable salt thereof, is an
atropisomer. A composition containing a mixture of atropisomers of
the compound of formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2),
(IB-3), or (IB-4), or a pharmaceutically acceptable salt thereof,
is also provided herein. "Atropisomers" refers to conformational
stereoisomers which occur when rotation about a single bond in the
molecule is prevented, or greatly slowed, as a result of steric
interactions with other parts of the molecule and the substituents
at both ends of the single bond are asymmetrical, i.e., they do not
require a stereocenter. Where the rotational barrier about the
single bond is high enough, and interconversion between
conformations is slow enough, separation and isolation of the
isomeric species may be permitted. Atropisomers are enantiomers
without a single asymmetric atom. As an example, Compound 142 can
be resolved into its individual atropisomers as depicted below.
##STR00043##
[0235] Representative compounds of the invention are listed in
Table 1 below in its non-isomeric form. The compounds in Table 1
are named using ChemBioDraw Ultra 12.0 and it should be understood
that other names may be used to identify compounds of the same
structure. Other compounds or radicals may be named with common
names, or systematic or non-systematic names. The compounds may
also be named using other nomenclature systems and symbols that are
commonly recognized in the art of chemistry including, for example,
Chemical Abstract Service (CAS) and International Union of Pure and
Applied Chemistry (IUPAC). The naming and numbering of the
compounds of the present disclosure is illustrated with
representative compounds of formula (J), (I), (IA-1), (IA-2),
(IB-1), (IB-2), (IB-3), or (IB-4) shown in Table 1 below. The
compounds provided in Table 1 may be a single enantiomer (e.g.,
(S)-enantiomer, (R)-enantiomer), or the compounds may be present in
a composition having an enantiomeric mixture.
TABLE-US-00001 TABLE 1 Representative Compounds # Structure Name 1.
##STR00044## 2,4-diamino-6-((1-(5- chloro-3-(3,5-
difluorophenyl)-4-oxo- 3,4-dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 2. ##STR00045## 2,4-diamino-6-((1-(5-
hydroxy-4-oxo-3-phenyl- 3,4-dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 3. ##STR00046## 2,4-diamino-6-((1-(8-
methyl-4-oxo-3-phenyl- 3,4-dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 4. ##STR00047## 2,4-diamino-6-((1-(5-
chloro-8-methyl-4-oxo-3- phenyl-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 5. ##STR00048## 2,4-diamino-6-((1-(5- chloro-3-(3-
chlorophenyl)-8-methyl- 4-oxo-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 6. ##STR00049## 2,4-diamino-6-((1-(3-(3-
chlorophenyl)-8-methyl- 4-oxo-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 7. ##STR00050## 2-(1-((2,6-diamino-5-
cyanopyrimidin-4- yl)amino)ethyl)-4-oxo-3- phenyl-3,4-
dihydroquinazoline-5- carbonitrile a: (S)-enantiomer
b:(R)-enantiomer 8. ##STR00051## 2,4-diamino-6-((1-(5- chloro-3-(3-
chlorophenyl)-4-oxo-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 9. ##STR00052## 2,4-diamino-6-((1-(6-
fluoro-4-oxo-3-phenyl- 3,4-dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 10. ##STR00053## 2,4-diamino-6-((1-(3-
(3,5-difluorophenyl)-5- fluoro-4-oxo-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 11. ##STR00054## 2,4-diamino-6-((1-(3-
(3,5-difluorophenyl)-6- fluoro-4-oxo-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 12. ##STR00055## 2,4-diamino-6-((1-(5- chloro-3-(3-
cyanophenyl)-4-oxo-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 13. ##STR00056## 2,4-diamino-6-((1-(3-(3-
cyanophenyl)-6-fluoro-4- oxo-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 14. ##STR00057## 2,4-diamino-6-((1-(3-(3-
chlorophenyl)-6-fluoro- 4-oxo-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 15. ##STR00058## 2,4-diamino-6-((1-(5-
chloro-3-(3,5- difluorophenyl)-8-fluoro- 4-oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 16. ##STR00059##
2,4-diamino-6-((1-(3- (3,5-difluorophenyl)-8- fluoro-4-oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 17. ##STR00060##
2,4-diamino-6-((1-(3- (3,5-difluorophenyl)-8- fluoro-4-oxo-3,4-
dihydroquinazolin-2- yl)propyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 18. ##STR00061##
2,4-diamino-6-((1-(3- (3,5-difluorophenyl)-5- methyl-4-oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 19. ##STR00062##
2,4-diamino-6-((1-(3- (3,5-difluorophenyl)-5- methyl-4-oxo-3,4-
dihydroquinazolin-2- yl)propyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 20. ##STR00063##
2,4-diamino-6-((1-(5- chloro-3-(3-cyano-5- fluorophenyl)-4-oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 21. ##STR00064##
2,4-diamino-6-((1-(3- (3,5-difluorophenyl)-5,8- difluoro-4-oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 22. ##STR00065##
2,4-diamino-6-((1-(8- chloro-4-oxo-3-phenyl-
3,4-dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile
a: (S)-enantiomer b: (R)-enantiomer 23. ##STR00066##
2,4-diamino-6-((1-(5- methyl-4-oxo-3-phenyl-
3,4-dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile
a: (S)-enantiomer b: (R)-enantiomer 24. ##STR00067##
2,4-diamino-6-((1-(3-(3- cyano-5-fluorophenyl)-5- methyl-4-oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 25. ##STR00068##
2,4-diamino-6-((1-(3- (3,5-difluorophenyl)-8- fluoro-5
methyl-4-oxo- 3,4-dihydroquinazolin-2- yl)ethyl)amino)pyrimidine-
5-carbonitrile a: (S)-enantiomer b: (R)-enantiomer 26. ##STR00069##
2,4-diamino-6-((1-(3- (3,5-difluorophenyl)-6- fluoro-4-oxo-3,4-
dihydroquinazolin-2- yl)propyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 27. ##STR00070##
2,4-diamino-6-((1-(3- (3,5-difluorophenyl)-5,8- difluoro-4-oxo-3,4-
dihydroquinazolin-2- yl)propyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 28. ##STR00071##
2,4-diamino-6-((1-(3- (3,5-difluorophenyl)-4- oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 29. ##STR00072##
2,4-diamino-6-((1-(3- (3,5-difluorophenyl)-5,6- difluoro-4-oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 30. ##STR00073##
2,4-diamino-6-((1-(3- (3,5-difluorophenyl)-5,6- difluoro-4-oxo-3,4-
dihydroquinazolin-2- yl)propyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 31. ##STR00074##
2,4-diamino-6-((1-(3-(3- cyano-5-fluorophenyl)-8-
fluoro-5-methyl-4-oxo- 3,4-dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 32. ##STR00075## 2,4-diamino-6-((1-(3-(3-
cyano-5-fluorophenyl)-5- fluoro-4-oxo-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 33. ##STR00076## 2,4-diamino-6-((1-(5-
fluoro-3-(3-fluoro-5- (trifluoromethyl)phenyl)- 4-oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 34. ##STR00077##
2,4-diamino-6-((1-(3- (3,5-difluorophenyl)-4-
oxo-8-(trifluoromethyl)- 3,4-dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 35. ##STR00078## 2,4-diamino-6-((1-(3-
(3,5-difluorophenyl)-5- fluoro-8-methyl-4-oxo-
3,4-dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile
a: (S)-enantiomer b: (R)-enantiomer 36. ##STR00079##
2,4-diamino-6-((1-(3- (3,5-difluorophenyl)-4- oxo-3,4-
dihydroquinazolin-2- yl)propyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 37. ##STR00080##
2,4-diamino-6-((1-(3- (3,5-difluorophenyl)-5-
fluoro-8-methyl-4-oxo- 3,4-dihydroquinazolin-2-
yl)propyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 38. ##STR00081## 2,4-diamino-6-((1-(3-(3-
cyanophenyl)-5-fluoro-4- oxo-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 39. ##STR00082## 2,4-diamino-6-((1-(8-
methyl-4-oxo-3-(3- (trifluoromethyl)phenyl)-
3,4-dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile
a: (S)-enantiomer b: (R)-enantiomer 40. ##STR00083##
2,4-diamino-6-((1-(5- fluoro-4-oxo-3-(3- (trifluoromethyl)phenyl)-
3,4-dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile
a: (S)-enantiomer b: (R)-enantiomer 41. ##STR00084##
2,4-diamino-6-((1-(5- chloro-3-(3,5- dichlorophenyl)-4-oxo-
3,4-dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile
a: (S)-enantiomer b: (R)-enantiomer 42. ##STR00085##
2,4-diamino-6-((1-(3- (3,5-dichlorophenyl)-5- fluoro-4-oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 43. ##STR00086##
2,4-diamino-6-((1-(5- chloro-3-(3-chloro-5-
fluorophenyl)-4-oxo-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 44. ##STR00087## 2,4-diamino-6-((1-(3-(3-
chloro-5-fluorophenyl)- 5-fluoro-4-oxo-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 45. ##STR00088## 2,4-diamino-6-((1-(5-
chloro-3-(3-fluoro-5- (trifluoromethyl)phenyl)- 4-oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 46. ##STR00089##
2,4-diamino-6-((1-(5- fluoro-4-oxo-3-(3- (trifluoromethyl)phenyl)-
3,4-dihydroquinazolin-2- yl)propyl)amino)pyrimidine- 5-carbonitrile
a: (S)-enantiomer b: (R)-enantiomer 47. ##STR00090##
2,4-diamino-6-((1-(5- chloro-4-oxo-3-(3- (trifluoromethyl)phenyl)-
3,4-dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile
a: (S)-enantiomer b: (R)-enantiomer 48. ##STR00091##
2,4-diamino-6-((1-(5- chloro-3-(3-cyano-5-
fluorophenyl)-8-fluoro-4- oxo-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 49. ##STR00092## 2,4-diamino-6-((1-(5-
chloro-4-oxo-3-phenyl- 3,4-dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantitiomer 50. ##STR00093## 2,4-diamino-6-((1-(5,8-
dichloro-4-oxo-3-phenyl- 3,4-dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 51. ##STR00094## 2,4-diamino-6-((1-(5-
chloro-3-(3,5- dimethoxyphenyl)-4-oxo- 3,4-dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 52. ##STR00095## 2,4-diamino-6-((1-(5-
(difluoromethyl)-3-(3,5- difluorophenyl)-4-oxo-
3,4-dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile
a: (S)-enantiomer b: (R)-enantiomer 53. ##STR00096##
2,4-diamino-6-((1-(5- (difluoromethyl)-3-(3,5-
difluorophenyl)-4-oxo- 3,4-dihydroquinazolin-2-
yl)propyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 54. ##STR00097## 2,4-diamino-6-((1-(3-(3-
(difluoromethyl)-5- fluorophenyl)-5-fluoro-4- oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 55. ##STR00098##
2,4-diamino-6-((1-(5- chloro-3-(3- (difluoromethyl)-5-
fluorophenyl)-4-oxo-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 56. ##STR00099## 2,4-diamino-6-((1-(8-
(difluoromethyl)-4-oxo- 3-phenyl-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 57. ##STR00100## 2,4-diamino-6-((1-(8-
(difluoromethyl)-3-(3,5- difluorophenyl)-4-oxo-
3,4-dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 58. ##STR00101## 2,4-diamino-6-((1-(8-
fluoro-4-oxo-3-phenyl- 3,4-dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 59. ##STR00102## 2,4-diamino-6-((1-(5,8-
difluoro-4-oxo-3-phenyl- 3,4-dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 60. ##STR00103## 2,4-diamino-6-((1-(8-
fluoro-5-methyl-4-oxo-3- phenyl-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 61. ##STR00104## 2,4-diamino-6-((1-(5-
fluoro-8-methyl-4-oxo-3- phenyl-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 62. ##STR00105## 2,4-diamino-6-((1-(5-
(difluoromethyl)-4-oxo- 3-phenyl-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 63. ##STR00106## 2,4-diamino-6-((1-(3-(3-
cyanophenyl)-5- (difluoromethyl)-4-oxo- 3,4-dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 64. ##STR00107## 2,4-diamino-6-((1-(3-(3-
cyanophenyl)-8-fluoro-5- methyl-4-oxo-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 65. ##STR00108## 2,4-diamino-6-((1-(3-(3-
(difluoromethyl)-5- fluorophenyl)-5-fluoro-4- oxo-3,4-
dihydroquinazolin-2- yl)propyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 66. ##STR00109##
2,4-diamino-6-((1-(5- chloro-3-(3- (difluoromethyl)-5-
fluorophenyl)-4-oxo-3,4- dihydroquinazolin-2-
yl)propyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 67. ##STR00110## 2,4-diamino-6-((1-(8-
chloro-3-(3,5- difluorophenyl)-5-fluoro- 4-oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 68. ##STR00111##
2,4-diamino-6-((1-(3- (3,5-difluorophenyl)-8- methoxy-4-oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 69. ##STR00112##
2,4-diamino-6-((1-(3- (3,5-difluorophenyl)-6,8- difluoro-4-oxo-3,4-
dihydroquinazolin-2- yl)propyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 70. ##STR00113##
2,4-diamino-6-((1-(3- (3,5-difluorophenyl)-6,8- difluoro-4-oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 71. ##STR00114##
2,4-diamino-6-((1-(8- chloro-3-(3,5- difluorophenyl)-4-oxo-
3,4-dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile
a: (S)-enantiomer b: (R)-enantiomer 72. ##STR00115##
2,4-diamino-6-((1-(8- chloro-3-(3,5- difluorophenyl)-4-oxo-
3,4-dihydroquinazolin-2- yl)propyl)amino)pyrimidine- 5-carbonitrile
a: (S)-enantiomer b: (R)-enantiomer 73. ##STR00116##
2,4-diamino-6-((1-(5- chloro-3-(3,5- difluorophenyl)-8-
methyl-4-oxo-3,4- dihydroquinazolin-2- yl)ethyl)amino)pyrimidine-
5-carbonitrile a: (S)-enantiomer b: (R)-enantiomer 74. ##STR00117##
2,4-diamino-6-((1-(5,8- dichloro-3-(3,5- difluorophenyl)-4-oxo-
3,4-dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile
a: (S)-enantiomer b: (R)-enantiomer 75. ##STR00118##
2,4-diamino-6-((1-(3- (3,5-difluorophenyl)-8- methyl-4-oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 76. ##STR00119##
2,4-diamino-6-((1-(3- (3,5-difluorophenyl)-8- methyl-4-oxo-3,4-
dihydroquinazolin-2- yl)propyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 77. ##STR00120##
2,4-diamino-6-((1-(3- (3,5-difluorophenyl)-5- fluoro-4-oxo-3,4-
dihydroquinazolin-2- yl)propyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 78. ##STR00121##
2,4-diamino-6-((1-(5- chloro-3-(3,5- difluorophenyl)-4-oxo-
3,4-dihydroquinazolin-2- yl)propyl)amino)pyrimidine- 5-carbonitrile
a: (S)-enantiomer b: (R)-enantiomer 79. ##STR00122##
2,4-diamino-6-((1-(3- (3,5-difluorophenyl)-6,7- difluoro-4-oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 80. ##STR00123##
2,4-diamino-6-(((3-(3,5- difluorophenyl)-6,7- difluoro-4-oxo-3,4-
dihydroquinazolin-2- yl)methyl)amino)pyrimidine- 5-carbonitrile 81.
##STR00124## 2,4-diamino-6-((1-(5- fluoro-4-oxo-3-phenyl-
3,4-dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile
a: (S)-enantiomer b: (R)-enantiomer 82. ##STR00125##
2,4-diamino-6-((1-(3-(3- cyanophenyl)-5-fluoro-8- methyl-4-oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 83. ##STR00126##
2,4-diamino-6-((1-(3-(3- cyano-5-fluorophenyl)-5-
fluoro-8-methyl-4-oxo- 3,4-dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 84. ##STR00127## 2,4-diamino-6-(((8- chloro-3-(3-
cyanophenyl)-4-oxo-3,4- dihydroquinazolin-2-
yl)methyl)amino)pyrimidine- 5-carbonitrile 85. ##STR00128##
2,4-diamino-6-((1-(6- chloro-3-(3,5- difluorophenyl)-5-fluoro-
4-oxo-3,4- dihydroquinazolin-2- yl)ethyl)amino)pyrimidine-
5-carbonitrile a: (S)-enantiomer b: (R)-enantiomer 86. ##STR00129##
2,4-diamino-6-((1-(6- chloro-3-(3,5- difluorophenyl)-5-fluoro-
4-oxo-3,4- dihydroquinazolin-2- yl)propyl)amino)pyrimidine-
5-carbonitrile a: (S)-enantiomer b: (R)-enantiomer 87. ##STR00130##
5-(5-chloro-2-(1-((2,6- diamino-5- cyanopyrimidin-4-
yl)amino)ethyl)-4- oxoquinazolin-3(4H)- yl)isophthalonitrile a:
(S)-enantiomer b: (R)-enantiomer 88. ##STR00131##
2,4-diamino-6-((1-(3- (3,5- bis(trifluoromethyl)phen-
yl)-5-fluoro-4-oxo-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 89. ##STR00132## 2,4-diamino-6-((1-(8-
chloro-3-(3,5- difluorophenyl)-6-fluoro- 4-oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 90. ##STR00133##
2,4-diamino-6-(1-(5- chloro-3-(3,5- difluorophenyl)-4-oxo-
3,4-dihydroquinazolin-2- yl)ethylamino)pyrimidine- 5-carboxamide a:
(S)-enantiomer b: (R)-enantiomer 91. ##STR00134##
2-(1-((2,6-diamino-5- cyanopyrimidin-4- yl)amino)ethyl)-3-(3,5-
difluorophenyl)-4-oxo- 3,4-dihydroquinazoline- 5-carboxamide a:
(S)-enantiomer b: (R)-enantiomer 92. ##STR00135##
2-(1-((2,6-diamino-5- cyanopyrimidin-4- yl)amino)ethyl)-4-oxo-3-
phenyl-3,4- dihydroquinazoline-5- carboxamide a: (S)-enantiomer b:
(R)-enantiomer 93. ##STR00136## 2,4-diamino-6-(1-(5- chloro-3-(3-
(difluoromethyl)-5- fluorophenyl)-4-oxo-3,4- dihydroquinazolin-2-
yl)ethylamino)pyrimidine- 5-carboxamide a: (S)-enantiomer b:
(R)-enantiomer 94. ##STR00137## 5-chloro-2-(1-(2,6- diamino-5-
(methylsulfonyl)pyrimidin- 4-ylamino)ethyl)-3- (3,5-
difluorophenyl)quinazolin- 4(3H)-one a: (S)-enantiomer b:
(R)-enantiomer 95. ##STR00138## 2,4-diamino-6-(1-(5-
(methylsulfonyl)-4-oxo- 3-phenyl-3,4- dihydroquinazolin-2-
yl)ethylamino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 96. ##STR00139## 2,4-diamino-6-(1-(3-(3,5-
difluorophenyl)-5- (methylsulfonyl)-4-oxo- 3,4-dihydroquinazolin-2-
yl)ethylamino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 97. ##STR00140## 2,4-diamino-6-(1-(3-(3-
(difluoromethyl)phenyl)- 5-fluoro-4-oxo-3,4- dihydroquinazolin-2-
yl)ethylamino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 98. ##STR00141## 2,4-diamino-6-(1-(3-(3-
(difluoromethyl)-5- fluorophenyl)-5- (methylsulfonyl)-4-oxo-
3,4-dihydroquinazolin-2- yl)ethylamino)pyrimidine- 5-carbonitrile
a: (S)-enantiomer b: (R)-enantiomer 99. ##STR00142##
2,4-diamino-6-(1-(5- (difluoromethyl)-3-(3- (difluoromethyl)-5-
fluorophenyl)-4-oxo-3,4- dihydroquinazolin-2-
yl)ethylamino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 100. ##STR00143## 2,4-diamino-6-(1-(5- chloro-3-(3-
(difluoromethyl)phenyl)- 4-oxo-3,4- dihydroquinazolin-2-
yl)ethylamino)pyrimidine- 5-carboxamide a: (S)-enantiomer b:
(R)-enantiomer 101. ##STR00144## 2-(1-((2,6-diamino-5-
cyanopyrimidin-4- yl)amino)ethyl)-3-(3,5- difluorophenyl)-4-oxo-
3,4-dihydroquinazoline- 8-carbonitrile- a: (S)-enantiomer b:
(R)-enantiomer 102. ##STR00145## 2,4-diamino-6-((1-(8-
chloro-3-(3,5- difluorophenyl)-5-fluoro- 4-oxo-3,4-
dihydroquinazolin-2- yl)propyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 103. ##STR00146##
2,4-diamino-6-((1-(3- (3,5-difluorophenyl)-8- ethyl-4-oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 104. ##STR00147##
5-chloro-2-(1-((2,6- diamino-5- chloropyrimidin-4-
yl)amino)ethyl)-3- phenylquinazolin-4(3H)- one a: (S)-enantiomer b:
(R)-enantiomer 105. ##STR00148## 2-(1-((2,6-diamino-5-
chloropyrimidin-4- yl)amino)propyl)-3-(3,5- difluorophenyl)-5-
fluoroquinazolin-4(3H)- one a: (S)-enantiomer b: (R)-enantiomer
106. ##STR00149## 2,4-diamino-6-(1-(5- chloro-3-(3-
(difluoromethyl)phenyl)- 4-oxo-3,4- dihydroquinazolin-2-
yl)ethylamino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 107. ##STR00150## 2,4-diamino-6-(1-(5- chloro-3-(3-
isopropylphenyl)-4-oxo- 3,4-dihydroquinazolin-2-
yl)ethylamino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 108. ##STR00151## 2,4-diamino-6-(1-(5- chloro-3-(3-
fluorophenyl)-4-oxo-3,4- dihydroquinazolin-2-
yl)ethylamino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 109. ##STR00152## 2,4-diamino-6-(1-(5-
chloro-3-(3-methoxy-2- methylphenyl)-4-oxo-
3,4-dihydroquinazolin-2- yl)ethylamino)pyrimidine- 5-carbonitrile
a: (S)-enantiomer a-1 and a-2: atropisomers b: (R)-enantiomer b-1
and b-2: atropisomers 110. ##STR00153## 2,4-diamino-6-(1-(5-
chloro-3-(5 fluoro-3- methoxy-2- methylphenyl)-4-oxo-
3,4-dihydroquinazolin-2- yl)ethylamino)pyrimidine- 5-carbonitrile
a: (S)-enantiomer a-1 and a-2: atropisomers b: (R)-enantiomer b-1
and b-2: atropisomers 111 ##STR00154## 2,4-diamino-6-((1-(5-
methoxy-4-oxo-3- phenyl-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 112 ##STR00155## 2-(1-((2,6-diamino-5-
cyanopyrimidin-4- yl)amino)ethyl)-3-(3,5- difluorophenyl)-4-oxo-
3,4-dihydroquinazoline- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 113 ##STR00156## 3-(3-cyano-5- fluorophenyl)-2-(1-
((2,6-diamino-5- cyanopyrimidin-4- yl)amino)ethyl)-4-oxo-
3,4-dihydroquinazoline- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 114 ##STR00157## 2,4-diamino-6-((1-(3- (3-chloro-5-
(difluoromethyl)phenyl)- 5-fluoro-4-oxo-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer
115 ##STR00158## 2,4-diamino-6-((1-(5- chloro-3-(3-chloro-5-
(difluoromethyl)phenyl)- 4-oxo-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 116 ##STR00159## 2,4-diamino-6-((1-(3- (3-
(difluoromethyl)phenyl)- 5-(methylsulfonyl)-4- oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 117 ##STR00160##
2,4-diamino-6-((1-(3- (3-fluorophenyl)-5- (methylsulfonyl)-4-oxo-
3,4-dihydroquinazolin- 2- yl)ethyl)amino)pyrimidine- 5-carbonitrile
a: (S)-enantiomer b: (R)-enantiomer 118 ##STR00161##
2,4-diamino-6-((1-(3- (3,5- bis(difluoromethyl)phen-
yl)-5-fluoro-4-oxo-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 119 ##STR00162## 2,4-diamino-6-((1-(3- (3,5-
bis(difluoromethyl)phen- yl)-5-chloro-4-oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 120 ##STR00163##
2,4-diamino-6-((1-(5- chloro-3-(3-(2,2- difluoroethyl)phenyl)-4-
oxo-3,4- dihydroquinazolin-2- yl)ethyl)amino)pyrimidine-
5-carbonitrile a: (S)-enantiomer b: (R)-enantiomer 121 ##STR00164##
2,4-diamino-6-((1-(3- (3-(2,2- difluoroethyl)phenyl)-5-
fluoro-4-oxo-3,4- dihydroquinazolin-2- yl)ethyl)amino)pyrimidine-
5-carbonitrile a: (S)-enantiomer b: (R)-enantiomer 122 ##STR00165##
2-(1-((2,6-diamino-5- cyanopyrimidin-4- yl)amino)ethyl)-4-oxo-
3-phenyl-3,4- dihydroquinazoline-8- carbonitrile a: (S)-enantiomer
b: (R)-enantiomer 124 ##STR00166## 2-(1-((2,6-diamino-5-
cyanopyrimidin-4- yl)amino)ethyl)-8- fluoro-4-oxo-3-phenyl-
3,4-dihydroquinazoline- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 125 ##STR00167## 2-(1-((2,6-diamino-5-
cyanopyrimidin-4- yl)amino)ethyl)-3-(3,5- difluorophenyl)-8-
fluoro-4-oxo-3,4- dihydroquinazoline-5- carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 127 ##STR00168##
5-chloro-2-(1-((2,6- diamino-5- chloropyrimidin-4-
yl)amino)ethyl)-8- fluoro-3- phenylquinazolin- 4(3H)-one a:
(S)-enantiomer b: (R)-enantiomer 129 ##STR00169##
2,4-diamino-6-((1-(5- bromo-4-oxo-3-phenyl- 3,4-dihydroquinazolin-
2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 130 ##STR00170## 2,4-diamino-6-((1-(5- bromo-3-(3-
fluorophenyl)-4-oxo- 3,4-dihydroquinazolin- 2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 131 ##STR00171## 2-(1-((2,6-diamino-5-
cyanopyrimidin-4- yl)amino)ethyl)-3-(3- fluorophenyl)-4-oxo-
3,4-dihydroquinazoline- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 132 ##STR00172## 2,4-diamino-6-((3,3,3-
trifluoro-1-(6-fluoro-4- oxo-3-phenyl-3,4- dihydroquinazolin-2-
yl)propyl)amino)pyrimi- dine-5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 133 ##STR00173## 2,4-diamino-6-((1-(3-
(3,5-difluorophenyl)-6- fluoro-4-oxo-3,4- dihydroquinazolin-2-
yl)-3,3,3- trifluoropropyl)amino) pyrimidine-5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 135 ##STR00174##
2,4-diamino-6-((1-(5- chloro-3-(3,5- difluorophenyl)-4-oxo-
3,4-dihydroquinazolin- 2-yl)-2- methoxyethyl)amino)
pyrimidine-5-carbonitrile a: (S)-enantiomer b: (R)-enantiomer 136
##STR00175## 2,4-diamino-6-((1-(3- (3,5- bis(difluoromethyl)phen-
yl)-5-fluoro-4-oxo-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 137 ##STR00176## 2,4-diamino-6-((1-(3- (3,5-
bis(difluoromethyl)phen- yl)-5-chloro-4-oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 138 ##STR00177##
2-(1-((2,6-diamino-5- cyanopyrimidin-4- yl)amino)ethyl)-3-(3-
(difluoromethyl)-5- fluorophenyl)-4-oxo- 3,4-dihydroquinazoline-
5-carbonitrile a: (S)-enantiomer b: (R)-enantiomer 140 ##STR00178##
2,4-diamino-6-((1-(5- chloro-3-(3,5- difluorophenyl)-6-
fluoro-4-oxo-3,4- dihydroquinazolin-2- yl)ethyl)amino)pyrimidine-
5-carbonitrile a: (S)-enantiomer b: (R)-enantiomer 141 ##STR00179##
2,4-diamino-6-((1-(5- chloro-3-(3- (difluoromethyl)-5-
fluorophenyl)-6-fluoro- 4-oxo-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 145 ##STR00180## 2,4-diamino-6-((1-(5- (2,6-
difluorophenyl)-4-oxo- 3,4-dihydroquinazolin- 2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 146 ##STR00181## 2,4-diamino-6-((1-(3-
(2,6-difluorophenyl)-5- (methylsulfonyl)-4-oxo-
3,4-dihydroquinazolin- 2- yl)ethyl)amino)pyrimidine- 5-carbonitrile
a: (S)-enantiomer b: (R)-enantiomer 148 ##STR00182##
2,4-diamino-6-((1-(5,8- difluoro-3-(3- fluorophenyl)-4-oxo-
3,4-dihydroquinazolin- 2- yl)ethyl)amino)pyrimidine- 5-carbonitrile
a: (S)-enantiomer b: (R)-enantiomer 149 ##STR00183##
2,4-diamino-6-((1-(3- (3-cyanophenyl)-5,8- difluoro-4-oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 150 ##STR00184##
2,4-diamino-6-((1-(5,8- difluoro-4-oxo-3- phenyl-3,4-
dihydroquinazolin-2- yl)propyl)amino)pyrimi- dine-5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 151 ##STR00185##
2,4-diamino-6-((1-(5,8- difluoro-3-(3- fluorophenyl)-4-oxo-
3,4-dihydroquinazolin- 2- yl)propyl)amino)pyrimi-
dine-5-carbonitrile a: (S)-enantiomer b: (R)-enantiomer 152
##STR00186## 2,4-diamino-6-((1-(3- (3-cyanophenyl)-5,8-
difluoro-4-oxo-3,4- dihydroquinazolin-2- yl)propyl)amino)pyrimi-
dine-5-carbonitrile a: (S)-enantiomer b: (R)-enantiomer 153
##STR00187## 2-(1-((2,6-diamino-5- chloropyrimidin-4-
yl)amino)ethyl)-3-(3- fluorophenyl)-5- (methylsulfonyl)quina-
zolin-4(3H)-one a: (S)-enantiomer b: (R)-enantiomer 154
##STR00188## 2-(1-((2,6-diamino-5- cyanopyrimidin-4-
yl)amino)ethyl)-6- fluoro-3-(3- fluorophenyl)-4-oxo-
3,4-dihydroquinazoline- 8-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 155 ##STR00189## 2-(1-((2,6-diamino-5-
cyanopyrimidin-4- yl)amino)ethyl)-6- fluoro-4-oxo-3-phenyl-
3,4-dihydroquinazoline- 8-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 156 ##STR00190## 2,4-diamino-6-((1-(8-
methoxy-4-oxo-3- phenyl-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 159 ##STR00191## 2-(1-((2,6-diamino-5-
cyanopyrimidin-4- yl)amino)ethyl)-4-oxo- 3-phenyl-3,4-
dihydroquinazoline-6- carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 160 ##STR00192## 2-(1-((2,6-diamino-5-
cyanopyrimidin-4- yl)amino)ethyl)-3-(3- (difluoromethyl)phenyl)-
4-oxo-3,4- dihydroquinazoline-8- carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 161 ##STR00193## 2-(1-((2,6-diamino-5-
cyanopyrimidin-4- yl)amino)ethyl)-3-(3,5- difluorophenyl)-6-
fluoro-4-oxo-3,4- dihydroquinazoline-8- carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 162 ##STR00194##
2-(1-((2,6-diamino-5- cyanopyrimidin-4- yl)amino)ethyl)-4-oxo-
3-phenyl-3,4- dihydroquinazoline-5- carboxylic acid a:
(S)-enantiomer b: (R)-enantiomer 163 ##STR00195##
2,4-diamino-6-((1-(5- chloro-3-(3,5- difluorophenyl)-4-oxo-
3,4-hydroquinazolin- 2-yl)-3- methylbutyl)amino)
pyrimidine-5-carbonitrile a: (S)-enantiomer b: (R)-enantiomer 164
##STR00196## 2,4-diamino-6-((1-(5- chloro-3-(3,5-
difluorophenyl)-4-oxo- 3,4-dihydroquinazolin- 2-yl)-2-
methylbutyl)amino) pyrimidine-5-carbonitrile a: (1S, 2S) b: (1S,
2R) c: (1R, 1R) d: (1R, 2S) 165 ##STR00197## 2,4-diamino-6-((1-(5-
chloro-3-(3,5- difluorophenyl)-4-oxo- 3,4-dihydroquinazolin-
2-yl)-3,3,3- trifluoropropyl)amino) pyrimidine-5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 166 ##STR00198##
2,4-diamino-6-((1-(3- (3,5-difluorophenyl)-5- fluoro-4-oxo-3,4-
dihydroquinazolin-2- yl)-3,3,3- trifluoropropyl)amino)
pyrimidine-5-carbonitrile a: (S)-enantiomer b: (R)-enantiomer 167
##STR00199## 2,4-diamino-6-((1-(5- chloro-3-(3- cyanophenyl)-4-oxo-
3,4-dihydroquinazolin- 2-yl)-3- methylbutyl)amino)
pyrimidine-5-carbonitrile a: (S)-enantiomer b: (R)-enantiomer 168
##STR00200## 2,4-diamino-6-((1-(5- chloro-3-(3-
fluorophenyl)-4-oxo- 3,4-dihydroquinazolin- 2-yl)-3-
methylbutyl)amino) pyrimidine-5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 175 ##STR00201## 2,4-diamino-6-((1-(3-
(3,5-difluorophenyl)-5- fluoro-4-oxo-3,4- dihydroquinazolin-2-
yl)butyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 176 ##STR00202## 2,4-diamino-6-((1-(5- chloro-3-(3-
cyanophenyl)-6-fluoro- 4-oxo-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 178 ##STR00203## 2,4-diamino-6-((1-(6- fluoro-3-(3-
fluorophenyl)-4-oxo- 3,4-dihydroquinazolin- 2-
yl)propyl)amino)pyrimi- dine-5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 179 ##STR00204## 2,4-diamino-6-((1-(5- fluoro-3-(3-
fluorophenyl)-4-oxo- 3,4-dihydroquinazolin- 2-
yl)propyl)amino)pyrimi- dine-5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 181 ##STR00205## 2,4-diamino-6-((1-(5- chloro-3-(3-
cyanophenyl)-8-fluoro- 4-oxo-3,4- dihydroquinazolin-2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 182 ##STR00206## 2,4-diamino-6-((1-(5- fluoro-3-(3-
fluorophenyl)-4-oxo- 3,4-dihydroquinazolin- 2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 183 ##STR00207## 2,4-diamino-6-((1-(5-
chloro-4-oxo-3-phenyl- 3,4-dihydroquinazolin- 2-
yl)ethyl)amino)pyrimidine- 5-carboxamide a: (S)-enantiomer b:
(R)-enantiomer 184 ##STR00208## 2,4-diamino-6-((1-(5-
chloro-3-(3-methoxy-4- methylphenyl)-4-oxo- 3,4-dihydroquinazolin-
2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 185 ##STR00209## 2,4-diamino-6-((1-(5- chloro-3-(3-
methoxyphenyl)-4-oxo- 3,4-dihydroquinazolin- 2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 186 ##STR00210## 2,4-diamino-6-((1-(5-
chloro-3-(4-fluoro-3- methoxyphenyl)-4-oxo- 3,4-dihydroquinazolin-
2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 190 ##STR00211## 2,4-diamino-6-((1-(5- chloro-3-(3-
(difluoromethyl)-5- methoxyphenyl)-4-oxo- 3,4-dihydroquinazolin- 2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 192 ##STR00212## 2,4-diamino-6-((1-(5-
chloro-3-(3-fluoro-5- methoxyphenyl)-4-oxo- 3,4-dihydroquinazolin-
2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 193 ##STR00213## 2,4-diamino-6-((1-(5-
chloro-3-(3-fluoro-5- (trifluoromethoxy)phen- yl)-4-oxo-3,4-
dihydroquinazolin-2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 194 ##STR00214##
5-chloro-2-(1-((2,6- diamino-5- fluoropyrimidin-4-
yl)amino)ethyl)-3- phenylquinazolin- 4(3H)-one a: (S)-enantiomer b:
(R)-enantiomer 195 ##STR00215## 8-chloro-3-(1-((2,6- diamino-5-
chloropyrimidin-4- yl)amino)ethyl)-2- phenylisoquinolin- 1(2H)-one
a: (S)-enantiomer b: (R)-enantiomer
196 ##STR00216## 2,4-diamino-6-((1-(8- chloro-1-oxo-2-phenyl-
1,2-dihydroisoquinolin- 3- yl)ethyl)amino)pyrimidine-
5-carbonitrile a: (S)-enantiomer b: (R)-enantiomer 197 ##STR00217##
2,4-diamino-6-((1-(5- chloro-4-oxo-3-phenyl- 3,4-dihydroquinazolin-
2-yl)-2- methylpropyl)amino) pyrimidine-5-carbonitrile a:
(S)-enantiomer b: (R)-enantiomer 198 ##STR00218##
2,4-diamino-6-((1-(5- chloro-3-(3,5- difluorophenyl)-4-oxo-
3,4-dihydroquinazolin- 2-yl)-2- methylpropyl)amino)
pyrimidine-5-carbonitrile a: (S)-enantiomer b: (R)-enantiomer 205
##STR00219## 2,4-diamino-6-((1-(5- chloro-3-(3-fluoro-5-
methoxyphenyl)-4-oxo- 3,4-dihydroquinazolin- 2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 206 ##STR00220## 2,4-diamino-6-((1-(5- chloro-3-(3-
methoxyphenyl)-4-oxo- 3,4-dihydroquinazolin-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer b:
(R)-enantiomer 142 ##STR00221## 2,4-diamino-6-((1-(3-
(2-fluorophenyl)-5- (methylsulfonyl)-4-oxo- 3,4-dihydroquinazolin-
2- yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer a-1
and a-2: atropisomers b: (R)-enantiomer b-1 and b-2: atropisomers
187 ##STR00222## 2,4-diamino-6-((1-(5- chloro-3-(5-methoxy-2-
methylphenyl)-4-oxo- 3,4-dihydroquinazolin- 2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer a-1 and
a-2: atropisomers b: (R)-enantiomer b-1 and b-2: atropisomers 188
##STR00223## 2,4-diamino-6-((1-(5- chloro-3-(5- (difluoromethyl)-2-
methylphenyl)-4-oxo- 3,4-dihydroquinazolin- 2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer a-1 and
a-2: atropisomers b: (R)-enantiomer b-1 and b-2: atropisomers 189
##STR00224## 2,4-diamino-6-((1-(5- chloro-3-(3- (difluoromethyl)-2-
methylphenyl)-4-oxo- 3,4-dihydroquinazolin- 2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer a-1 and
a-2: atropisomers b: (R)-enantiomer b-1 and b-2: atropisomers 191
##STR00225## 2,4-diamino-6-((1-(5- chloro-3-(2,5-
dimethylphenyl)-4-oxo- 3,4-dihydroquinazolin- 2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer a-1 and
a-2: atropisomers b: (R)-enantiomer b-1 and b-2: atropisomers 199
##STR00226## 2,4-diamino-6-((1-(5- chloro-3-(3-fluoro-2-
methylphenyl)-4-oxo- 3,4-dihydroquinazolin- 2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer a-1 and
a-2: atropisomers b: (R)-enantiomer b-1 and b-2: atropisomers 200
##STR00227## 2,4-diamino-6-((1-(5- chloro-3-(3,5-difluoro-
2-methylphenyl)-4-oxo- 3,4-dihydroquinazolin- 2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer a-1 and
a-2: atropisomers b: (R)-enantiomer b-1 and b-2: atropisomers 201
##STR00228## 2,4-diamino-6-((1-(5- chloro-3-(5-fluoro-2-
methylphenyl)-4-oxo- 3,4-dihydroquinazolin- 2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer a-1 and
a-2: atropisomers b: (R)-enantiomer b-1 and b-2: atropisomers 202
##STR00229## 2,4-diamino-6-((1-(5- chloro-3-(2,3-
dimethylphenyl)-4-oxo- 3,4-dihydroquinazolin- 2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer a-1 and
a-2: atropisomers b: (R)-enantiomer b-1 and b-2: atropisomers 203
##STR00230## 2,4-diamino-6-((1-(5- chloro-3-(4-fluoro-2,3-
dimethylphenyl)-4-oxo- 3,4-dihydroquinazolin- 2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer a-1 and
a-2: atropisomers b: (R)-enantiomer b-1 and b-2: atropisomers 204
##STR00231## 2,4-diamino-6-((1-(5- chloro-3-(3,4-difluoro-
2-methylphenyl)-4-oxo- 3,4-dihydroquinazolin- 2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer a-1 and
a-2: atropisomers b: (R)-enantiomer b-1 and b-2: atropisomers 207
##STR00232## 2,4-diamino-6-((1-(5- chloro-3-(5-fluoro-3- methoxy-2-
methylphenyl)-4-oxo- 3,4-dihydroquinazolin- 2-
yl)ethyl)amino)pyrimidine- 5-carbonitrile a: (S)-enantiomer a-1 and
a-2: atropisomers b: (R)-enantiomer b-1 and b-2: atropisomers
[0236] Provided are also compounds of formula (J), (I), (IA-1),
(IA-2), (IB-1), (IB-2), (IB-3), or (IB-4), or pharmaceutically
acceptable salts, prodrugs, or solvates thereof, in which from 1 to
n hydrogen atoms attached to a carbon atom may be replaced by a
deuterium atom or D, in which n is the number of hydrogen atoms in
the molecule. As known in the art, the deuterium atom is a
non-radioactive isotope of the hydrogen atom. Such compounds may
increase resistance to metabolism, and thus may be useful for
increasing the half-life of the compounds of formula (J), (I),
(IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or (IB-4), or
pharmaceutically acceptable salts, prodrugs, or solvates thereof,
when administered to a mammal. See, e.g., Foster, "Deuterium
Isotope Effects in Studies of Drug Metabolism", Trends Pharmacol.
Sci., 5(12):524-527 (1984). Such compounds are synthesized by means
well known in the art, for example by employing starting materials
in which one or more hydrogen atoms have been replaced by
deuterium.
[0237] Provided are also pharmaceutically acceptable salts,
hydrates, solvates, tautomeric forms, polymorphs, and prodrugs of
the compounds of formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2),
(IB-3), or (IB-4).
[0238] "Pharmaceutically acceptable salts" include, for example,
salts with inorganic acids and salts with an organic acid. In
addition, if the compounds described herein are obtained as an acid
addition salt, the free base can be obtained by basifying a
solution of the acid salt. Conversely, if the product is a free
base, an addition salt, particularly a pharmaceutically acceptable
addition salt, may be produced by dissolving the free base in a
suitable organic solvent and treating the solution with an acid, in
accordance with conventional procedures for preparing acid addition
salts from base compounds. Those skilled in the art will recognize
various synthetic methodologies that may be used to prepare
nontoxic pharmaceutically acceptable addition salts.
[0239] A "solvate" is formed by the interaction of a solvent and a
compound. Solvates of salts of the compounds of formula (J), (I),
(IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or (IB-4) are also
provided. Hydrates of the compounds of formula (J), (I), (IA-1),
(IA-2), (IB-1), (IB-2), (IB-3), or (IB-4) are also provided.
[0240] A "prodrug" includes any compound that becomes a compound of
formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or (IB-4)
when administered to a subject, e.g., upon metabolic processing of
the prodrug.
[0241] In certain embodiments, provided are optical isomers,
racemates, atropisomers, or other mixtures thereof, of the
compounds of formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2),
(IB-3), or (IB-4), or pharmaceutically acceptable salts, prodrugs,
or solvates thereof. In those situations, the single enantiomer or
diastereomer, i.e., optically active form, can be obtained by
asymmetric synthesis or by resolution of the racemate. Resolution
of racemates can be accomplished, for example, by conventional
methods such as crystallization in the presence of a resolving
agent, or chromatography, using, for example a chiral high pressure
liquid chromatography (HPLC) column. In addition, provided are also
Z- and E-forms (or cis- and trans-forms) of the compounds of
formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or
(IB-4), or pharmaceutically acceptable salts, prodrugs, or solvates
thereof with carbon-carbon double bonds. Provided are also all
tautomeric forms of the compounds of formula (J), (I), (IA-1),
(IA-2), (IB-1), (IB-2), (IB-3), or (IB-4), or pharmaceutically
acceptable salts, prodrugs, or solvates thereof.
[0242] Compositions provided herein that include a compound of
formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or
(IB-4), or a pharmaceutically acceptable salt, prodrug, or solvate
thereof, may include racemic mixtures, or mixtures containing an
enantiomeric excess of one enantiomer or single diastereomers or
diastereomeric mixtures. All such isomeric forms of these compounds
are expressly included herein the same as if each and every
isomeric form were specifically and individually listed.
[0243] In certain embodiments, provided herein are also crystalline
and amorphous forms of the compounds of formula (J), (I), (IA-1),
(IA-2), (IB-1), (IB-2), (IB-3), or (IB-4), or pharmaceutically
acceptable salts, prodrugs, or solvates thereof.
[0244] In certain embodiments, provided are also chelates,
non-covalent complexes, and mixtures thereof, of the compounds of
formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or
(IB-4), or pharmaceutically acceptable salts, prodrugs, or solvates
thereof. A "chelate" is formed by the coordination of a compound to
a metal ion at two (or more) points. A "non-covalent complex" is
formed by the interaction of a compound and another molecule
wherein a covalent bond is not formed between the compound and the
molecule. For example, complexation can occur through van der Waals
interactions, hydrogen bonding, and electrostatic interactions
(also called ionic bonding).
Therapeutic Uses of the Compounds
[0245] The compounds of formula (J), (I), (IA-1), (IA-2), (IB-1),
(IB-2), (IB-3), or (IB-4), or a pharmaceutically acceptable salt,
prodrug, or solvate thereof may be used for the treatment of
diseases and/or conditions mediated by PI3K isomers, such as
MK& Thus, provided herein are methods for inhibiting one or
more PI3K isomers. In one embodiment, provided are methods for
inhibiting PI3K.delta. activity using a compound of formula (J),
(I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or (IB-4), or a
pharmaceutically acceptable salt, prodrug, or solvate thereof. The
MK isomers may be selectively or specifically inhibited.
Additionally, the compounds may be used to inhibit PI3K activity
therapeutically or prophylactically.
[0246] In some embodiments, the methods include administering a
compound of formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2),
(IB-3), or (IB-4), or a pharmaceutically acceptable salt, prodrug,
or solvate thereof, in a therapeutically effective amount to a
subject (including a human) in need thereof. The method can be
employed to treat a subject who has or is believed to have a
disease or condition whose symptoms or pathology is mediated by
PI3K.delta. expression or activity.
[0247] In addition to the therapeutic uses described herein,
certain compounds of formula (J), (I), (IA-1), (IA-2), (IB-1),
(IB-2), (IB-3), or (IB-4), or a pharmaceutically acceptable salt,
prodrug, or solvate thereof, have one or more properties selected
from: (i) selectivity to any PI3K isoforms, such as PI3K.delta.;
(ii) hepatocyte stability; and (iii) potency in a cellular assay.
In one embodiment, certain compounds of formula (J), (I), (IA-1),
(IA-2), (IB-1), (IB-2), (IB-3), or (IB-4), or a pharmaceutically
acceptable salt, prodrug, or solvate thereof, have selectivity to
any PI3K isoforms, such as PI3K.delta.. In other embodiments,
certain compounds of formula (J), (I), (IA-1), (IA-2), (IB-1),
(IB-2), (IB-3), or (IB-4), or a pharmaceutically acceptable salt,
prodrug, or solvate thereof, have selectivity to at least
PI3K.delta.. In yet other embodiments, certain compounds of formula
(J), (I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or (IB-4), or a
pharmaceutically acceptable salt, prodrug, or solvate thereof, have
one of the properties selected from: (i) selectivity to
PI3K.delta.; (ii) hepatocyte stability; and (iii) potency in a
cellular assay. In yet other embodiments, certain compounds of
formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or
(IB-4), or a pharmaceutically acceptable salt, prodrug, or solvate
thereof, have: selectivity to PI3K.delta. and hepatocyte stability;
or selectivity to PI3K.delta. and potency in a cellular assay: or
hepatocyte stability and potency in a cellular assay. In some
embodiments, certain compounds of formula (J), (I), (IA-1), (IA-2),
(IB-1), (IB-2), (IB-3), or (IB-4), or a pharmaceutically acceptable
salt, prodrug, or solvate thereof, have selectivity to PI3K.delta.,
hepatocyte stability, and potency in a cellular assay.
[0248] In another embodiment, certain compounds of formula (J),
(I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or (IB-4), or a
pharmaceutically acceptable salt, prodrug, or solvate thereof have
hepatocyte stability. Hepatocyte stability of a subject can be
determined using any methods currently known in the art, including
the methods described in the Examples below. For example,
hepatocyte stability may be characterized based on clearance or
half-life. In some embodiments, the half-life is greater than or
about 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9
hours, 10 hours, 11 hours, 12 hours, or 15 hours in human
hepatocytes.
[0249] In yet another embodiment, certain compounds of formula (J),
(I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or (IB-4), or a
pharmaceutically acceptable salt, prodrug, or solvate thereof have
potency in a cellular assay. Potency in a cellular assay can be
determined using any methods currently known in the art, including
the methods described in the Examples below. In some embodiments,
the activity in the cellular assay is less than 10 nM, 9 nM, 8 nM,
7 nM, 6 nM, 5 nM, 4 nM, 3 nM, 2 nM, 1 nM, 0.1 nM, or 0.01 nM.
[0250] For example, certain compounds may have selectivity to at
least one PI3K isomer, including PI3K.delta., and have hepatocyte
stability based on a half-life of greater than 3 hours.
[0251] "Treatment" or "treating" is an approach for obtaining
beneficial or desired results including clinical results.
Beneficial or desired clinical results may include one or more of
the following:
[0252] a) inhibiting the disease or condition (e.g., decreasing one
or more symptoms resulting from the disease or condition, and/or
diminishing the extent of the disease or condition);
[0253] b) slowing or arresting the development of one or more
clinical symptoms associated with the disease or condition (e.g.,
stabilizing the disease or condition, preventing or delaying the
worsening or progression of the disease or condition, and/or
preventing or delaying the spread (e.g., metastasis) of the disease
or condition); and/or
[0254] c) relieving the disease, that is, causing the regression of
clinical symptoms (e.g., ameliorating the disease state, providing
partial or total remission of the disease or condition, enhancing
effect of another medication, delaying the progression of the
disease, increasing the quality of life, and/or prolonging
survival.
[0255] "Prevention" or "preventing" means any treatment of a
disease or condition that causes the clinical symptoms of the
disease or condition not to develop. Compounds may, in some
embodiments, be administered to a subject (including a human) who
is at risk or has a family history of the disease or condition.
[0256] "Subject" refers to an animal, such as a mammal (including a
human), that has been or will be the object of treatment,
observation or experiment. The methods described herein may be
useful in human therapy and/or veterinary applications. In some
embodiments, the subject is a mammal. In one embodiment, the
subject is a human.
[0257] The term "therapeutically effective amount" of a compound of
formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or
(IB-4), or a pharmaceutically acceptable salt, prodrug, or solvate
thereof, means an amount sufficient to effect treatment when
administered to a subject, to provide a therapeutic benefit such as
amelioration of symptoms or slowing of disease progression. For
example, a therapeutically effective amount may be an amount
sufficient to decrease a symptom of a disease or condition
responsive to inhibition of PI3K.delta. activity. The
therapeutically effective amount may vary depending on the subject,
and disease or condition being treated, the weight and age of the
subject, the severity of the disease or condition, and the manner
of administering, which can readily be determined by one or
ordinary skill in the art.
[0258] The term "inhibition" indicates a decrease in the baseline
activity of a biological activity or process. "Inhibition of
activity of PI3K isomers" or variants thereof refer to a decrease
in activity in any PI3K isomer (e.g., alpha, beta, gamma, or delta)
as a direct or indirect response to the presence of a compound of
formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or
(IB-4), or a pharmaceutically acceptable salt, prodrug, or solvent
thereof, relative to the activity of PI3K isomer in the absence of
the compound of formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2),
(IB-3), or (IB-4), or a pharmaceutically acceptable salt, prodrug,
or solvent thereof. "Inhibition of PI3K.delta. activity" or
variants thereof refer to a decrease in PI3K.delta. activity as a
direct or indirect response to the presence of a compound of
formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or
(IB-4), or a pharmaceutically acceptable salt, prodrug, or solvate
thereof, relative to the activity of PI3K.delta. in the absence of
the compound of formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2),
(IB-3), or (IB-4), or a pharmaceutically acceptable salt, prodrug,
or solvate thereof. In some embodiments, the inhibition of
PI3K.delta. activity may be compared in the same subject prior to
treatment, or other subjects not receiving the treatment.
[0259] Without wishing to be bound to any theory, the decrease in
PI3K.delta. activity may be due to the direct interaction of the
compound with PI3K.delta., or due to the interaction of the
compounds described herein with one or more other factors that in
turn affect PI3K.delta. activity. For example, the presence of the
compounds of formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2),
(IB-3), or (IB-4), or a pharmaceutically acceptable salt, prodrug,
or solvate thereof, may decrease PI3K.delta. activity by directly
binding to the PI3K.delta., by causing (directly or indirectly)
another factor to decrease PI3K.delta. activity, or by (directly or
indirectly) decreasing the amount of PI3K.delta. present in the
cell or organism.
[0260] The terms "PI3K isoform selective inhibitor" generally
refers to a compound that inhibits the activity of one or more PI3K
isoforms more effectively than the other remaining PI3K isoforms.
By way of example, the term "PI3K.delta. selective inhibitor"
generally refers to a compound that inhibits the activity of the
PI3K.delta. isoform more effectively than other isoforms of the
PI3K family (e.g., PI3K .alpha., .beta., or .gamma.). The term
"PI3K.alpha. selective inhibitor" generally refers to a compound
that inhibits the activity of the PI3K.alpha. isoform more
effectively than other isoforms of the PI3K family (e.g., PI3K
.beta., .delta., or .gamma.). The term "PI3K.beta. selective
inhibitor" generally refers to a compound that inhibits the
activity of the PI3K.beta. isoform more effectively than other
isoforms of the PI3K family (e.g., PI3K .alpha., .delta., or
.gamma.). The term "dual PI3K.alpha./.beta. selective inhibitor
generally refers to a compound that inhibits the activity of the
PI3K.alpha. and PI3K.beta. isoforms more effectively than other
isoforms of the PI3K family (e.g., PI3K .delta. or .gamma.).
[0261] The relative efficacies of compounds as inhibitors of an
enzyme activity (or other biological activity) can be established
by determining the concentrations at which each compound inhibits
the activity to a predefined extent and then comparing the results.
In one embodiment, the efficacy of a compound as an inhibitor of
one or more PI3K isoforms can be measured by the concentration that
inhibits 50% of the activity in a biochemical assay, i.e., the 50%
inhibitory concentration or "IC.sub.50". IC.sub.50 determinations
can be accomplished using conventional techniques known in the art,
including the techniques describes in the Examples below. In
general, an IC.sub.50 can be determined by measuring the activity
of a given enzyme in the presence of a range of concentrations of
the compound under study. The experimentally obtained values of
enzyme activity may then be plotted against the compound
concentrations used. The concentration of the inhibitor that shows
50% enzyme activity (as compared to the activity in the absence of
any inhibitor) is taken as the IC.sub.50 value. Analogously, other
inhibitory concentrations can be defined through appropriate
determinations of activity. For example, in some settings it may be
desirable to establish a 90% inhibitory concentration, i.e.,
IC.sub.90.
[0262] In one embodiment, a PI3K.delta. selective inhibitor is a
compound that exhibits a 50% inhibitory concentration (IC.sub.50)
with respect to PI3K.delta. that is at least 10-fold, in another
aspect at least 20-fold, and in another aspect at least 30-fold,
lower than the IC.sub.50 value with respect to any or all of the
other Class I PI3K family members. In another embodiment, a
PI3K.delta. selective inhibitor is a compound that exhibits an
IC.sub.50 with respect to PI3K.delta. that is at least 50-fold, in
another aspect at least 100-fold, in an additional aspect at least
200-fold, and in yet another aspect at least 500-fold, lower than
the IC.sub.50 with respect to any or all of the other PI3K Class I
family members. A PI3K.delta. selective inhibitor is typically
administered in an amount such that it selectively inhibits
PI3K.delta. activity, as described above.
[0263] In one embodiment, a PI3K.alpha. selective inhibitor is a
compound that exhibits a 50% inhibitory concentration (IC.sub.50)
with respect to PI3K.beta. that is at least 10-fold, in another
aspect at least 20-fold, and in another aspect at least 30-fold,
lower than the IC.sub.50 value with respect to any or all of the
other Class I PI3K family members. In another embodiment, a
PI3K.alpha. selective inhibitor is a compound that exhibits an
IC.sub.50 with respect to PI3K.alpha. that is at least 50-fold, in
another aspect at least 100-fold, in an additional aspect at least
200-fold, and in yet another aspect at least 500-fold, lower than
the IC.sub.50 with respect to any or all of the other PI3K Class I
family members. A PI3K.alpha. selective inhibitor is typically
administered in an amount such that it selectively inhibits
PI3K.alpha. activity, as described above
[0264] In one embodiment, a PI3K.beta. selective inhibitor is a
compound that exhibits a 50% inhibitory concentration (IC.sub.50)
with respect to PI3K.beta. that is at least 10-fold, in another
aspect at least 20-fold, and in another aspect at least 30-fold,
lower than the IC.sub.50 value with respect to any or all of the
other Class I PI3K family members. In another embodiment, a
PI3K.beta. selective inhibitor is a compound that exhibits an
IC.sub.50 with respect to PI3K.beta. that is at least 50-fold, in
another aspect at least 100-fold, in an additional aspect at least
200-fold, and in yet another aspect at least 500-fold, lower than
the IC.sub.50 with respect to any or all of the other PI3K Class I
family members. A PI3K.beta. selective inhibitor is typically
administered in an amount such that it selectively inhibits
PI3K.beta. activity, as described above.
[0265] In one embodiment, a dual PI3K.alpha./.beta. selective
inhibitor is a compound that exhibits a 50% inhibitory
concentration (IC.sub.50) with respect to PI3K.alpha. and
PI3K.beta. that is at least 10-fold, in another aspect at least
20-fold, and in another aspect at least 30-fold, lower than the
IC.sub.50 value with respect to any or all of the other Class I
PI3K family members. In another embodiment, a dual
PI3K.alpha./.beta. selective inhibitor is a compound that exhibits
an IC.sub.50 with respect to PI3K.alpha. and PI3K.beta. that is at
least 50-fold, in another aspect at least 100-fold, in an
additional aspect at least 200-fold, and in yet another aspect at
least 500-fold, lower than the IC.sub.50 with respect to any or all
of the other PI3K Class I family members. A dual PI3K.alpha./.beta.
selective inhibitor is typically administered in an amount such
that it selectively inhibits PI3K.alpha. and PI3K.beta. activity,
as described above.
[0266] The methods described herein may be applied to cell
populations in vivo or ex vivo. "In vivo" means within a living
individual, as within an animal or human. In this context, the
methods described herein may be used therapeutically in an
individual. "Ex vivo" means outside of a living individual.
Examples of ex vivo cell populations include in vitro cell cultures
and biological samples including fluid or tissue samples obtained
from individuals. Such samples may be obtained by methods well
known in the art. Exemplary biological fluid samples include blood,
cerebrospinal fluid, urine, and saliva. Exemplary tissue samples
include tumors and biopsies thereof. In this context, the invention
may be used for a variety of purposes, including therapeutic and
experimental purposes. For example, the invention may be used ex
vivo to determine the optimal schedule and/or dosing of
administration of a PI3K.delta. selective inhibitor for a given
indication, cell type, individual, and other parameters.
Information gleaned from such use may be used for experimental
purposes or in the clinic to set protocols for in vivo treatment.
Other ex vivo uses for which the invention may be suited are
described below or will become apparent to those skilled in the
art. The selected compounds of formula (J), (I), (IA-1), (IA-2),
(IB-1), (IB-2), (IB-3), or (IB-4), or a pharmaceutically acceptable
salt, prodrug, or solvate thereof, may be further characterized to
examine the safety or tolerance dosage in human or non-human
subjects. Such properties may be examined using commonly known
methods to those skilled in the art.
[0267] Compared to other PI3K isoforms, PI3K.delta. is generally
expressed in hematopoietic cells. Consequently, the direct effects
of selective inhibitors of PI3K.delta. can be observed in
hematopoietic cells. Hematopoietic cells typically differentiate
into either lymphoid progenitor cells or myeloid progenitor cells,
both of which ultimately differentiate into various mature cell
types including leukocytes. Aberrant proliferation of hematopoietic
cells of one type often interferes with the production or survival
of other hematopoietic cell types, which can result in compromised
immunity, anemia, and/or thrombocytopenia. The methods described
herein may treat aberrant proliferation of hematopoietic cells by
inhibiting aberrant proliferation of hematopoietic cells. As a
result, these methods may also ameliorate the symptoms and
secondary conditions that result from a primary effect such as
excessive system or localized levels of leukocytes or
lymphocytes.
[0268] In some embodiments, the compounds described herein may be
used to treat subjects having various disease states, disorders,
and conditions (also collectively referred to as "indications")
involving aberrant proliferation of hematopoietic cells (including
excessive production of lymphoid progenitor cell-derived cells
and/or myeloid progenitor cell-derived cells). Such indications may
include, for example, leukemias, lymphomas, myeloproliferative
disorders, myelodysplastic syndromes, and plasma cell neoplasms. In
certain embodiments, the compounds described herein may be used to
treat hematologic malignancies, inflammation, autoimmune disorders,
allergic conditions, cardiovascular disease, and autoimmune
diseases. In certain embodiments, allergic conditions may include
all forms of hypersensitivity.
[0269] In other embodiments, the compounds described herein may be
used to treat cancers that are mediated by, dependent on or
associated with PI3K activity, such as PI3K.delta. activity. In
certain embodiments, the disease is a hematologic malignancy. In
certain embodiments, the disease is lymphoma, multiple myeloma, or
leukemia. In particular embodiments, the hematologic malignancy is
leukemia or lymphoma. In specific embodiments, the disease is acute
lymphocytic leukemia (ALL), acute myeloid leukemia (AML), chronic
lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL),
myelodysplastic syndrome (MDS), myeloproliferative disease (MPD),
chronic myeloid leukemia (CML), juvenile myelomonocytic leukemia
(JMML), multiple myeloma (MM), Hodgkin lymphoma, indolent
non-Hodgkin's lymphoma (iNHL), refractory iNHL, non-Hodgkin's
lymphoma (NHL), mantle cell lymphoma (MCL), follicular lymphoma,
Waldestrom's macroglobulinemia (WM), minimal residual disease
(MRD), T-cell lymphoma, B-cell lymphoma, diffuse large B-cell
lymphoma (DLBCL), T-cell acute lymphoblastic leukemia (T-ALL),
B-cell acute lymphoblastic leukemia (B-ALL), lymphoplasmacytic
lymphoma, marginal zone lymphoma, or Burkitt lymphoma. In one
embodiment, the disease is T-cell acute lymphoblastic leukemia
(T-ALL), or B-cell acute lymphoblastic leukemia (B-ALL). It should
be understood that the non-Hodgkin lymphoma may, in certain
embodiments, encompass the indolent B-cell diseases that include,
for example, follicular lymphoma, lymphoplasmacytic lymphoma,
Waldenstrom macroglobulinemia, and marginal zone lymphoma, as well
as the aggressive lymphomas that include, for example, Burkitt
lymphoma, diffuse large B-cell lymphoma (DLBCL) and mantle cell
lymphoma (MCL).
[0270] In other embodiments, the disease is a solid tumor. In
particular embodiments, the solid tumor is from pancreatic cancer,
bladder cancer, colorectal cancer, breast cancer, prostate cancer,
renal cancer, hepatocellular cancer, lung cancer, ovarian cancer,
cervical cancer, gastric cancer, esophageal cancer, head and neck
cancer, melanoma, neuroendocrine cancers, CNS cancers, brain tumors
(e.g., glioma, anaplastic oligodendroglioma, adult glioblastoma
multiforme, and adult anaplastic astrocytoma), bone cancer, or soft
tissue sarcoma. In some embodiments, the solid tumor is from
non-small cell lung cancer, small-cell lung cancer, colon cancer,
CNS cancer, melanoma, ovarian cancer, renal cancer, prostate
cancer, or breast cancer.
[0271] In some embodiments, the disease is an autoimmune disease.
In particular embodiments, the autoimmune disease is systemic lupus
erythematosus (SLE), myestenia gravis, rheumatoid arthritis (RA),
acute disseminated encephalomyelitis, idiopathic thrombocytopenic
purpura, multiple sclerosis (MS), Sjoegren's syndrome, psoriasis,
autoimmune hemolytic anemia, asthma, or chronic obstructive
pulmonary disease (COPD). In other embodiments, the disease is
inflammation. In yet other embodiments, the disease is excessive or
destructive immune reactions, such as asthma, rheumatoid arthritis,
multiple sclerosis, chronic obstructive pulmonary disease (COPD),
and lupus.
[0272] Provided is a method for treating a subject, who has or is
suspected of having a disease or condition responsive or believed
to be responsive to the inhibition of PI3K.delta. activity by
administering to the subject a compound of formula (J), (I),
(IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or (IB-4), or a
pharmaceutically acceptable salt, prodrug, or solvate thereof.
[0273] Provided is also a method of inhibiting kinase activity of a
phosphatidylinositol 3-kinase delta polypeptide by contacting the
polypeptide with a compound of formula (J), (I), (IA-1), (IA-2),
(IB-1), (IB-2), (IB-3), or (IB-4), or a pharmaceutically acceptable
salt, prodrug, or solvate thereof.
[0274] Provided is also a method of disrupting leukocyte function
comprising contacting the leukocytes with an effective amount of a
compound of formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2),
(IB-3), or (IB-4), or a pharmaceutically acceptable salt, prodrug,
or solvate thereof, in a subject in need thereof (e.g., a
human).
[0275] Provided is also a method of inhibiting a growth or a
proliferation of cancer cells of hematopoietic origin comprising
contacting the cancer cells with an effective amount of a compound
of formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or
(IB-4), or a pharmaceutically acceptable salt, prodrug, or solvate
thereof. Also provided is a method for increasing sensitivity of
cancer cells to chemotherapy, comprising administering to a patient
undergoing chemotherapy with a chemotherapeutic agent an amount a
compound of formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2),
(IB-3), or (IB-4), or a pharmaceutically acceptable salt, prodrug,
or solvate thereof, sufficient to increase the sensitivity of
cancer cells to the chemotherapeutic agent.
Combination Therapies
[0276] In one embodiment, the compounds of the present application
(e.g., a compound of formula (J), (I), (IA-1), (IA-2), (IB-1),
(IB-2), (IB-3), or (IB-4), or a pharmaceutically acceptable salt,
prodrug, or solvate thereof) may be used in combination with one or
more additional therapeutic agent that are being used and/or
developed to treat cancers or inflammatory disorders. The one or
more additional therapeutic agent may be an inhibitor to PI3K such
as PI3K.gamma., PI3K.beta., and/or PI3K.alpha., Janus kinase (JAK)
such as JAK1, JAK2 and/or JAK3, spleen tyrosine kinase (SYK),
Bruton's tyrosine kinase (BTK), bromodomain containing protein
inhibitor (BRD) such as BRD4, a lysyl oxidase protein (LOX), lysyl
oxidase-like protein (LOXL) such as LOXL1-5, matrix metalloprotease
(MMP) such as MMP 1-10, adenosine A2B receptor (A2B), isocitrate
dehydrogenase (IDH) such as IDH1, apoptosis signal-regulating
kinase (ASK) such as ASK1, serine/threonine kinase TPL2, discoidin
domain receptor (DDR) such as DDR1 and DDR2, histone deacetylase
(HDAC), protein kinase C (PKC), or any combination thereof.
[0277] One, two, three, or more of the therapeutic agents (e.g. a
PI3K inhibitor, a JAK inhibitor, a SYK inhibitor, a BTK inhibitor,
a BRD4 inhibitor, a LOXL2 inhibitor, a MMP9 inhibitor, a A2B
inhibitor, an IDH inhibitor, an ASK inhibitor, a TPL2 inhibitor, a
DDR1 inhibitor, a TBK inhibitor, a HDAC inhibitor, a PKC inhibitor)
may be further used or combined with a chemotherapeutic agent, an
immunotherapeutic agent, a radiotherapeutic agent, an
anti-neoplastic agent, an anti-cancer agent, an anti-fibrotic
agent, an anti-angiogenic agent, a therapeutic antibody, or any
combination thereof.
[0278] Chemotherapeutic agents may be categorized by their
mechanism of action into, for example, the following groups:
anti-metabolites/anti-cancer agents, such as pyrimidine analogs
(floxuridine, capecitabine, and cytarabine); purine analogs, folate
antagonists and related inhibitors antiproliferative/antimitotic
agents including natural products such as vinca alkaloid
(vinblastine, vincristine) and microtubule such as taxane
(paclitaxel, docetaxel), vinblastin, nocodazole, epothilones and
navelbine, epidipodophyllotoxins (etoposide, teniposide); DNA
damaging agents (actinomycin, amsacrine, busulfan, carboplatin,
chlorambucil, cisplatin, cyclophosphamide, Cytoxan, dactinomycin,
daunorubicin, doxorubicin, epirubicin, iphosphamide, melphalan,
merchlorehtamine, mitomycin, mitoxantrone, nitrosourea,
procarbazine, taxol, taxotere, teniposide, etoposide,
triethylenethiophosphoramide); antibiotics such as dactinomycin
(actinomycin D), daunorubicin, doxorubicin (adriamycin),
idarubicin, anthracyclines, mitoxantrone, bleomycins, plicamycin
(mithramycin) and mitomycin; enzymes (L-asparaginase which
systemically metabolizes L-asparagine and deprives cells which do
not have the capacity to synthesize their own asparagine);
antiplatelet agents; antiproliferative/antimitotic alkylating
agents such as nitrogen mustards cyclophosphamide and analogs,
melphalan, chlorambucil), and (hexamethylmelamine and thiotepa),
alkyl nitrosoureas (BCNU) and analogs, streptozocin),
trazenes-dacarbazinine (DTIC); antiproliferative/antimitotic
antimetabolites such as folic acid analogs (methotrexate); platinum
coordination complexes (cisplatin, oxiloplatinim, carboplatin),
procarbazine, hydroxyurea, mitotane, aminoglutethimide; hormones,
hormone analogs (estrogen, tamoxifen, goserelin, bicalutamide,
nilutamide) and aromatase inhibitors (letrozole, anastrozole);
anticoagulants (heparin, synthetic heparin salts and other
inhibitors of thrombin); fibrinolytic agents (such as tissue
plasminogen activator, streptokinase and urokinase), aspirin,
dipyridamole, ticlopidine, clopidogrel; antimigratory agents;
antisecretory agents (breveldin); immunosuppressives tacrolimus
sirolimus azathioprine, mycophenolate; compounds (TNP-470,
genistein) and growth factor inhibitors (vascular endothelial
growth factor inhibitors, fibroblast growth factor inhibitors);
angiotensin receptor blocker, nitric oxide donors; anti-sense
oligonucleotides; antibodies (trastuzumab, rituximab); cell cycle
inhibitors and differentiation inducers (tretinoin); inhibitors,
topoisomerase inhibitors (doxorubicin (adriamycin), daunorubicin,
dactinomycin, eniposide, epirubicin, etoposide, idarubicin,
irinotecan and mitoxantrone, topotecan, irinotecan, camptothesin),
corticosteroids (cortisone, dexamethasone, hydrocortisone,
methylpednisolone, prednisone, and prenisolone); growth factor
signal transduction kinase inhibitors; dysfunction inducers, toxins
such as Cholera toxin, ricin, Pseudomonas exotoxin, Bordetella
pertussis adenylate cyclase toxin, or diphtheria toxin, and caspase
activators; and chromatin.
[0279] As used herein the term "chemotherapeutic agent" or
"chemotherapeutic" (or "chemotherapy," in the case of treatment
with a chemotherapeutic agent) may encompass any non-proteinaceous
(e.g., non-peptidic) chemical compound useful in the treatment of
cancer. Examples of chemotherapeutic agents include alkylating
agents such as thiotepa and cyclophosphamide; alkyl sulfonates such
as busulfan, improsulfan and piposulfan; aziridines such as
benzodopa, carboquone, meturedopa, and uredopa; emylerumines and
memylamelamines including alfretamine, triemylenemelamine,
triethylenephosphoramide, triethylenethiophosphoramide and
trimemylolomelamine; acetogenins (especially bullatacin and
bullatacinone); a camptothecin (including synthetic analogue
topotecan); bryostatin; callystatin; CC-1065 (including its
adozelesin, carzelesin and bizelesin synthetic analogues);
cryptophycins (articularly cryptophycin 1 and cryptophycin 8);
dolastatin; duocarmycin (including the synthetic analogues, KW-2189
and CBI-TMI); eleutherobin; pancratistatin; a sarcodictyin;
spongistatin; nitrogen mustards such as chlorambucil,
chlornaphazine, cholophosphamide, estramustine, ifosfamide,
mechlorethamine, mechlorethamine oxide hydrochloride, melphalan,
novembichin, phenesterine, prednimustine, trofosfamide, uracil
mustard; nitrosoureas such as carmustine, chlorozotocin,
foremustine, lomustine, nimustine, ranimustine; antibiotics such as
the enediyne antibiotics (e.g., calicheamicin, especially
calicheamicin gammaII and calicheamicin phiI1, see, e.g., Agnew,
Chem. Intl. Ed. Engl, 33:183-186 (1994); dynemicin, including
dynemicin A; bisphosphonates, such as clodronate; an esperamicin;
as well as neocarzinostatin chromophore and related chromoprotein
enediyne antibiotic chromomophores), aclacinomysins, actinomycin,
authramycin, azaserine, bleomycins, cactinomycin, carabicin,
carrninomycin, carzinophilin, chromomycins, dactinomycin,
daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin
(including morpholino-doxorubicin, cyanomorpholino-doxorubicin,
2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin,
esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin
C, mycophenolic acid, nogalamycin, olivomycins, peplomycin,
potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin,
streptozocin, tubercidin, ubenimex, zinostatin, zorubicin;
anti-metabolites such as methotrexate and 5-fluorouracil (5-FU);
folic acid analogues such as demopterin, methotrexate, pteropterin,
trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine,
thiamiprine, thioguanine; pyrimidine analogues such as ancitabine,
azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine,
doxifluridine, enocitabine, floxuridine; androgens such as
calusterone, dromostanolone propionate, epitiostanol, mepitiostane,
testolactone; anti-adrenals such as aminoglutethimide, mitotane,
trilostane; folic acid replinisher such as frolinic acid;
aceglatone; aldophosphamide glycoside; aminolevulinic acid;
eniluracil; amsacrine; hestrabucil; bisantrene; edatraxate;
defofamine; demecolcine; diaziquone; elformthine; elliptinium
acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea;
lentinan; leucovorin; lonidamine; maytansinoids such as maytansine
and ansamitocins; mitoguazone; mitoxantrone; mopidamol; nitracrine;
pentostatin; phenamet; pirarubicin; losoxantrone; fluoropyrimidine;
folinic acid; podophyllinic acid; 2-ethylhydrazide; procarbazine;
PSK.RTM.; razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic
acid; triaziquone; 2,2',2''-tricUorotriemylamine; trichothecenes
(especially T-2 toxin, verracurin A, roridin A and anguidine);
urethane; vindesine; dacarbazine; mannomustine; mitobronitol;
mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C");
cyclophosphamide; thiopeta; taxoids, e.g., paclitaxel (TAXOL.RTM.)
and docetaxel (TAXOTERE.RTM.); chlorambucil; gemcitabine
(Gemzar.RTM.); 6-thioguanine; mercaptopurine; methotrexate;
platinum analogs such as cisplatin and carboplatin; vinblastine;
platinum; etoposide (VP-16); ifosfamide; mitroxantrone;
vancristine; vinorelbine (Navelbine.RTM.); novantrone; teniposide;
edatrexate; daunomycin; aminopterin; xeoloda; ibandronate; CPT-11;
topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO);
retinoids such as retinoic acid; capecitabine; FOLFIRI
(fluorouracil, leucovorin, and irinotecan) and pharmaceutically
acceptable salts, acids or derivatives of any of the above. One or
more chemotherapeutic agent are used or included in the present
application. For example, gemcitabine, nab-paclitaxel, and
gemcitabine/nab-paclitaxel are used with the JAK inhibitor and/or
PI3K.delta. inhibitor for treating hyperproliferative
disorders.
[0280] Chemotherapeutic agents may also include, for example,
anti-hormonal agents that act to regulate or inhibit hormone action
on tumors such as anti-estrogens and selective estrogen receptor
modulators (SERMs), including, for example, tamoxifen (including
Nolvadex.TM.), raloxifene, droloxifene, 4-hydroxytamoxifen,
trioxifene, keoxifene, LY117018, onapristone, and toremifene
(Fareston.RTM.); inhibitors of the enzyme aromatase, which
regulates estrogen production in the adrenal glands, such as, for
example, 4(5)-imidazoles, aminoglutethimide, megestrol acetate
(Megace.RTM.), exemestane, formestane, fadrozole, vorozole
(Rivisor.RTM.), letrozole (Femara.RTM.), and anastrozole
(Arimidex.RTM..); and anti-androgens such as flutamide, nilutamide,
bicalutamide, leuprohde, and goserelin; and pharmaceutically
acceptable salts, acids or derivatives of any of the above.
[0281] The anti-angiogenic agents include, but are not limited to,
retinoid acid and derivatives thereof, 2-methoxyestradiol,
ANGIOSTATIN.RTM., ENDOSTATIN.RTM., suramin, squalamine, tissue
inhibitor of metalloproteinase-1, tissue inhibitor of
metalloproternase-2, plasminogen activator inhibitor-1, plasminogen
activator inbibitor-2, cartilage-derived inhibitor, paclitaxel
(nab-paclitaxel), platelet factor 4, protamine sulphate (clupeine),
sulphated chitin derivatives (prepared from queen crab shells),
sulphated polysaccharide peptidoglycan complex (sp-pg),
staurosporine, modulators of matrix metabolism, including for
example, proline analogs ((1-azetidine-2-carboxylic acid (LACA),
cishydroxyproline, d,I-3,4-dehydroproline, thiaproline,
.alpha.-dipyridyl, beta-aminopropionitrile fumarate,
4-propyl-5-(4-pyridinyl)-2(3h)-oxazolone; methotrexate,
mitoxantrone, heparin, interferons, 2 macroglobulin-serum, chimp-3,
chymostatin, beta-cyclodextrin tetradecasulfate, eponemycin;
fumagillin, gold sodium thiomalate, d-penicillamine (CDPT),
beta-1-anticollagenase-serum, alpba-2-antiplasmin, bisantrene,
lobenzarit disodium, n-2-carboxyphenyl-4-chloroanthronilic acid
disodium or "CCA", thalidomide; angiostatic steroid,
cargboxynaminolmidazole; metalloproteinase inhibitors such as BB94.
Other anti-angiogenesis agents include antibodies, preferably
monoclonal antibodies against these angiogenic growth factors:
beta-FGF, alpha-FGF, FGF-5, VEGF isoforms, VEGF-C, HGF/SF and
Ang-1/Ang-2. See Ferrara N. and Alitalo, K. "Clinical application
of angiogenic growth factors and their inhibitors" (1999) Nature
Medicine 5:1359-1364.
[0282] The anti-fibrotic agents include, but are not limited to,
the compounds such as beta-aminoproprionitrile (BAPN), as well as
the compounds disclosed in U.S. Pat. No. 4,965,288 to Palfreyman,
et al., issued Oct. 23, 1990, entitled "Inhibitors of lysyl
oxidase," relating to inhibitors of lysyl oxidase and their use in
the treatment of diseases and conditions associated with the
abnormal deposition of collagen; U.S. Pat. No. 4,997,854 to Kagan,
et al., issued Mar. 5, 1991, entitled "Anti-fibrotic agents and
methods for inhibiting the activity of lysyl oxidase in situ using
adjacently positioned diamine analogue substrate," relating to
compounds which inhibit LOX for the treatment of various
pathological fibrotic states, which are herein incorporated by
reference. Further exemplary inhibitors are described in U.S. Pat.
No. 4,943,593 to Palfreyman, et al., issued Jul. 24, 1990, entitled
"Inhibitors of lysyl oxidase," relating to compounds such as
2-isobutyl-3-fluoro-, chloro-, or bromo-allylamine; as well as,
e.g., U.S. Pat. No. 5,021,456; U.S. Pat. No. 5,5059,714; U.S. Pat.
No. 5,120,764; U.S. Pat. No. 5,182,297; U.S. Pat. No. 5,252,608
(relating to 2-(1-naphthyloxymemyl)-3-fluoroallylamine); and U.S.
Patent Application No. 2004/0248871, which are herein incorporated
by reference. Exemplary anti-fibrotic agents also include the
primary amines reacting with the carbonyl group of the active site
of the lysyl oxidases, and more particularly those which produce,
after binding with the carbonyl, a product stabilized by resonance,
such as the following primary amines: emylenemamine, hydrazine,
phenylhydrazine, and their derivatives, semicarbazide, and urea
derivatives, aminonitriles, such as beta-aminopropionitrile (BAPN),
or 2-nitroethylamine, unsaturated or saturated haloamines, such as
2-bromo-ethylamine, 2-chloroethylamine, 2-trifluoroethylamine,
3-bromopropylamine, p-halobenzylamines, selenohomocysteine lactone.
Also, the anti-fibrotic agents are copper chelating agents,
penetrating or not penetrating the cells. Exemplary compounds
include indirect inhibitors such compounds blocking the aldehyde
derivatives originating from the oxidative deamination of the lysyl
and hydroxylysyl residues by the lysyl oxidases, such as the
thiolamines, in particular D-penicillamine, or its analogues such
as 2-amino-5-mercapto-5-methylhexanoic acid,
D-2-amino-3-methyl-3((2-acetamidoethyl)dithio)butanoic acid,
p-2-amino-3-methyl-3-((2-aminoethyl)dithio)butanoic acid,
sodium-4-((p-1-dimethyl-2-amino-2-carboxyethyl)dithio)butane
sulphurate, 2-acetamidoethyl-2-acetamidoethanethiol sulphanate,
sodium-4-mercaptobutanesulphinate trihydrate.
[0283] The immunotherapeutic agents include and are not limited to
therapeutic antibodies suitable for treating patients; such as
abagovomab, adecatumumab, afutuzumab, alemtuzumab, altumomab,
amatuximab, anatumomab, arcitumomab, bavituximab, bectumomab,
bevacizumab, bivatuzumab, blinatumomab, brentuximab, cantuzumab,
catumaxomab, cetuximab, citatuzumab, cixutumumab, clivatuzumab,
conatumumab, daratumumab, drozitumab, duligotumab, dusigitumab,
detumomab, dacetuzumab, dalotuzumab, ecromeximab, elotuzumab,
ensituximab, ertumaxomab, etaracizumab, farietuzumab, ficlatuzumab,
figitumumab, flanvotumab, futuximab, ganitumab, gemtuzumab,
girentuximab, glembatumumab, ibritumomab, igovomab, imgatuzumab,
indatuximab, inotuzumab, intetumumab, ipilimumab, iratumumab,
labetuzumab, lexatumumab, lintuzumab, lorvotuzumab, lucatumumab,
mapatumumab, matuzumab, milatuzumab, minretumomab, mitumomab,
moxetumomab, narnatumab, naptumomab, necitumumab, nimotuzumab,
nofetumomabn, ocaratuzumab, ofatumumab, olaratumab, onartuzumab,
oportuzumab, oregovomab, panitumumab, parsatuzumab, patritumab,
pemtumomab, pertuzumab, pintumomab, pritumumab, racotumomab,
radretumab, rilotumumab, rituximab, robatumumab, satumomab,
sibrotuzumab, siltuximab, simtuzumab, solitomab, tacatuzumab,
taplitumomab, tenatumomab, teprotumumab, tigatuzumab, tositumomab,
trastuzumab, tucotuzumab, ublituximab, veltuzumab, vorsetuzumab,
votumumab, zalutumumab, CC49 and 3F8. The exemplified therapeutic
antibodies may be further labeled or combined with a radioisotope
particle, such as indium In 111, yttrium Y 90, iodine 1-131.
[0284] The application also provides method for treating a subject
who is undergoing one or more standard therapies, such as
chemotherapy, radiotherapy, immunotherapy, surgery, or combination
thereof. Accordingly, one or more therapeutic agent or inhibitors
may be administered before, during, or after administration of
chemotherapy, radiotherapy, immunotherapy, surgery or combination
thereof.
[0285] In certain embodiments, the subject may be a human who is
(i) substantially refractory to at least one chemotherapy
treatment, or (ii) in relapse after treatment with chemotherapy, or
both (i) and (ii). In some of embodiments, the subject is
refractory to at least two, at least three, or at least four
chemotherapy treatments (including standard or experimental
chemotherapies).
[0286] In certain embodiments, the subject is refractory to at
least one, at least two, at least three, or at least four
chemotherapy treatment (including standard or experimental
chemotherapy) selected from fludarabine, rituximab, obinutuzumab,
alkylating agents, alemtuzumab and other chemotherapy treatments
such as CHOP (cyclophosphamide, doxorubicin, vincristine,
prednisone); R-CHOP (rituximab-CHOP); hyperCVAD (hyperfractionated
cyclophosphamide, vincristine, doxorubicin, dexamethasone,
methotrexate, cytarabine); R-hyperCVAD (rituximab-hyperCVAD); FCM
(fludarabine, cyclophosphamide, mitoxantrone); R-FCM (rituximab,
fludarabine, cyclophosphamide, mitoxantrone); bortezomib and
rituximab; temsirolimus and rituximab; temsirolimus and
Velcade.RTM.; Iodine-131 tositumomab (Bexxar.RTM.) and CHOP; CVP
(cyclophosphamide, vincristine, prednisone); R-CVP (rituximab-CVP);
ICE (iphosphamide, carboplatin, etoposide); R-ICE (rituximab-ICE);
FCR (fludarabine, cyclophosphamide, rituximab); FR (fludarabine,
rituximab); and D.T. PACE (dexamethasone, thalidomide, cisplatin,
Adriamycin.RTM., cyclophosphamide, etoposide).
[0287] Other examples of chemotherapy treatments (including
standard or experimental chemotherapies) are described below. In
addition, treatment of certain lymphomas is reviewed in Cheson, B.
D., Leonard, J. P., "Monoclonal Antibody Therapy for B-Cell
Non-Hodgkin's Lymphoma" The New England Journal of Medicine 2008,
359(6), p. 613-626; and Wierda, W. G., "Current and Investigational
Therapies for Patients with CLL" Hematology 2006, p. 285-294.
Lymphoma incidence patterns in the United States is profiled in
Morton, L. M., et al. "Lymphoma Incidence Patterns by WHO Subtype
in the United States, 1992-2001" Blood 2006, 107(1), p.
265-276.
[0288] Examples of immunotherapeutic agents treating lymphoma or
leukemia include, but are not limited to, rituximab (such as
Rituxan), alemtuzumab (such as Campath, MabCampath), anti-CD19
antibodies, anti-CD20 antibodies, anti-MN-14 antibodies,
anti-TRAIL, Anti-TRAIL DR4 and DR5 antibodies, anti-CD74
antibodies, apolizumab, bevacizumab, CHIR-12.12, epratuzumab
(hLL2-anti-CD22 humanized antibody), galiximab, ha20, ibritumomab
tiuxetan, lumiliximab, milatuzumab, ofatumumab, PRO131921, SGN-40,
WT-1 analog peptide vaccine, WT1 126-134 peptide vaccine,
tositumomab, autologous human tumor-derived HSPPC-96, and
veltuzumab. Additional immunotherapy agents includes using cancer
vaccines based upon the genetic makeup of an individual patient's
tumor, such as lymphoma vaccine example is GTOP-99
(MyVax.RTM.).
[0289] Examples of chemotherapy agents for treating lymphoma or
leukemia include aldesleukin, alvocidib, antineoplaston AS2-1,
antineoplaston A10, anti-thymocyte globulin, amifostine trihydrate,
aminocamptothecin, arsenic trioxide, beta alethine, Bcl-2 family
protein inhibitor ABT-263, BMS-345541, bortezomib (Velcade.RTM.),
bryostatin 1, busulfan, carboplatin, campath-1H, CC-5103,
carmustine, caspofungin acetate, clofarabine, cisplatin, Cladribine
(Leustarin), Chlorambucil (Leukeran), Curcumin, cyclosporine,
Cyclophosphamide (Cyloxan, Endoxan, Endoxana, Cyclostin),
cytarabine, denileukin diftitox, dexamethasone, DT PACE, docetaxel,
dolastatin 10, Doxorubicin (Adriamycin.RTM., Adriblastine),
doxorubicin hydrochloride, enzastaurin, epoetin alfa, etoposide,
Everolimus (RAD001), fenretinide, filgrastim, melphalan, mesna,
Flavopiridol, Fludarabine (Fludara), Geldanamycin (17-AAG),
ifosfamide, irinotecan hydrochloride, ixabepilone, Lenalidomide
(Revlimid.RTM., CC-5013), lymphokine-activated killer cells,
melphalan, methotrexate, mitoxantrone hydrochloride, motexafin
gadolinium, mycophenolate mofetil, nelarabine, oblimersen
(Genasense) Obatoclax (GX15-070), oblimersen, octreotide acetate,
omega-3 fatty acids, oxaliplatin, paclitaxel, PD0332991, PEGylated
liposomal doxorubicin hydrochloride, pegfilgrastim, Pentstatin
(Nipent), perifosine, Prednisolone, Prednisone, R-roscovitine
(Selicilib, CYC202), recombinant interferon alfa, recombinant
interleukin-12, recombinant interleukin-11, recombinant flt3
ligand, recombinant human thrombopoietin, rituximab, sargramostim,
sildenafil citrate, simvastatin, sirolimus, Styryl sulphones,
tacrolimus, tanespimycin, Temsirolimus (CC1-779), Thalidomide,
therapeutic allogeneic lymphocytes, thiotepa, tipifarnib,
Velcade.RTM. (bortezomib or PS-341), Vincristine (Oncovin),
vincristine sulfate, vinorelbine ditartrate, Vorinostat (SAHA),
vorinostat, and FR (fludarabine, rituximab), CHOP
(cyclophosphamide, doxorubicin, vincristine, prednisone), CVP
(cyclophosphamide, vincristine and prednisone), FCM (fludarabine,
cyclophosphamide, mitoxantrone), FCR (fludarabine,
cyclophosphamide, rituximab), hyperCVAD (hyperfractionated
cyclophosphamide, vincristine, doxorubicin, dexamethasone,
methotrexate, cytarabine), ICE (iphosphamide, carboplatin and
etoposide), MCP (mitoxantrone, chlorambucil, and prednisolone),
R-CHOP (rituximab plus CHOP), R-CVP (rituximab plus CVP), R-FCM
(rituximab plus FCM), R-ICE (rituximab-ICE), and R-MCP (R-MCP).
[0290] The therapeutic treatments can be supplemented or combined
with any of the abovementioned therapies with stem cell
transplantation or treatment. One example of modified approach is
radioimmunotherapy, wherein a monoclonal antibody is combined with
a radioisotope particle, such as indium In 111, yttrium Y 90,
iodine 1-131. Examples of combination therapies include, but are
not limited to, Iodine-131 tositumomab)(Bexxar.RTM., Yttrium-90
ibritumomab tiuxetan)(Zevalin.RTM., Bexxar.RTM. with CHOP.
[0291] Other therapeutic procedures include peripheral blood stem
cell transplantation, autologous hematopoietic stem cell
transplantation, autologous bone marrow transplantation, antibody
therapy, biological therapy, enzyme inhibitor therapy, total body
irradiation, infusion of stem cells, bone marrow ablation with stem
cell support, in vitro-treated peripheral blood stem cell
transplantation, umbilical cord blood transplantation, immunoenzyme
technique, pharmacological study, low-LET cobalt-60 gamma ray
therapy, bleomycin, conventional surgery, radiation therapy, and
nonmyeloablative allogeneic hematopoietic stem cell
transplantation.
Kits
[0292] Provided herein are also kits that include a compound of
formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or
(IB-4), or a pharmaceutically acceptable salt, prodrug, or solvate
thereof, and suitable packaging. In one embodiment, a kit further
includes instructions for use. In one aspect, a kit includes a
compound of formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2),
(IB-3), or (IB-4), or a pharmaceutically acceptable salt, prodrug,
or solvate thereof, and a label and/or instructions for use of the
compounds in the treatment of the indications, including the
diseases or conditions, described herein.
[0293] Provided herein are also articles of manufacture that
include a compound of formula (J), (I), (IA-1), (IA-2), (IB-1),
(IB-2), (IB-3), or (IB-4), or a pharmaceutically acceptable salt,
prodrug, or solvate thereof, in a suitable container. The container
may be a vial, jar, ampoule, preloaded syringe, and intravenous
bag.
Pharmaceutical Compositions and Modes of Administration
[0294] Compounds provided herein are usually administered in the
form of pharmaceutical compositions. Thus, provides herein are also
pharmaceutical compositions that contain one or more of the
compounds of formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2),
(IB-3), or (IB-4), or a pharmaceutically acceptable salt, prodrug,
or solvate thereof, and one or more pharmaceutically acceptable
vehicles selected from carriers, adjuvants and excipients. Suitable
pharmaceutically acceptable vehicles may include, for example,
inert solid diluents and fillers, diluents, including sterile
aqueous solution and various organic solvents, permeation
enhancers, solubilizers and adjuvants. Such compositions are
prepared in a manner well known in the pharmaceutical art. See,
e.g., Remington's Pharmaceutical Sciences, Mace Publishing Co.,
Philadelphia, Pa. 17th Ed. (1985); and Modern Pharmaceutics, Marcel
Dekker, Inc. 3rd Ed. (G. S. Banker & C. T. Rhodes, Eds.).
[0295] The pharmaceutical compositions may be administered in
either single or multiple doses. The pharmaceutical composition may
be administered by various methods including, for example, rectal,
buccal, intranasal and transdermal routes. In certain embodiments,
the pharmaceutical composition may be administered by
intra-arterial injection, intravenously, intraperitoneally,
parenterally, intramuscularly, subcutaneously, orally, topically,
or as an inhalant. In certain embodiments, the compound of formula
(J), (I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or (IB-4), or a
pharmaceutically acceptable salt, prodrug, or solvate thereof, is
administered intraveneously, intramuscularly, parenterally, nasally
or orally.
[0296] One mode for administration is parenteral, for example, by
injection. The forms in which the pharmaceutical compositions
described herein may be incorporated for administration by
injection include, for example, aqueous or oil suspensions, or
emulsions, with sesame oil, corn oil, cottonseed oil, or peanut
oil, as well as elixirs, mannitol, dextrose, or a sterile aqueous
solution, and similar pharmaceutical vehicles.
[0297] Oral administration may be another route for administration
of the compounds described herein. Administration may be via, for
example, capsule or enteric coated tablets. In making the
pharmaceutical compositions that include at least one compound of
formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or
(IB-4), or a pharmaceutically acceptable salt, prodrug, or solvate
thereof, the active ingredient is usually diluted by an excipient
and/or enclosed within such a carrier that can be in the form of a
capsule, sachet, paper or other container. When the excipient
serves as a diluent, it can be in the form of a solid, semi-solid,
or liquid material, which acts as a vehicle, carrier or medium for
the active ingredient. Thus, the compositions can be in the form of
tablets, pills, powders, lozenges, sachets, cachets, elixirs,
suspensions, emulsions, solutions, syrups, aerosols (as a solid or
in a liquid medium), ointments containing, for example, up to 10%
by weight of the active compound, soft and hard gelatin capsules,
sterile injectable solutions, and sterile packaged powders.
[0298] Some examples of suitable excipients include lactose,
dextrose, sucrose, sorbitol, mannitol, starches, gum acacia,
calcium phosphate, alginates, tragacanth, gelatin, calcium
silicate, microcrystalline cellulose, polyvinylpyrrolidone,
cellulose, sterile water, syrup, and methyl cellulose. The
formulations can additionally include lubricating agents such as
talc, magnesium stearate, and mineral oil; wetting agents;
emulsifying and suspending agents; preserving agents such as methyl
and propylhydroxy-benzoates; sweetening agents; and flavoring
agents.
[0299] The compositions that include at least one compound of
formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or
(IB-4), or a pharmaceutically acceptable salt, prodrug, or solvate
thereof, can be formulated so as to provide quick, sustained or
delayed release of the active ingredient after administration to
the subject by employing procedures known in the art. Controlled
release drug delivery systems for oral administration include
osmotic pump systems and dissolutional systems containing
polymer-coated reservoirs or drug-polymer matrix formulations.
Examples of controlled release systems are given in U.S. Pat. Nos.
3,845,770; 4,326,525; 4,902,514; and 5,616,345. Another formulation
for use in the methods of the present invention employs transdermal
delivery devices ("patches"). Such transdermal patches may be used
to provide continuous or discontinuous infusion of the compounds
described herein in controlled amounts. The construction and use of
transdermal patches for the delivery of pharmaceutical agents is
well known in the art. See, e.g., U.S. Pat. Nos. 5,023,252,
4,992,445 and 5,001,139. Such patches may be constructed for
continuous, pulsatile, or on demand delivery of pharmaceutical
agents.
[0300] For preparing solid compositions such as tablets, the
principal active ingredient may be mixed with a pharmaceutical
excipient to form a solid preformulation composition containing a
homogeneous mixture of a compound of formula (J), (I), (IA-1),
(IA-2), (IB-1), (IB-2), (IB-3), or (IB-4), or a pharmaceutically
acceptable salt, prodrug, or solvate thereof. When referring to
these preformulation compositions as homogeneous, the active
ingredient may be dispersed evenly throughout the composition so
that the composition may be readily subdivided into equally
effective unit dosage forms such as tablets, pills and
capsules.
[0301] Exemplary unit dosage levels of a compound of formula (J),
(I), (IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or (IB-4), or a
pharmaceutically acceptable salt, prodrug, or solvate thereof, for
a human subject may, in certain variations, be between about 0.01
mg to about 1000 mg, between about 1 mg to about 15 mg, or between
about 50 mg to about 200 mg, or about 5 mg, about 10 mg, about 15
mg, about 25 mg, about 50 mg, about 75 mg, about 100 mg, about 125
mg, or about 150 mg, or about 175 mg, about 200 mg, or about 250
mg.
[0302] The tablets or pills of the compounds described herein may
be coated or otherwise compounded to provide a dosage form
affording the advantage of prolonged action, or to protect from the
acid conditions of the stomach. For example, the tablet or pill can
include an inner dosage and an outer dosage component, the latter
being in the form of an envelope over the former. The two
components can be separated by an enteric layer that serves to
resist disintegration in the stomach and permit the inner component
to pass intact into the duodenum or to be delayed in release. A
variety of materials can be used for such enteric layers or
coatings, such materials including a number of polymeric acids and
mixtures of polymeric acids with such materials as shellac, cetyl
alcohol, and cellulose acetate.
[0303] Compositions for inhalation or insufflation may include
solutions and suspensions in pharmaceutically acceptable, aqueous
or organic solvents, or mixtures thereof, and powders. The liquid
or solid compositions may contain suitable pharmaceutically
acceptable excipients as described supra. In some embodiments, the
compositions are administered by the oral or nasal respiratory
route for local or systemic effect. In other embodiments,
compositions in pharmaceutically acceptable solvents may be
nebulized by use of inert gases. Nebulized solutions may be inhaled
directly from the nebulizing device or the nebulizing device may be
attached to a facemask tent, or intermittent positive pressure
breathing machine. Solution, suspension, or powder compositions may
be administered, preferably orally or nasally, from devices that
deliver the formulation in an appropriate manner.
Dosing
[0304] The specific dose level of a compound of formula (J), (I),
(IA-1), (IA-2), (IB-1), (IB-2), (IB-3), or (IB-4), for any
particular subject will depend upon a variety of factors including
the activity of the specific compound employed, the age, body
weight, general health, sex, diet, time of administration, route of
administration, and rate of excretion, drug combination and the
severity of the particular disease in the subject undergoing
therapy. For example, a dosage may be expressed as a number of
milligrams of a compound of formula (J), (I), (IA-1), (IA-2),
(IB-1), (IB-2), (IB-3), or (IB-4) per kilogram of the subject's
body weight (mg/kg). Dosages of between about 0.1 and 150 mg/kg may
be appropriate. In some embodiments, about 0.1 and 100 mg/kg may be
appropriate. In other embodiments a dosage of between 0.5 and 60
mg/kg may be appropriate. Normalizing according to the subject's
body weight is particularly useful when adjusting dosages between
subjects of widely disparate size, such as occurs when using the
drug in both children and adult humans or when converting an
effective dosage in a non-human subject such as dog to a dosage
suitable for a human subject.
[0305] The daily dosage may also be described as a total amount of
a compound of formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2),
(IB-3), or (IB-4) administered per dose or per day. Daily dosage of
a compound of formula (J), (I), (IA-1), (IA-2), (IB-1), (IB-2),
(IB-3), or (IB-4) may be between about 1 mg/day and 4,000 mg/day,
between about 2,000 mg/day to 4,000 mg/day, between about 1 mg/day
to 2,000 mg/day, between about 1 mg/day to 1,000 mg/day, between
about 10 mg/day to 500 mg/day, between about 20 mg/day to 500
mg/day, between about 50 mg/day to 300 mg/day, between about 75
mg/day to 200 mg/day, between about 15 mg/day to 150 mg/day, or
between 1 mg/day and 15 mg/day.
[0306] When administered orally, the total daily dosage for a human
subject may be between 1 mg and 1,000 mg, between about 10-500
mg/day, between about 50-300 mg/day, between about 75-200 mg/day,
or between about 100-150 mg/day.
[0307] The compounds of formula (J), (I), (IA-1), (IA-2), (IB-1),
(IB-2), (IB-3), or (IB-4) or the compositions thereof may be
administered once, twice, three, or four times daily, using any
suitable mode described above. Also, administration or treatment
with the compounds formula (J), (I), (IA-1), (IA-2), (IB-1),
(IB-2), (IB-3), or (IB-4) may be continued for a number of days;
for example, commonly treatment would continue for at least 7 days,
14 days, or 28 days, for one cycle of treatment. Treatment cycles
are well known in cancer chemotherapy, and are frequently
alternated with resting periods of about 1 to 28 days, commonly
about 7 days or about 14 days, between cycles. The treatment
cycles, in other embodiments, may also be continuous.
[0308] In a particular embodiment, the method comprises
administering to the subject an initial daily dose of about 1 to
500 mg of a compound of formula (J), (I), (IA-1), (IA-2), (IB-1),
(IB-2), (IB-3), or (IB-4) and increasing the dose by increments
until clinical efficacy is achieved. Increments of about 5, 10, 25,
50, or 100 mg can be used to increase the dose. The dosage can be
increased daily, every other day, twice per week, or once per
week.
Synthesis of the Compounds of Formula (I)
[0309] The compounds of formula (J), (I), (IA-1), (IA-2), (IB-1),
(IB-2), (IB-3), or (IB-4) may be prepared using the methods
disclosed herein and routine modifications thereof, which will be
apparent given the disclosure herein and methods well known in the
art. Conventional and well-known synthetic methods may be used in
addition to the teachings herein. The synthesis of typical
compounds described herein may be accomplished as described in the
following examples. If available, reagents may be purchased
commercially, e.g., from Sigma Aldrich or other chemical
suppliers.
General Synthesis
[0310] Typical embodiments of compounds described herein may be
synthesized using the general reaction schemes described below. It
will be apparent given the description herein that the general
schemes may be altered by substitution of the starting materials
with other materials having similar structures to result in
products that are correspondingly different. Descriptions of
syntheses follow to provide numerous examples of how the starting
materials may vary to provide corresponding products. Given a
desired product for which the substituent groups are defined, the
necessary starting materials generally may be determined by
inspection. Starting materials are typically obtained from
commercial sources or synthesized using published methods. For
synthesizing compounds which are embodiments described in the
present disclosure, inspection of the structure of the compound to
be synthesized will provide the identity of each substituent group.
The identity of the final product will generally render apparent
the identity of the necessary starting materials by a simple
process of inspection, given the examples herein.
Synthetic Reaction Parameters
[0311] The terms "solvent", "inert organic solvent", or "inert
solvent" refer to a solvent inert under the conditions of the
reaction being described in conjunction therewith (including, for
example, benzene, toluene, acetonitrile, tetrahydrofuran ("THF"),
dimethylformamide ("DMF"), chloroform, methylene chloride (or
dichloromethane), diethyl ether, methanol, pyridine and the like).
Unless specified to the contrary, the solvents used in the
reactions of the present invention are inert organic solvents, and
the reactions are carried out under an inert gas, preferably
nitrogen.
[0312] The term "q.s." means adding a quantity sufficient to
achieve a stated function, e.g., to bring a solution to the desired
volume (i.e., 100%).
Compounds of Formula I
[0313] One method of preparing compounds of formula (I) is shown in
Reaction Scheme I.
##STR00233##
Step 1--Preparation of a Compound of Formula (1)
[0314] The compound of formula (1) can be made by combining
compounds (A), (B) and (C) in the presence of a dehydrating agent.
Compounds (A), (B) and (C) are commercially available or can be
made by methods known in the art. With respect to compound (A),
R.sup.1 is as defined herein. With respect to compound (B), R.sup.3
is as defined herein. With respect to compound (C), R.sup.2 is as
defined herein. Compound (A) can be mixed with Compound (B) in the
presence of a coupling agent such as diphenyl phosphite in a
solvent such as pyridine. After stirring at a temperature between
ambient and 100.degree. C. for between 1 and 5 hours, compound (C)
is added. After further stirring at a temperature between ambient
and 100.degree. C. for between 5 and 24 hours, the reaction mixture
is allowed to cool to room temperature. To extract the compound of
formula (1), an organic solvent such as ethyl acetate (EtOAc) may
be added, followed by washing with, mild acid, water, and brine.
The organic phase can be concentrated to obtain the compound of
formula (1). The compound of formula (1) may be purified by any
suitable methods known in the art, such as chromatography on silica
gel. Alternatively, the compound of formula (1) may be used in the
next step without purification.
Step 2--Preparation of a Compound of Formula (2)
[0315] The compound of formula (2) can be made by removing the
protecting group(s) from the compound of formula (1). The compound
of formula (1) is dissolved in a suitable solvent and treated with
a suitable acid. Suitable solvents may include, for example,
dichloromethane, dioxane, or other suitable solvents. Suitable
acids may include, for example, trifluoroacetic acid, hydrochloric
acid, or boron tribromide (BBr.sub.3). The reaction can be carried
out at temperatures between -78.degree. C. to ambient temperature.
On reaction completion, solvent is removed to obtain the compound
of formula (2). In the case of a reaction using BBr.sub.3 the
reaction may first be treated with MeOH before an aqueous work-up
to obtain a compound of formula (2).
Step 3--Preparation of a Compound of Formula (3)
[0316] The compound of formula (3) can be made by treating
5-substituted-2,4,6-trihalopyrimidine with ammonium hydroxide in a
suitable solvent such as dioxane, where the halo is either chloro
or fluoro. The reaction is carried out at an elevated temperature
between 30 and 80.degree. C. for a suitable time, typically between
2 and 8 hours or when the reaction is complete. Upon completion,
water is added to the cooled solution, and the precipitate is
collected by filtration. The nitrile can be converted to the
carboxamide under standard conditions.
Step 4--Preparation of a Compound of Formula (I)
[0317] The compound of formula (I) can generally be prepared by
coupling compound of formula (2) and compound of formula (3) in the
presence of a suitable base in a suitable solvent. An example of a
suitable base is diisopropylethylamine. An example of a suitable
solvent is N-methylpyrrolidone (NMP). The reaction is typically
performed at a temperature between 50.degree. C. to 150.degree. C.
for about 30 minutes to 24 hours. In some instance, the reaction
can be performed at a temperature between 20.degree. C. to
100.degree. C. for about 12 hours to 120 hours. Alternatively the
reaction can be performed in a microwave at a temperature between
100.degree. C. to 150.degree. C. for about 30 minutes to 24 hours.
Water can be added to quench the reaction upon completion, and the
precipitate may be filtered and then dissolved in an organic
solvent such as dichloromethane (DCM). The product can be isolated
by methods known in the art, for example by removal of solvent
under reduced pressure. The product can be purified using any
suitable methods known in the art, for example, chromatography of
the residue on a silica column.
[0318] It should be understood that the compounds of formula (J)
can be prepared according to the methods provided in Reaction
Scheme 1, starting from materials known to one of skill in the
art.
Example 1
Preparation of a Compound of Formula (1)
[0319] A. Preparation of a Compound of Formula (1) in which n is 1,
R.sup.1 is Chloro, m is 0, and R.sup.3 is Methyl
##STR00234##
[0320] Diphenyl phosphite (1.9 mL, 10 mmol) was added to a solution
of 2-amino-6-chlorobenzoic acid (495 mg, 2.9 mmol) and
(S)-2-(tert-butoxycarbonylamino)propanoic acid (710 mg, 3.77 mmol)
in pyridine (3 mL). The reaction mixture was stirred at 40.degree.
C. for 2 hours. Aniline (274 mg, 3.48 mmol) was then added to the
reaction mixture, which was then stirred at 55.degree. C. for 12
hours. The reaction mixture was cooled to room temperature. This
mixture was then diluted with EtOAc (50 mL), washed with 1N aqueous
HCl (2.times.50 mL), brine (50 mL), and dried over sodium sulfate.
The organics layer was filtered and concentrated in vacuuo to
afford material which was purified by column chromatography on
SiO.sub.2 eluting with EtOAc in hexanes (0-50%) to afford
(S)-tert-butyl
1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethylcarbamate
as a solid. ES/MS m/z=400.1 (M+H.+-.).
B. Preparation of a Compound of Formula (1), Varying R.sup.1,
R.sup.2, and R.sup.3
[0321] Following the procedure described in Example lA and Reaction
Scheme I, but varying the R.sup.1, R.sup.2 and R.sup.3
substituents, other compounds of formula (1) were prepared
including:
[0322] (S)-tert-butyl
1-(8-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethylcarbamate,
ES/MS m/z=384.1 (M+H.sup.+);
[0323] (S)-tert-butyl
1-(5,8-dichloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethylcarbamate,
ES/MS m/z=434.2 (M+H.sup.+);
[0324] (S)-tert-butyl
1-(5-chloro-8-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethylcarba-
mate, ES/MS m/z=418.1 (M+H.sup.+);
[0325] (S)-tert-butyl
1-(8-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethylcarbamate,
ES/MS m/z=400.1 (M+H.sup.+);
[0326] (S)-tert-butyl
1-(5,8-difluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethylcarbamate,
ES/MS m/z=402.1 (M+H.sup.+);
[0327] (S)-tert-butyl
1-(5-chloro-4-oxo-3-(3,5-difluorophenyl)-3,4-dihydroquinazolin-2-yl)ethyl-
carbamate;
[0328] (S)-tert-butyl
1-(5-chloro-4-oxo-3-(3,5-difluorophenyl)-3,4-dihydroquinazolin-2-yl)propy-
lcarbamate;
[0329] (S)-tert-butyl
1-(5-fluoro-4-oxo-3-(3,5-difluorophenyl)-3,4-dihydroquinazolin-2-yl)propy-
lcarbamate;
[0330] (S)-tert-butyl
1-(5-chloro-4-oxo-3-(3-fluorophenyl)-3,4-dihydroquinazolin-2-yl)ethylcarb-
amate;
[0331] (S)-tert-butyl
1-(5-fluoro-4-oxo-3-(3,5-difluorophenyl)-3,4-dihydroquinazolin-2-yl)ethyl-
carbamate;
[0332] (S)-tert-butyl
1-(6-fluoro-4-oxo-3-(3,5-difluorophenyl)-3,4-dihydroquinazolin-2-yl)ethyl-
carbamate;
[0333] (S)-tert-butyl
1-(6-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethylcarbamate;
[0334] (S)-tert-butyl
1-(5-chloro-3-(3-cyanophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethylcarba-
mate;
[0335] (S)-tert-butyl
1-(6-fluoro-3-(3-cyanophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethylcarba-
mate;
[0336] (S)-tert-butyl
1-(6-fluoro-3-(3-chlorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethylcarb-
amate;
[0337] (S)-tert-butyl
1-(8-fluoro-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl-
carbamate;
[0338] (S)-tert-butyl
1-(3-(3,5-difluorophenyl)-5-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl-
carbamate;
[0339] (S)-tert-butyl
1-(3-(3,5-difluorophenyl)-8-fluoro-4-oxo-3,4-dihydroquinazolin-2-yl)propy-
lcarbamate;
[0340] (S)-tert-butyl
1-(3-(3,5-difluorophenyl)-5-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)propy-
lcarbamate;
[0341] (S)-tert-butyl
1-(3-(3,5-difluorophenyl)-8-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)propy-
lcarbamate;
[0342] (S)-tert-butyl
1-(3-(3,5-difluorophenyl)-8-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl-
carbamate;
[0343] (S)-tert-butyl
1-(5,8-dichloro-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)e-
thylcarbamate;
[0344] (S)-tert-butyl
1-(5-chloro-3-(3,5-dicyanophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethylc-
arbamate;
[0345] (S)-tert-butyl
1-(5-chloro-3-(3-cyano-5-fluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)e-
thylcarbamate;
[0346] (S)-tert-butyl
1-(5-hydroxy-3-phenyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethylcarbamate;
[0347] (S)-tert-butyl
1-(5,8-difluoro-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)e-
thylcarbamate;
[0348] (S)-tert-butyl
1-(5-chloro-3-(3,5-difluorophenyl)-8-methyl-4-oxo-3,4-dihydroquinazolin-2-
-yl)ethylcarbamate;
[0349] (S)-tert-butyl
1-(3-(3-cyano-5-fluorophenyl)-5-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)e-
thylcarbamate;
[0350] (S)-tert-butyl
1-(5-methyl-3-phenyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethylcarbamate;
[0351] (S)-tert-butyl
1-(3-(3,5-difluorophenyl)-8-fluoro-5-methyl-4-oxo-3,4-dihydroquinazolin-2-
-yl)ethylcarbamate;
[0352] (S)-tert-butyl
1-(5-chloro-3-(3,5-dimethoxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethy-
lcarbamate;
[0353] (S)-tert-butyl
1-(6,7-difluoro-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)e-
thylcarbamate;
[0354] (S)-tert-butyl
1-(8-chloro-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl-
carbamate;
[0355] (S)-tert-butyl
1-(8-chloro-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)propy-
lcarbamate;
[0356] (S)-tert-butyl
1-(5-(difluoromethyl)-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquinazolin--
2-yl)ethylcarbamate;
[0357] (S)-tert-butyl
1-(5-(difluoromethyl)-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquinazolin--
2-yl)propylcarbamate;
[0358] (S)-tert-butyl
1-(3-(3,5-difluorophenyl)-6-fluoro-4-oxo-3,4-dihydroquinazolin-2-yl)propy-
lcarbamate;
[0359] (S)-tert-butyl
1-(3-(3,5-difluorophenyl)-5,8-difluoro-4-oxo-3,4-dihydroquinazolin-2-yl)p-
ropylcarbamate;
[0360] (S)-tert-butyl
1-(3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethylcarbamate-
;
[0361] (S)-tert-butyl
1-(3-(3,5-difluorophenyl)-5,6-difluoro-4-oxo-3,4-dihydroquinazolin-2-yl)p-
ropylcarbamate;
[0362] (S)-tert-butyl
1-(3-(3,5-difluorophenyl)-5,6-difluoro-4-oxo-3,4-dihydroquinazolin-2-yl)e-
thylcarbamate;
[0363]
(S)-3-(2-(1-aminoethyl)-8-fluoro-5-methyl-4-oxoquinazolin-3(4H)-yl)-
-5-fluorobenzonitrile;
[0364] (S)-tert-butyl
1-(3-(3-cyano-5-fluorophenyl)-8-fluoro-5-methyl-4-oxo-3,4-dihydroquinazol-
in-2-yl)ethylcarbamate;
[0365] (S)-tert-butyl
1-(5-chloro-3-(3-cyano-5-fluorophenyl)-8-fluoro-4-oxo-3,4-dihydroquinazol-
in-2-yl)ethylcarbamate;
[0366] (S)-tert-butyl
1-(3-(3,5-difluorophenyl)-6,8-difluoro-4-oxo-3,4-dihydroquinazolin-2-yl)p-
ropylcarbamate;
[0367] (S)-tert-butyl
1-(3-(3,5-difluorophenyl)-6,8-difluoro-4-oxo-3,4-dihydroquinazolin-2-yl)e-
thylcarbamate;
[0368] (S)-tert-butyl
1-(3-(3-cyano-5-fluorophenyl)-5-fluoro-4-oxo-3,4-dihydroquinazolin-2-yl)e-
thylcarbamate;
[0369] (S)-tert-butyl
1-(5-fluoro-3-(3-fluoro-5-(trifluoromethyl)phenyl)-4-oxo-3,4-dihydroquina-
zolin-2-yl)ethylcarbamate;
[0370] (S)-tert-butyl
1-(3-(3,5-difluorophenyl)-4-oxo-8-(trifluoromethyl)-3,4-dihydroquinazolin-
-2-yl)ethylcarbamate;
[0371] (S)-tert-butyl
1-(3-(3,5-difluorophenyl)-5-fluoro-8-methyl-4-oxo-3,4-dihydroquinazolin-2-
-yl)ethylcarbamate;
[0372] (S)-tert-butyl
1-(3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)propylcarbamat-
e;
[0373] (S)-tert-butyl
1-(3-(3,5-difluorophenyl)-5-fluoro-8-methyl-4-oxo-3,4-dihydroquinazolin-2-
-yl)propylcarbamate;
[0374] (S)-tert-butyl
1-(8-chloro-3-(3,5-difluorophenyl)-6-fluoro-4-oxo-3,4-dihydroquinazolin-2-
-yl)ethylcarbamate;
[0375] (S)-tert-butyl
1-(3-(3-(difluoromethyl)-5-fluorophenyl)-5-fluoro-4-oxo-3,4-dihydroquinaz-
olin-2-yl)ethylcarbamate;
[0376] (S)-tert-butyl
1-(5-chloro-3-(3-(difluoromethyl)-5-fluorophenyl)-4-oxo-3,4-dihydroquinaz-
olin-2-yl)ethylcarbamate;
[0377] (S)-tert-butyl
1-(3-(3,5-difluorophenyl)-8-methoxy-4-oxo-3,4-dihydroquinazolin-2-yl)ethy-
lcarbamate;
[0378] (S)-tert-butyl
1-(3-(3-cyanophenyl)-5-fluoro-4-oxo-3,4-dihydroquinazolin-2-yl)ethylcarba-
mate;
[0379] (S)-tert-butyl
1-(8-methyl-4-oxo-3-(3-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-2-y-
l)ethylcarbamate;
[0380] (S)-tert-butyl
1-(5-fluoro-4-oxo-3-(3-(trifluoromethyl)phenyl)-3,4-dihydroquinazolin-2-y-
l)ethylcarbamate;
[0381] (S)-tert-butyl
1-(8-(difluoromethyl)-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquinazolin--
2-yl)ethylcarbamate;
[0382] (S)-tert-butyl
1-(8-(difluoromethyl)-3-phenyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethylcarb-
amate;
[0383] (S)-tert-butyl
1-(8-methyl-3-phenyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethylcarbamate;
[0384] (S)-tert-butyl
1-(5-fluoro-3-phenyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethylcarbamate;
[0385] (S)-tert-butyl
1-(8-fluoro-3-phenyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethylcarbamate;
[0386] (S)-tert-butyl
1-(5-chloro-3-(3-fluorophenyl)-8-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)-
ethylcarbamate;
[0387] (S)-tert-butyl
1-(5-chloro-3-(3-chlorophenyl)-8-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)-
ethylcarbamate;
[0388] (S)-tert-butyl
1-(5-chloro-8-methyl-3-phenyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethylcarba-
mate;
[0389] (S)-tert-butyl
1-(5-fluoro-8-methyl-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethylcarba-
mate;
[0390] (S)-tert-butyl
1-(8-fluoro-5-methyl-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethylcarba-
mate;
[0391] (S)-tert-butyl
1-(5-(difluoromethyl)-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethylcarb-
amate;
[0392] (S)-tert-butyl
3-(3-cyanophenyl)-1-(5-(difluoromethyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-
ethylcarbamate;
[0393]
(S)-3-(2-(1-aminoethyl)-8-fluoro-5-methyl-4-oxoquinazolin-3(4H)-yl)-
benzonitrile;
[0394] (S)-tert-butyl
1-(3-(3-cyanophenyl)-8-fluoro-5-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)e-
thylcarbamate;
[0395] (S)-tert-butyl
1-(5-chloro-3-(3,5-dichlorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl-
carbamate;
[0396] (S)-tert-butyl
1-(3-(3,5-dichlorophenyl)-5-fluoro-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl-
carbamate;
[0397] (S)-tert-butyl
1-(8-chloro-3-(3,5-difluorophenyl)-5-fluoro-4-oxo-3,4-dihydroquinazolin-2-
-yl)ethylcarbamate;
[0398] (S)-tert-butyl
1-(3-(3-chlorophenyl)-8-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethylcarb-
amate;
[0399] (S)-tert-butyl
1-(5-cyano-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethylcarbamate;
[0400] (S)-tert-butyl
1-(5-chloro-3-(3-chloro-5-fluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-
ethylcarbamate;
[0401] (S)-tert-butyl
1-(3-(3-chloro-5-fluorophenyl)-5-fluoro-4-oxo-3,4-dihydroquinazolin-2-yl)-
ethylcarbamate;
[0402] (S)-tert-butyl
1-(5-chloro-3-(3-fluoro-5-(trifluoromethyl)phenyl)-4-oxo-3,4-dihydroquina-
zolin-2-yl)ethylcarbamate;
[0403] (S)-tert-butyl
1-(5-fluoro-3-(5-trifluoromethylphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-
propylcarbamate;
[0404] (S)-tert-butyl
1-(5-chloro-3-(5-trifluoromethylphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-
ethylcarbamate;
[0405] (S)-tert-butyl
1-(3-(3-cyano-5-fluorophenyl)-5-fluoro-8-methyl-4-oxo-3,4-dihydroquinazol-
in-2-yl)ethylcarbamate;
[0406] (S)-tert-butyl
1-(3-(3-cyanophenyl)-5-fluoro-8-methyl-4-oxo-3,4-dihydroquinazolin-2-yl)e-
thylcarbamate;
[0407] (S)-tert-butyl
1-(3-(3-(difluoromethyl)-5-fluorophenyl)-5-fluoro-4-oxo-3,4-dihydroquinaz-
olin-2-yl)propylcarbamate;
[0408] (S)-tert-butyl
1-(5-chloro-3-(3-(difluoromethyl)-5-fluorophenyl)-4-oxo-3,4-dihydroquinaz-
olin-2-yl)propylcarbamate;
[0409] (S)-tert-butyl
1-(3-(3-(difluoromethyl)-5-fluorophenyl)-5-(methylsulfonyl)-4-oxo-3,4-dih-
ydroquinazolin-2-yl)ethylcarbamate;
[0410] (S)-tert-butyl
1-(5-(difluoromethyl)-3-(3-(difluoromethyl)-5-fluorophenyl)-4-oxo-3,4-dih-
ydroquinazolin-2-yl)ethylcarbamate;
[0411] (S)-tert-butyl
1-(3-(3-(difluoromethyl)phenyl)-5-fluoro-4-oxo-3,4-dihydroquinazolin-2-yl-
)ethylcarbamate;
[0412] (S)-tert-butyl
1-(3-(3,5-difluorophenyl)-5-(methylsulfonyl)-4-oxo-3,4-dihydroquinazolin--
2-yl)ethylcarbamate;
[0413] (S)-tert-butyl
1-(5-(methylsulfonyl)-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethylcarb-
amate;
[0414] (S)-tert-butyl
(1-(3-(3,5-difluorophenyl)-8-iodo-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)-
carbamate;
[0415] (S)-tert-butyl
1-(8-chloro-3-(3,5-difluorophenyl)-5-fluoro-4-oxo-3,4-dihydroquinazolin-2-
-yl)propylcarbamate;
[0416] (S)-tert-butyl
1-(3-(3,5-difluorophenyl)-8-ethyl-4-oxo-3,4-dihydroquinazolin-2-yl)ethylc-
arbamate;
[0417] (S)-tert-butyl
1-(5-chloro-3-(3-(difluoromethyl)phenyl)-4-oxo-3,4-dihydroquinazolin-2-yl-
)ethylcarbamate;
[0418] (S)-tert-butyl
1-(5-chloro-3-(3-isopropylphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethylc-
arbamate;
[0419] (S)-tert-butyl
1-(5-chloro-3-(3-fluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethylcarb-
amate;
[0420] (S)-tert-butyl
1-(5-carbamoyl-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)et-
hylcarbamate;
[0421] (S)-tert-butyl
1-(5-carbamoyl-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethylcarbamate;
[0422] (S)-tert-butyl
1-(5-methoxy-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethylcarbamate.
[0423] (S)-tert-butyl
1-(5-cyano-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethylc-
arbamate;
[0424] (S)-tert-butyl
1-(5-cyano-3-(3-cyano-5-fluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)et-
hylcarbamate;
[0425] (S)-tert-butyl
1-(3-(3-chloro-5-(difluoromethyl)phenyl)-5-fluoro-4-oxo-3,4-dihydroquinaz-
olin-2-yl)ethylcarbamate;
[0426] (S)-tert-butyl
1-(5-chloro-3-(3-chloro-5-(difluoromethyl)phenyl)-4-oxo-3,4-dihydroquinaz-
olin-2-yl)ethylcarbamate;
[0427] (S)-tert-butyl
1-(3-(3-(difluoromethyl)phenyl)-5-(methylsulfonyl)-4-oxo-3,4-dihydroquina-
zolin-2-yl)ethylcarbamate;
[0428] (S)-tert-butyl
1-(3-(3-fluorophenyl)-5-(methylsulfonyl)-4-oxo-3,4-dihydroquinazolin-2-yl-
)ethylcarbamate;
[0429] (S)-tert-butyl
1-(3-(3,5-bis(difluoromethyl)phenyl)-5-fluoro-4-oxo-3,4-dihydroquinazolin-
-2-yl)ethylcarbamate;
[0430] (S)-tert-butyl
1-(3-(3,5-bis(difluoromethyl)phenyl)-5-chloro-4-oxo-3,4-dihydroquinazolin-
-2-yl)ethylcarbamate.
[0431] (S)-tert-butyl
1-(5-chloro-3-(3-(difluoromethyl)phenyl)-4-oxo-3,4-dihydroquinazolin-2-yl-
)ethylcarbamate;
[0432] (S)-tert-butyl
1-(3-(3-(difluoromethyl)phenyl)-5-fluoro-4-oxo-3,4-dihydroquinazolin-2-yl-
)ethylcarbamate;
[0433] (S)-tert-butyl
1-(5-bromo-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethylcarbamate;
[0434] (S)-tert-butyl
1-(5-bromo-4-oxo-3-(3-fluorophenyl)-3,4-dihydroquinazolin-2-yl)ethylcarba-
mate;
[0435]
(S)-2-(1-amino-3,3,3-trifluoropropyl)-3-phenyl-6-fluoroquinazolin-4-
(3H)-one;
[0436]
(S)-2-(1-amino-3,3,3-trifluoropropyl)-3-(3,5-difluorophenyl)-6-fluo-
roquinazolin-4(3H)-one;
[0437] (R)-tert-butyl
(1-(5-chloro-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-2-m-
ethoxyethyl)carbamate;
[0438] (S)-tert-butyl
(1-(3-(3,5-bis(difluoromethyl)phenyl)-5-fluoro-4-oxo-3,4-dihydroquinazoli-
n-2-yl)ethyl)carbamate;
[0439] (S)-tert-butyl
(1-(3-(3,5-bis(difluoromethyl)phenyl)-5-chloro-4-oxo-3,4-dihydroquinazoli-
n-2-yl)ethyl)carbamate;
[0440] (S)-tert-butyl
(1-(5-cyano-3-(3-(difluoromethyl)-5-fluorophenyl)-4-oxo-3,4-dihydroquinaz-
olin-2-yl)ethyl)carbamate;
[0441] (S)-tert-butyl
(1-(5-chloro-3-(3,5-difluorophenyl)-6-fluoro-4-oxo-3,4-dihydroquinazolin--
2-yl)ethyl)carbamate;
[0442] (S)-tert-butyl
(1-(5-chloro-3-(3-(difluoromethyl)-5-fluorophenyl)-6-fluoro-4-oxo-3,4-dih-
ydroquinazolin-2-yl)ethyl)carbamate;
[0443] (S)-tert-butyl
(1-(3-(2-fluorophenyl)-5-(methylsulfonyl)-4-oxo-3,4-dihydroquinazolin-2-y-
l)ethyl)carbamate;
[0444] (S)-tert-butyl
(1-(3-(3-cyanophenyl)-5,8-difluoro-4-oxo-3,4-dihydroquinazolin-2-yl)propy-
l)carbamate;
[0445] (S)-tert-butyl
(1-(5,8-difluoro-3-(3-fluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)prop-
yl)carbamate;
[0446] (S)-tert-butyl
(1-(5,8-difluoro-3-phenyl-4-oxo-3,4-dihydroquinazolin-2-yl)propyl)carbama-
te;
[0447] (S)-tert-butyl
(1-(3-(3-cyanophenyl)-5,8-difluoro-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl-
)carbamate;
[0448] (S)-tert-butyl
(1-(5,8-difluoro-3-(3-fluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethy-
l)carbamate;
[0449] (S)-tert-butyl
(1-(3-(2,6-difluorophenyl)-5-(methylsulfonyl)-4-oxo-3,4-dihydroquinazolin-
-2-yl)ethyl)carbamate;
[0450] (S)-tert-butyl
(1-(5-chloro-3-(2,6-difluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethy-
l)carbamate;
[0451] (S)-tert-butyl
(1-(6-fluoro-3-(3-fluorophenyl)-8-iodo-4-oxo-3,4-dihydroquinazolin-2-yl)e-
thyl)carbamate;
[0452] (S)-tert-butyl
(1-(3-(3-fluorophenyl)-8-iodo-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)carb-
amate;
[0453]
(S)-2-(1-aminoethyl)-3-(3,5-difluorophenyl)-8-iodoquinazolin-4(3H)--
one;
[0454] (S)-tert-butyl
(1-(6-fluoro-3-phenyl-8-iodo-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)carba-
mate;
[0455] (S)-tert-butyl
(1-(8-methoxy-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)carbamate;
[0456] (S)-tert-butyl
(1-(6-iodo-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)carbamate;
[0457] (S)-tert-butyl
(1-(3-(3-(difluoromethyl)phenyl)-8-iodo-4-oxo-3,4-dihydroquinazolin-2-yl)-
ethyl)carbamate;
[0458] (S)-tert-butyl
(1-(3-(3,5-difluorophenyl)-6-fluoro-8-iodo-4-oxo-3,4-dihydroquinazolin-2--
yl)ethyl)carbamate;
[0459] (S)-tert-butyl
(1-(5-chloro-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-3-m-
ethylbutyl)carbamate;
[0460] (S)-tert-butyl
(1-(5-chloro-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-2-m-
ethylbutyl)carbamate;
[0461] (S)-tert-butyl
(1-(5-chloro-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-3,3-
,3-trifluoropropyl)carbamate;
[0462] (S)-tert-butyl
(1-(3-(3,5-difluorophenyl)-5-fluoro-4-oxo-3,4-dihydroquinazolin-2-yl)-3,3-
,3-trifluoropropyl)carbamate;
[0463] (S)-tert-butyl
(1-(5-chloro-3-(3-cyanophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-3-methyl-
butyl)carbamate;
[0464] (S)-tert-butyl
(1-(5-chloro-3-(3-fluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-3-methy-
lbutyl)carbamate;
[0465] (S)-tert-butyl
(1-(3-(3,5-difluorophenyl)-5-fluoro-4-oxo-3,4-dihydroquinazolin-2-yl)buty-
l)carbamate;
[0466] (S)-tert-butyl
(1-(5-chloro-3-(3-cyanophenyl)-6-fluoro-4-oxo-3,4-dihydroquinazolin-2-yl)-
ethyl)carbamate;
[0467] (S)-tert-butyl
(1-(6-fluoro-3-(3-fluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)propyl)c-
arbamate;
[0468] (S)-tert-butyl
(1-(5-fluoro-3-(3-fluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)propyl)c-
arbamate;
[0469] (S)-tert-butyl
(1-(5-chloro-3-(3-cyanophenyl)-8-fluoro-4-oxo-3,4-dihydroquinazolin-2-yl)-
ethyl)carbamate;
[0470] (S)-tert-butyl
(1-(5-fluoro-3-(3-fluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)ca-
rbamate;
[0471] (S)-tert-butyl
(1-(5-chloro-3-(3-methoxy-4-methylphenyl)-4-oxo-3,4-dihydroquinazolin-2-y-
l)ethyl)carbamate;
[0472] (S)-tert-butyl
(1-(5-chloro-3-(3-methoxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)c-
arbamate;
[0473] (S)-tert-butyl
(1-(5-chloro-3-(5-methoxy-2-methylphenyl)-4-oxo-3,4-dihydroquinazolin-2-y-
l)ethyl)carbamate;
[0474] (S)-tert-butyl
(1-(5-chloro-3-(4-fluoro-3-methoxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-y-
l)ethyl)carbamate;
[0475] (S)-tert-butyl
(1-(5-chloro-3-(5-(difluoromethyl)-2-methylphenyl)-4-oxo-3,4-dihydroquina-
zolin-2-yl)ethyl)carbamate;
[0476] (S)-tert-butyl
(1-(5-chloro-3-(3-(difluoromethyl)-2-methylphenyl)-4-oxo-3,4-dihydroquina-
zolin-2-yl)ethyl)carbamate;
[0477] (S)-tert-butyl
(1-(5-chloro-3-(3-(difluoromethyl)-5-methoxyphenyl)-4-oxo-3,4-dihydroquin-
azolin-2-yl)ethyl)carbamate;
[0478] (S)-tert-butyl
(1-(5-chloro-3-(2,5-dimethylphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethy-
l)carbamate;
[0479] (S)-tert-butyl
(1-(5-chloro-3-(3-fluoro-5-methoxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-y-
l)ethyl)carbamate;
[0480] (S)-tert-butyl
(1-(5-chloro-3-(3-fluoro-5-(trifluoromethoxy)phenyl)-4-oxo-3,4-dihydroqui-
nazolin-2-yl)ethyl)carbamate;
[0481] (S)-tert-butyl
(1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)-2-methylpropyl)ca-
rbamate;
[0482] (S)-tert-butyl
(1-(5-chloro-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)-2-m-
ethylpropyl)carbamate;
[0483] (S)-tert-butyl
(1-(5-chloro-3-(3-fluoro-2-methylphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl-
)ethyl)carbamate;
[0484] (S)-tert-butyl
(1-(5-chloro-3-(3,5-difluoro-2-methylphenyl)-4-oxo-3,4-dihydroquinazolin--
2-yl)ethyl)carbamate;
[0485] (S)-tert-butyl
(1-(5-chloro-3-(5-fluoro-2-methylphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl-
)ethyl)carbamate;
[0486] (S)-tert-butyl
(1-(5-chloro-3-(2,3-dimethylphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethy-
l)carbamate;
[0487] (S)-tert-butyl
(1-(5-chloro-3-(4-fluoro-2,3-dimethylphenyl)-4-oxo-3,4-dihydroquinazolin--
2-yl)ethyl)carbamate;
[0488] (S)-tert-butyl
(1-(5-chloro-3-(3,4-difluoro-2-methylphenyl)-4-oxo-3,4-dihydroquinazolin--
2-yl)ethyl)carbamate;
[0489] (S)-tert-butyl
(1-(5-chloro-3-(3-methoxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)c-
arbamate; and
[0490] (S)-tert-butyl
(1-(5-chloro-3-(3-fluoro-5-methoxyphenyl)-4-oxo-3,4-dihydroquinazolin-2-y-
l)ethyl)carbamate.
Example 1b
Preparation of Compound of Formula 1b
[0491] A. Preparation of a Compound of Formula (1b) in which n is
1, R.sup.1 is cyano, m is 0, and R.sup.3 is methyl.
##STR00235##
[0492] (S)-tert-butyl
(1-(5-bromo-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)carbamate
(500 mg, 1.13 mmol), zinc cyanide (166 mg, 1.41 mmol), and
tetrakis(triphenylphosphine)Pd(0) (124 mg, 0.11 mmol) were combined
in NMP (5 mL). The mixture was degassed under Ar and heated to
90.degree. C. overnight. The reaction was poured into EtOAc, washed
with water (3.times.), and purified by flash chromatography (40 g
silica, 0-50% EtOAc/hexanes) to give (S)-tert-butyl
(1-(5-cyano-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)carbamate
as a white solid. ES/MS 391.2 (M+H.sup.+).
B. Preparation of a Compound of Formula (2), varying n, m, R.sup.1,
R.sup.2, and R.sup.3, with one R.sup.1.dbd.CN.
[0493] (S)-tert-butyl
(1-(5-cyano-3-(3-fluorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)car-
bamate;
[0494] (S)-tert-butyl
(1-(5-cyano-8-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)carb-
amate; and
[0495] (S)-tert-butyl
(1-(5-cyano-3-(3,5-difluorophenyl)-8-fluoro-4-oxo-3,4-dihydroquinazolin-2-
-yl)ethyl)carbamate.
Example 1c
Preparation of a Compound of Formula (1c)
[0496] A. Preparation of a Compound of Formula (1c) in which n is
1, R.sup.1 is carboxamide, m is 0, and R.sup.3 is methyl.
##STR00236##
[0497] To a solution of (S)-tert-butyl
(1-(5-cyano-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)carbamate
(105 mg, 0.269 mmol) in THF/H.sub.2O (1 mL each) was added
Ghaffar's catalyst. The mixture was heated to 80.degree. C.
overnight. Purification by flash chromatography (25 g silica,
0-100% EtOAc/DCM) provided (S)-tert-butyl
(1-(5-carbamoyl-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethyl)carbamate
as a white solid. ES/MS 409.1 (M+H.sup.+).
Example 2
Preparation of a Compound of Formula (2)
[0498] A. Preparation of a Compound of Formula (2) in which n is 1,
R.sup.1 is Chloro, m is 0, and R.sup.3 is Methyl.
##STR00237##
[0499] Trifluoroacetic acid (3 mL) was added to a solution of
(5)-tert-butyl
1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)ethylcarbamate
(1 g, 2.5 mmol) in dichloromethane (3 mL). The resultant was
stirred at room temperature for 3 hours. The solvents was removed
in vacuuo to afford
(S)-2-(1-aminoethyl)-5-chloro-3-phenylquinazolin-4(3H)-one
2,2,2-trifluoroacetic acid salt. ES/MS m/z=300.1 (M+H.sup.+).
B. Preparation of a Compound of Formula (2), Varying R.sup.1,
R.sup.2, and R.sup.3
[0500] Following the procedure described in Example 2A and Reaction
Scheme I, but varying the R.sup.1, R.sup.2, and R.sup.3
substituents, other compounds of formula (2) were prepared
including:
[0501] (S)-2-(1-aminoethyl)-8-fluoro-3-phenylquinazolin-4(3H)-one,
ES/MS m/z=284.1 (M+H.sup.+);
[0502]
(S)-2-(1-aminoethyl)-5,8-dichloro-3-phenylquinazolin-4(3H)-one,
ES/MS m/z=334.1 (M+H.sup.+);
[0503]
(S)-2-(1-aminoethyl)-5-chloro-8-fluoro-3-phenylquinazolin-4(3H)-one-
, ES/MS m/z=318.1 (M+H.sup.+);
[0504] (S)-2-(1-aminoethyl)-8-chloro-3-phenylquinazolin-4(3H)-one,
ES/MS m/z=300.1 (M+H.sup.+);
[0505]
(S)-2-(1-aminoethyl)-5,8-difluoro-3-phenylquinazolin-4(3H)-one,
ES/MS m/z=302.1 (M+H.sup.+);
[0506]
(S)-2-(1-aminoethyl)-5-chloro-3-(3,5-difluorophenyl)quinazolin-4(3H-
)-one;
[0507]
(S)-2-(1-aminopropyl)-5-chloro-3-(3,5-difluorophenyl)quinazolin-4(3-
H)-one;
[0508]
(S)-2-(1-aminopropyl)-5-fluoro-3-(3,5-difluorophenyl)quinazolin-4(3-
H)-one;
[0509]
(S)-2-(1-aminoethyl)-5-chloro-3-(3-fluorophenyl)quinazolin-4(3H)-on-
e;
[0510]
(S)-2-(1-aminoethyl)-3-(3,5-difluorophenyl)-5-fluoroquinazolin-4(3H-
)-one;
[0511]
(S)-2-(1-aminoethyl)-3-(3,5-difluorophenyl)-6-fluoroquinazolin-4(3H-
)-one;
[0512]
(S)-2-(1-aminoethyl)-3-phenyl-6-fluoroquinazolin-4(3H)-one;
[0513]
(S)-3-(2-(1-aminoethyl)-5-chloro-4-oxoquinazolin-3(4H)-yl)benzonitr-
ile;
[0514]
(S)-3-(2-(1-aminoethyl)-6-floro-4-oxoquinazolin-3(4H)-yl)benzonitri-
le;
[0515]
(S)-2-(1-aminoethyl)-3-(3-chlorophenyl)-6-fluoroquinazolin-4(3H)-on-
e;
[0516]
(S)-2-(1-aminoethyl)-3-(3,5-difluorophenyl)-8-fluoroquinazolin-4(3H-
)-one;
[0517]
(S)-2-(1-aminopropyl)-3-(3,5-difluorophenyl)-8-fluoroquinazolin-4(3-
H)-one;
[0518]
(S)-2-(1-aminoethyl)-3-(3,5-difluorophenyl)-5-methylquinazolin-4(3H-
)-one;
[0519]
(S)-2-(1-aminopropyl)-3-(3,5-difluorophenyl)-5-methylquinazolin-4(3-
H)-one;
[0520]
(S)-2-(1-aminopropyl)-3-(3,5-difluorophenyl)-8-methylquinazolin-4(3-
H)-one;
[0521]
(S)-2-(1-aminoethyl)-3-(3,5-difluorophenyl)-8-methylquinazolin-4(3H-
)-one;
[0522]
(S)-2-(1-aminoethyl)-5,8-dichloro-3-(3,5-difluorophenyl)quinazolin--
4(3H)-one;
[0523]
(S)-5-(2-(1-aminoethyl)-5-chloro-4-oxoquinazolin-3(4H)-yl)isophthal-
onitrile;
[0524]
(S)-3-(2-(1-aminoethyl)-5-chloro-4-oxoquinazolin-3(4H)-yl)-5-fluoro-
benzonitrile;
[0525]
(S)-2-(1-aminoethyl)-5,8-difluoro-3-(3,5-difluorophenyl)quinazolin--
4(3H)-one;
[0526]
(S)-2-(1-aminoethyl)-5-chloro-3-(3,5-difluorophenyl)-8-methylquinaz-
olin-4(3H)-one;
[0527]
(S)-3-(2-(1-aminoethyl)-5-methyl-4-oxoquinazolin-3(4H)-yl)-5-fluoro-
benzonitrile;
[0528]
(S)-2-(1-aminoethyl)-5-methyl-3-phenylquinazolin-4(3H)-one;
[0529]
(S)-2-(1-aminoethyl)-3-(3,5-difluorophenyl)-8-fluoro-5-methylquinaz-
olin-4(3H)-one
[0530]
(S)-2-(1-aminoethyl)-5-chloro-3-(3,5-dimethoxyphenyl)quinazolin-4(3-
H)-one;
[0531]
(S)-2-(1-aminoethyl)-6,7-difluoro-3-(3,5-difluorophenyl)quinazolin--
4(3H)-one;
[0532]
(S)-2-(1-aminoethyl)-8-chloro-3-(3,5-difluorophenyl)quinazolin-4(3H-
)-one;
[0533]
(S)-2-(1-aminopropyl)-8-chloro-3-(3,5-difluorophenyl)quinazolin-4(3-
H)-one;
[0534]
(S)-2-(1-aminoethyl)-5-(difluoromethyl)-3-(3,5-difluorophenyl)quina-
zolin-4(3H)-one;
[0535]
(S)-2-(1-aminopropyl)-5-(difluoromethyl)-3-(3,5-difluorophenyl)quin-
azolin-4(3H)-one;
[0536]
(S)-2-(1-aminopropyl)-3-(3,5-difluorophenyl)-6-fluoroquinazolin-4(3-
H)-one;
[0537]
(S)-2-(1-aminopropyl)-3-(3,5-difluorophenyl)-5,8-difluoroquinazolin-
-4(3H)-one;
[0538]
(S)-2-(1-aminoethyl)-3-(3,5-difluorophenyl)quinazolin-4(3H)-one;
[0539]
(S)-2-(1-aminopropyl)-3-(3,5-difluorophenyl)-5,6-difluoroquinazolin-
-4(3H)-one;
[0540]
(S)-2-(1-aminoethyl)-3-(3,5-difluorophenyl)-5,6-difluoroquinazolin--
4(3H)-one;
[0541]
(S)-3-(2-(1-aminoethyl)-5-chloro-8-fluoro-4-oxoquinazolin-3(4H)-yl)-
-5-fluorobenzonitrile;
[0542]
(S)-2-(1-aminopropyl)-3-(3,5-difluorophenyl)-6,8-difluoroquinazolin-
-4(3H)-one;
[0543]
(S)-2-(1-aminoethyl)-3-(3,5-difluorophenyl)-6,8-difluoroquinazolin--
4(3H)-one;
[0544]
(S)-3-(2-(1-aminoethyl)-5-fluoro-4-oxoquinazolin-3(4H)-yl)-5-fluoro-
benzonitrile;
[0545]
(S)-2-(1-aminoethyl)-5-fluoro-3-(3-fluoro-5-(trifluoromethyl)phenyl-
)quinazolin-4(3H)-one;
[0546]
(S)-2-(1-aminoethyl)-3-(3,5-difluorophenyl)-8-(trifluoromethyl)quin-
azolin-4(3H)-one;
[0547]
(S)-2-(1-aminoethyl)-3-(3,5-difluorophenyl)-5-fluoro-8-methylquinaz-
olin-4(3H)-one;
[0548]
(S)-2-(1-aminopropyl)-3-(3,5-difluorophenyl)quinazolin-4(3H)-one;
[0549]
(S)-2-(1-aminopropyl)-3-(3,5-difluorophenyl)-5-fluoro-8-methylquina-
zolin-4(3H)-one;
[0550]
(S)-2-(1-aminoethyl)-8-chloro-3-(3,5-difluorophenyl)-6-fluoroquinaz-
olin-4(3H)-one;
[0551]
(S)-2-(1-aminoethyl)-3-(3-(difluoromethyl)-5-fluorophenyl)-5-fluoro-
quinazolin-4(3H)-one;
[0552]
(S)-2-(1-aminoethyl)-5-chloro-3-(3-(difluoromethyl)-5-fluorophenyl)-
quinazolin-4(3H)-one;
[0553]
(S)-2-(1-aminoethyl)-3-(3,5-difluorophenyl)-8-methoxyquinazolin-4(3-
H)-one;
[0554]
(S)-3-(2-(1-aminoethyl)-5-fluoro-4-oxoquinazolin-3(4H)-yl)benzonitr-
ile;
[0555]
(S)-2-(1-aminoethyl)-8-methyl-3-(3-(trifluoromethyl)phenyl)quinazol-
in-4(3H)-one;
[0556]
(S)-2-(1-aminoethyl)-5-fluoro-3-(3-(trifluoromethyl)phenyl)quinazol-
in-4(3H)-one;
[0557]
(S)-2-(1-aminoethyl)-8-(difluoromethyl)-3-(3,5-difluorophenyl)quina-
zolin-4(3H)-one;
[0558]
(S)-2-(1-aminoethyl)-8-(difluoromethyl)-3-phenylquinazolin-4(3H)-on-
e;
[0559]
(S)-2-(1-aminoethyl)-8-methyl-3-phenylquinazolin-4(3H)-one;
[0560]
(S)-2-(1-aminoethyl)-8-fluoro-3-phenylquinazolin-4(3H)-one;
[0561]
(S)-2-(1-aminoethyl)-5-fluoro-3-phenylquinazolin-4(3H)-one;
[0562]
(S)-2-(1-aminoethyl)-5-chloro-3-(3-chlorophenyl)-8-methylquinazolin-
-4(3H)-one;
[0563]
(S)-2-(1-aminoethyl)-5-chloro-8-methyl-3-phenylquinazolin-4(3H)-one-
;
[0564]
(S)-2-(1-aminoethyl)-8-fluoro-5-methyl-3-phenylquinazolin-4(3H)-one-
;
[0565]
(S)-2-(1-aminoethyl)-5-fluoro-8-methyl-3-phenylquinazolin-4(3H)-one-
;
[0566]
(S)-2-(1-aminoethyl)-5-(difluoromethyl)-3-phenylquinazolin-4(3H)-on-
e;
[0567]
(S)-3-(2-(1-aminoethyl)-5-(difluoromethyl)-4-oxoquinazolin-3(4H)-yl-
)benzonitrile;
[0568]
(S)-3-(2-(1-aminoethyl)-8-fluoro-5-methyl-4-oxoquinazolin-3(4H)-yl)-
benzonitrile;
[0569]
(S)-2-(1-aminoethyl)-3-(3,5-dichlorophenyl)-5-fluoro-quinazolin-4(3-
H)-one;
[0570]
(S)-2-(1-aminoethyl)-8-chloro-3-(3,5-difluorophenyl)-5-fluoroquinaz-
olin-4(3H)-one;
[0571]
(S)-2-(1-aminoethyl)-3-(3-chlorophenyl)-8-methylquinazolin-4(3H)-on-
e;
[0572]
(S)-2-(1-aminoethyl)-4-oxo-3-phenyl-3,4-dihydroquinazoline-5-carbon-
itrile;
[0573]
(S)-2-(1-aminoethyl)-5-chloro-3-(3-chloro-5-fluorophenyl)quinazolin-
-4(3H)-one;
[0574]
(S)-2-(1-aminoethyl)-3-(3-chloro-5-fluorophenyl)-5-fluoroquinazolin-
-4(3H)-one;
[0575]
(S)-2-(1-aminoethyl)-5-chloro-3-(3-fluoro-5-(trifluoromethyl)phenyl-
)quinazolin-4(3H)-one;
[0576]
(S)-2-(1-aminopropyl)-5-fluoro-3-(5-trifluoromethylphenyl)quinazoli-
n-4(3H)-one;
[0577]
(S)-2-(1-aminoethyl)-5-fluoro-3-(5-trifluoromethylphenyl)quinazolin-
-4(3H)-one;
[0578]
(S)-3-(2-(1-aminoethyl)-5-fluoro-8-methyl-4-oxoquinazolin-3(4H)-yl)-
-5-fluorobenzonitrile;
[0579]
(S)-3-(2-(1-aminoethyl)-5-fluoro-8-methyl-4-oxoquinazolin-3(4H)-yl)-
benzonitrile;
[0580]
(S)-2-(1-aminopropyl)-3-(3-(difluoromethyl)-5-fluorophenyl)-5-fluor-
oquinazolin-4(3H)-one;
[0581]
(S)-2-(1-aminopropyl)-5-chloro-3-(3-(difluoromethyl)-5-fluorophenyl-
)quinazolin-4(3H)-one;
[0582]
(S)-2-(1-aminoethyl)-3-(3-(difluoromethyl)-5-fluorophenyl)-5-(methy-
lsulfonyl)quinazolin-4(3H)-one;
[0583]
(S)-2-(1-aminoethyl)-5-(difluoromethyl)-3-(3-(difluoromethyl)-5-flu-
orophenyl)quinazolin-4(3H)-one;
[0584]
(S)-2-(1-aminoethyl)-3-(3-(difluoromethyl)phenyl)-5-fluoroquinazoli-
n-4(3H)-one;
[0585]
(S)-2-(1-aminoethyl)-3-(3,5-difluorophenyl)-5-(methylsulfonyl)quina-
zolin-4(3H)-one;
[0586]
(S)-2-(1-aminoethyl)-5-(methylsulfonyl)-3-phenylquinazolin-4(3H)-on-
e;
[0587]
(S)-2-(1-aminopropyl)-8-chloro-3-(3,5-difluorophenyl)-5-fluoroquina-
zolin-4(3H)-one;
[0588]
(S)-2-(1-aminoethyl)-3-(3,5-difluorophenyl)-8-ethylquinazolin-4(3H)-
-one;
[0589]
(S)-2-(1-aminoethyl)-5-chloro-3-(3-(difluoromethyl)phenyl)quinazoli-
n-4(3H)-one;
[0590]
(S)-2-(1-aminoethyl)-5-chloro-3-(3-isopropylphenyl)quinazolin-4(3H)-
-one;
[0591]
(S)-2-(1-aminoethyl)-5-chloro-3-(3-fluorophenyl)quinazolin-4(3H)-on-
e.
[0592]
(S)-2-(1-aminoethyl)-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquinaz-
oline-5-carboxamide;
[0593]
(S)-2-(1-aminoethyl)-4-oxo-3-phenyl-3,4-dihydroquinazoline-5-carbox-
amide;
[0594]
(S)-2-(1-aminoethyl)-5-methoxy-3-phenylquinazolin-4(3H)-one;
[0595]
(S)-2-(1-aminoethyl)-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquinaz-
oline-5-carbonitrile;
[0596]
(S)-2-(1-aminoethyl)-3-(3-cyano-5-fluorophenyl)-4-oxo-3,4-dihydroqu-
inazoline-5-carbonitrile;
[0597]
(S)-2-(1-aminoethyl)-3-(3-chloro-5-(difluoromethyl)phenyl)-5-fluoro-
quinazolin-4(3H)-one;
[0598]
(S)-2-(1-aminoethyl)-5-chloro-3-(3-chloro-5-(difluoromethyl)phenyl)-
quinazolin-4(3H)-one;
[0599]
(S)-2-(1-aminoethyl)-3-(3-(difluoromethyl)phenyl)-5-(methylsulfonyl-
)quinazolin-4(3H)-one;
[0600]
(S)-2-(1-aminoethyl)-3-(3-fluorophenyl)-5-(methylsulfonyl)quinazoli-
n-4(3H)-one;
[0601]
(S)-2-(1-aminoethyl)-3-(3,5-bis(difluoromethyl)phenyl)-5-fluoroquin-
azolin-4(3H)-one;
[0602]
(S)-2-(1-aminoethyl)-3-(3,5-bis(difluoromethyl)phenyl)-5-chloroquin-
azolin-4(3H)-one;
[0603]
(S)-2-(1-aminoethyl)-5-chloro-3-(3-(difluoromethyl)phenyl)quinazoli-
n-4(3H)-one;
[0604]
(S)-2-(1-aminoethyl)-3-(3-(difluoromethyl)phenyl)-5-fluoroquinazoli-
n-4(3H)-one;
[0605]
(S)-2-(1-aminoethyl)-4-oxo-3-phenyl-3,4-dihydroquinazoline-8-carbon-
itrile;
[0606]
(S)-2-(1-aminoethyl)-4-oxo-3-phenyl-3,4-dihydroquinazoline-5-carbon-
itrile;
[0607]
(S)-2-(1-aminoethyl)-4-oxo-3-(3-fluorophenyl)-3,4-dihydroquinazolin-
e-5-carbonitrile;
[0608]
(S)-2-(1-aminoethyl)-8-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazoline-
-5-carbonitrile;
[0609]
(S)-2-(1-aminoethyl)-4-oxo-3-(3,5-difluorophenyl)-3,4-dihydroquinaz-
oline-5-carbonitrile;
[0610]
(S)-2-(1-aminoethyl)-4-oxo-3-phenyl-3,4-dihydroquinazoline-5-carbox-
amide;
[0611]
(S)-2-(1-aminoethyl)-5-bromo-3-phenylquinazolin-4(3H)-one;
[0612]
(S)-2-(1-aminoethyl)-5-bromo-3-(3-fluorophenyl)quinazolin-4(3H)-one-
;
[0613]
(S)-2-(1-amino-3,3,3-trifluoropropyl)-3-phenyl-6-fluoroquinazolin-4-
(3H)-one
[0614]
(S)-2-(1-amino-3,3,3-trifluoropropyl)-3-(3,5-difluorophenyl)-6-fluo-
roquinazolin-4(3H)-one;
[0615]
(R)-2-(1-amino-2-methoxyethyl)-5-chloro-3-(3,5-difluorophenyl)quina-
zolin-4(3H)-one;
[0616]
(S)-2-(1-aminoethyl)-3-(3,5-bis(difluoromethyl)phenyl)-5-fluoroquin-
azolin-4(3H)-one;
[0617]
(S)-2-(1-aminoethyl)-3-(3,5-bis(difluoromethyl)phenyl)-5-chloroquin-
azolin-4(3H)-one;
[0618]
(S)-2-(1-aminoethyl)-3-(3-(difluoromethyl)-5-fluorophenyl)-4-oxo-3,-
4-dihydroquinazoline-5-carbonitrile;
[0619]
(S)-2-(1-aminoethyl)-5-chloro-3-(3,5-difluorophenyl)-6-fluoroquinaz-
olin-4(3H)-one;
[0620]
(S)-2-(1-aminoethyl)-5-chloro-3-(3-(difluoromethyl)-5-fluorophenyl)-
-6-fluoroquinazolin-4(3H)-one;
[0621]
(S)-2-(1-aminoethyl)-3-(2-fluorophenyl)-5-(methylsulfonyl)quinazoli-
n-4(3H)-one;
[0622]
(S)-3-(2-(1-aminopropyl)-5,8-difluoro-4-oxoquinazolin-3(4H)-yl)benz-
onitrile;
[0623]
(S)-2-(1-aminopropyl)-5,8-difluoro-3-(3-fluorophenyl)quinazolin-4(3-
H)-one;
[0624]
(S)-2-(1-aminopropyl)-5,8-difluoro-3-phenylquinazolin-4(3H)-one;
[0625]
(S)-3-(2-(1-aminoethyl)-5,8-difluoro-4-oxoquinazolin-3(4H)-yl)benzo-
nitrile;
[0626]
(S)-2-(1-aminoethyl)-5,8-difluoro-3-(3-fluorophenyl)quinazolin-4(3H-
)-one;
[0627]
(S)-2-(1-aminoethyl)-3-(2,6-difluorophenyl)-5-(methylsulfonyl)quina-
zolin-4(3H)-one;
[0628]
(S)-2-(1-aminoethyl)-5-chloro-3-(2,6-difluorophenyl)quinazolin-4(3H-
)-one;
[0629]
(S)-2-(1-aminoethyl)-6-fluoro-3-(3-fluorophenyl)-8-iodoquinazolin-4-
(3H)-one;
[0630]
(S)-2-(1-aminoethyl)-3-(3-fluorophenyl)-8-iodoquinazolin-4(3H)-one;
[0631]
(S)-2-(1-aminoethyl)-6-fluoro-3-phenyl-8-iodoquinazolin-4(3H)-one;
[0632]
(S)-2-(1-aminoethyl)-8-methoxy-3-phenylquinazolin-4(3H)-one;
[0633]
(S)-2-(1-aminoethyl)-6-iodo-3-phenylquinazolin-4(3H)-one;
[0634]
(S)-2-(1-aminoethyl)-3-(3-(difluoromethyl)phenyl)-8-iodoquinazolin--
4(3H)-one;
[0635]
(S)-2-(1-aminoethyl)-3-(3,5-difluorophenyl)-6-fluoro-8-iodoquinazol-
in-4(3H)-one;
[0636]
(S)-2-(1-amino-3-methylbutyl)-5-chloro-3-(3,5-difluorophenyl)quinaz-
olin-4(3H)-one;
(S)-2-(1-amino-2-methylbutyl)-5-chloro-3-(3,5-difluorophenyl)quinazolin-4-
(3H)-one;
[0637]
(S)-2-(1-amino-3,3,3-trifluoropropyl)-5-chloro-3-(3,5-difluoropheny-
l)quinazolin-4(3H)-one;
[0638]
(S)-2-(1-amino-3,3,3-trifluoropropyl)-3-(3,5-difluorophenyl)-5-fluo-
roquinazolin-4(3H)-one;
[0639]
(S)-3-(2-(1-amino-3-methylbutyl)-5-chloro-4-oxoquinazolin-3(4H)-yl)-
benzonitrile;
[0640]
(S)-2-(1-amino-3-methylbutyl)-5-chloro-3-(3-fluorophenyl)quinazolin-
-4(3H)-one;
[0641]
(S)-2-(1-aminobutyl)-3-(3,5-difluorophenyl)-5-fluoroquinazolin-4(3H-
)-one;
[0642]
(S)-3-(2-(1-aminoethyl)-5-chloro-6-fluoro-4-oxoquinazolin-3(4H)-yl)-
benzonitrile;
[0643]
(S)-2-(1-aminopropyl)-6-fluoro-3-(3-fluorophenyl)quinazolin-4(3H)-o-
ne;
[0644]
(S)-2-(1-aminopropyl)-5-fluoro-3-(3-fluorophenyl)quinazolin-4(3H)-o-
ne;
[0645]
(S)-3-(2-(1-aminoethyl)-5-chloro-8-fluoro-4-oxoquinazolin-3(4H)-yl)-
benzonitrile;
[0646]
(S)-2-(1-aminoethyl)-5-fluoro-3-(3-fluorophenyl)quinazolin-4(3H)-on-
e;
[0647]
(S)-2-(1-aminoethyl)-5-chloro-3-(3-methoxy-4-methylphenyl)quinazoli-
n-4(3H)-one;
[0648]
(S)-2-(1-aminoethyl)-5-chloro-3-(3-methoxyphenyl)quinazolin-4(3H)-o-
ne;
[0649]
(S)-2-(1-aminoethyl)-5-chloro-3-(5-methoxy-2-methylphenyl)quinazoli-
n-4(3H)-one;
[0650]
(S)-2-(1-aminoethyl)-5-chloro-3-(4-fluoro-3-methoxyphenyl)quinazoli-
n-4(3H)-one;
[0651]
(S)-2-(1-aminoethyl)-5-chloro-3-(5-(difluoromethyl)-2-methylphenyl)-
quinazolin-4(3H)-one;
[0652]
(S)-2-(1-aminoethyl)-5-chloro-3-(3-(difluoromethyl)-2-methylphenyl)-
quinazolin-4(3H)-one;
[0653]
(S)-2-(1-aminoethyl)-5-chloro-3-(3-(difluoromethyl)-5-methoxyphenyl-
)quinazolin-4(3H)-one;
[0654]
(S)-2-(1-aminoethyl)-5-chloro-3-(2,5-dimethylphenyl)quinazolin-4(3H-
)-one;
[0655]
(S)-2-(1-aminoethyl)-5-chloro-3-(3-fluoro-5-methoxyphenyl)quinazoli-
n-4(3H)-one;
[0656]
(S)-2-(1-aminoethyl)-5-chloro-3-(3-fluoro-5-(trifluoromethoxy)pheny-
l)quinazolin-4(3H)-one;
[0657]
(S)-2-(1-amino-2-methylpropyl)-5-chloro-3-phenylquinazolin-4(3H)-on-
e;
[0658]
(S)-2-(1-amino-2-methylpropyl)-5-chloro-3-(3,5-difluorophenyl)quina-
zolin-4(3H)-one;
[0659]
(S)-2-(1-aminoethyl)-5-chloro-3-(3-fluoro-2-methylphenyl)quinazolin-
-4(3H)-one;
[0660]
(S)-2-(1-aminoethyl)-5-chloro-3-(3,5-difluoro-2-methylphenyl)quinaz-
olin-4(3H)-one;
[0661]
(S)-2-(1-aminoethyl)-5-chloro-3-(5-fluoro-2-methylphenyl)quinazolin-
-4(3H)-one;
[0662]
(S)-2-(1-aminoethyl)-5-chloro-3-(2,3-dimethylphenyl)quinazolin-4(3H-
)-one;
[0663]
(S)-2-(1-aminoethyl)-5-chloro-3-(4-fluoro-2,3-dimethylphenyl)quinaz-
olin-4(3H)-one;
[0664]
(S)-2-(1-aminoethyl)-5-chloro-3-(3,4-difluoro-2-methylphenyl)quinaz-
olin-4(3H)-one;
[0665]
(S)-2-(1-aminoethyl)-5-chloro-3-(3-methoxyphenyl)quinazolin-4(3H)-o-
ne; and
[0666]
(S)-2-(1-aminoethyl)-5-chloro-3-(3-fluoro-5-methoxyphenyl)quinazoli-
n-4(3H)-one.
Example 3
Preparation of a Compound of Formula (3)
[0667] A. Preparation of a Compound of Formula (3) in which R.sup.4
is CN and X is Cl
(2,4-Diamino-6-Chloropyrimidine-5-Carbonitrile)
##STR00238##
[0668] Ammonium hydroxide (20 mL) was added to a solution of
2,4,6-trichloropyrimidine-5-carbonitrile (5.0 g, 24 mmol) in
dioxane (20 mL) at room temperature. The solution was warmed to
50.degree. C. and stirred for 3 hrs. The reaction mixture was
cooled to 10.degree. C. and water (50 mL) was added. The resulting
solid was filtered, washed with water, and dried under high vacuum
to afford the compound depicted above as a white solid (4.5
g).sup.13H NMR (100 MHz, DMSO) 164.8, 162.6, 161.9, 115.8, 77.6.
ES/MS m/z=169.9 (M+H).sup.+.
B. Preparation of a Compound of Formula (3), Varying R.sup.4 and
X
[0669] 5-chloro-6-fluoropyrimidine-2,4-diamine;
[0670] 6-chloro-5-(methylsulfonyl)pyrimidine-2,4-diamine;
[0671] 6-chloro-5-(trifluoromethyl)pyrimidine-2,4-diamine; and
[0672] 2,4-diamino-6-chloropyrimidine-5-carboxamide.
Example 4
Preparation of a Compound of Formula (I)
[0673] A. Preparation of a Compound of Formula (I) in which n=1,
R.sup.1 is Chloro, m=2, Both R.sup.2 are Fluoro, R.sup.3 is Methyl,
and R.sup.4 is Cyano (Compound 1a)
##STR00239##
[0674] Potassium fluoride (138 mg, 2.38 mmol) was added to a
solution of
(S)-2-(1-aminoethyl)-5-chloro-3-(3,5-difluorophenyl)quinazolin-4(3H)-one
(400 mg, 1.19 mmol) and
2,4-diamino-6-chloropyrimidine-5-carbonitrile (201 mg, 1.19 mmol)
in diisopropylethylamine (1.0 mL, 6.0 mmol) and DMSO (3 mL). The
resultant mixture was heated to 90.degree. C. for 14 hours, after
which time the reaction was cooled to room temperature, filtered,
and purified by HPLC eluting with 5%-95% water/acetonitrile (0.1%
v/v trifluoroacetic acid). The appropriate fractions were pooled
and lyophilized to afford Compound 1a as a white solid (479 mg).
.sup.1H NMR (400 MHz, DMSO) .delta. 7.78 (t, J=8.0 Hz, 1H), 7.65
(dd, J=8.2, 1.2 Hz, 1H), 7.58 (dd, J=7.8, 1.2 Hz, 1H), 7.43 (dm,
J=9.2 Hz, 1H), 7.29 (dt, J=9.2, 2.4 Hz, 1H), 7.24 (dm, J=11 Hz,
1H), 6.83 (d, J=6.8 Hz, 1H), 6.51 (br s, 1H), 6.24 (br s, 1H), 4.82
(dq, J=6.65, 6.65 Hz, 1H), 1.34 (d, J=6.65 Hz, 3H). ES/MS 469.1
(M+H.sup.+).
B. Preparation of a Compound of Formula (I), varying R.sup.1,
R.sup.2, and R.sup.3; and a Compound of Formula (J), varying
R.sup.1, R.sup.2, R.sup.3 and R.sup.4
[0675]
(S)-2,4-diamino-6-((1-(5-hydroxy-4-oxo-3-phenyl-3,4-dihydroquinazol-
in-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 2a):
.sup.1H NMR (400 MHz, DMSO) .delta. 11.56 (s, 1H), 7.96-7.78 (br.
M, 2H), 7.74 (t, J=8.2 Hz, 1H), 7.60-7.36 (m, 5H), 7.17 (dd, J=8.1,
0.9 Hz, 1H), 6.92 (dd, J=8.2, 0.9 Hz, 1H), 4.95-4.84 (m, 1H), 1.33
(d, J=6.7 Hz, 3H). ES/MS 415.1 (M+H.sup.+);
[0676]
(S)-2,4-diamino-6-((1-(8-methyl-4-oxo-3-phenyl-3,4-dihydroquinazoli-
n-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 3a): .sup.1H
NMR (400 MHz, DMSO) .delta. 7.96 (ddd, J=7.9, 1.5, 0.6 Hz, 1H),
7.75 (ddd, J=7.4, 1.5, 0.9 Hz, 1H), 7.57-7.41 (m, 6H), 4.96-4.86
(m, 1H), 2.62 (s, 3H), 1.33 (d, J=6.6 Hz, 3H). ES/MS 413.1
(M+H.sup.+);
[0677]
(S)-2,4-diamino-6-((1-(5-chloro-8-methyl-4-oxo-3-phenyl-3,4-dihydro-
quinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound
4a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.68 (dd, J=8.1, 0.8 Hz,
1H), 7.58-7.40 (br. M, 4H), 7.39-6.75 (m, 6H), 4.90-4.80 (m, 1H),
2.56 (s, 3H), 1.31 (d, J=6.6 Hz, 3H). ES/MS 447.1 (M+H.sup.+);
[0678]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-chlorophenyl)-8-methyl-4-oxo-3-
,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 5a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.78-7.67 (m,
3H), 7.55-7.40 (m, 5H), 4.99-4.84 (m, 1H), 2.60-2.54 (m, 3H),
1.41-1.30 (m, 3H). ES/MS 481.1 (M+H.sup.+);
[0679]
(S)-2,4-diamino-6-((1-(3-(3-chlorophenyl)-8-methyl-4-oxo-3,4-dihydr-
oquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound
6a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.97-7.92 (m, 1H),
7.76-7.71 (m, 1H), 7.62-7.41 (m, 5H), 6.96-6.79 (m, 1H), 6.59-6.46
(m, 2H), 6.34-6.12 (m, 2H), 4.90-4.80 (m, 1H), 2.64-2.58 (m, 3H),
1.37-1.27 (m, 3H). ES/MS 447.1 (M+H.sup.+);
[0680]
(S)-2-(1-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-p-
henyl-3,4-dihydroquinazoline-5-carbonitrile (Compound 7a): .sup.1H
NMR (400 MHz, DMSO) .delta. 8.05 (dd, J=4.8, 3.9 Hz, 1H), 7.99-7.95
(m, 2H), 7.62-7.45 (m, 5H), 6.80 (d, J=6.9 Hz, 1H), 6.54 (br. S,
2H), 6.25 (br. S, 2H), 4.79-4.70 (m, 1H), 1.30 (d, J=6.7 Hz, 3H).
ES/MS 424.1 (M+H.sup.+);
[0681]
(S)-2,4-diamino-6-(1-(5-chloro-3-(3-chlorophenyl)-4-oxo-3,4-dihydro-
quinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 8a):
.sup.1H NMR (400 MHz, DMSO) .delta. 7.79 (ddd, J=17.0, 10.3, 3.2
Hz, 1H), 7.67 (ddd, J=13.3, 8.2, 1.2 Hz, 1H), 7.60 (ddd, J=7.8,
4.6, 1.2 Hz, 1H), 7.53-7.44 (m, 2H), 7.40 (qd, J=6.6, 4.6 Hz, 1H),
5.00-4.83 (m, 1H), 1.36 (dd, J=9.4, 6.7 Hz, 2H). ES/MS 467.3
(M+H.sup.+);
[0682]
(S)-2,4-diamino-6-(1-(6-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-
-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 9a): .sup.1H
NMR (400 MHz, DMSO) .delta. 7.93 (s, 1H), 7.86-7.64 (m, 5H), 7.50
(dt, J=10.0, 4.2 Hz, 2H), 7.46-7.34 (m, 4H), 5.00-4.85 (m, 1H),
1.34 (d, J=6.7 Hz, 3H). ES/MS 417.1 (M+H.sup.+);
[0683]
(S)-2,4-diamino-6-(1-(3-(3,5-difluorophenyl)-5-fluoro-4-oxo-3,4-dih-
ydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound
10a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.87 (dd, J=13.6, 8.1 Hz,
1H), 7.57 (s, 2H), 7.55 (d, J=8.2 Hz, 1H), 7.46 (d, J=8.7 Hz, 1H),
7.38-7.19 (m, 2H), 7.15 (d, J=8.6 Hz, 1H), 5.11-4.85 (m, 1H), 1.38
(d, J=6.6 Hz, 3H). ES/MS 453.3 (M+H.sup.+);
[0684]
(S)-2,4-diamino-6-(1-(3-(3,5-difluorophenyl)-6-fluoro-4-oxo-3,4-dih-
ydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile Compound
11a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.88-7.67 (m, 4H), 7.48
(d, J=9.1 Hz, 1H), 7.38-7.18 (m, 2H), 7.12 (d, J=8.4 Hz, 2H),
5.11-4.88 (m, 1H), 1.34 (t, J=37.5 Hz, 3H). ES/MS 453.2
(M+H.sup.+);
[0685]
(S)-2,4-diamino-6-(1-(5-chloro-3-(3-cyanophenyl)-4-oxo-3,4-dihydroq-
uinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 12a):
.sup.1H NMR (400 MHz, DMSO) .delta. 8.13 (t, J=1.6 Hz, 1H), 7.93
(ddd, J=8.0, 2.0, 1.2 Hz, 1H), 7.88-7.83 (m, 1H), 7.80 (dd, J=9.5,
1.7 Hz, 2H), 7.75-7.66 (m, 3H), 7.61 (ddd, J=7.5, 4.3, 3.2 Hz, 1H),
7.18-7.08 (m, 1H), 6.77-6.68 (m, 1H), 4.96-4.77 (m, 1H), 1.33 (t,
J=16.1 Hz, 3H). ES/MS 457.9 (M+H.sup.+);
[0686]
(S)-2,4-diamino-6-(1-(3-(3-cyanophenyl)-6-fluoro-4-oxo-3,4-dihydroq-
uinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 13a):
.sup.1H NMR (400 MHz, DMSO) .delta. 8.14 (t, J=1.7 Hz, 1H), 7.94
(d, J=7.9 Hz, 1H), 7.90-7.75 (m, 6H), 7.75-7.65 (m, 1H), 7.60 (t,
J=7.9 Hz, 1H), 4.99-4.83 (m, 1H), 1.35 (t, J=13.0 Hz, 3H). ES/MS
442.1 (M+H.sup.+);
[0687]
(S)-2,4-diamino-6-(1-(3-(3-chlorophenyl)-6-fluoro-4-oxo-3,4-dihydro-
quinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound
14a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.14-7.74 (m, 6H),
7.71-7.28 (m, 5H), 5.14-4.69 (m, 1H), 1.38 (dd, J=9.0, 6.8 Hz, 3H).
ES/MS 451.5 (M+H.sup.+);
[0688]
(S)-2,4-diamino-6-(1-(5-chloro-3-(3,5-difluorophenyl)-8-fluoro-4-ox-
o-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 15a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.91-7.71 (m,
2H), 7.62 (dd, J=8.8, 4.5 Hz, 2H), 7.46 (d, J=9.0 Hz, 1H),
7.37-7.26 (m, 1H), 7.13 (d, J=9.1 Hz, 1H), 5.05-4.88 (m, 1H), 1.33
(t, J=36.2 Hz, 3H). ES/MS 487.6 (M+H.sup.+);
[0689]
(S)-2,4-diamino-6-(1-(3-(3,5-difluorophenyl)-8-fluoro-4-oxo-3,4-dih-
ydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound
16a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.95 (d, J=8.0 Hz, 2H),
7.86-7.69 (m, 2H), 7.58 (td, J=8.0, 4.7 Hz, 2H), 7.48 (d, J=9.0 Hz,
1H), 7.41-7.18 (m, 2H), 7.14 (d, J=9.0 Hz, 1H), 5.09-4.86 (m, 1H),
1.40 (d, J=6.6 Hz, 3H) ES/MS 453.1 (M+H.sup.+);
[0690]
(S)-2,4-diamino-6-(1-(3-(3,5-difluorophenyl)-8-fluoro-4-oxo-3,4-dih-
ydroquinazolin-2-yl)propylamino)pyrimidine-5-carbonitrile (Compound
17a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.95 (dd, J=8.0, 0.9 Hz,
1H), 7.86-7.69 (m, 1H), 7.55 (ddd, J=30.0, 16.6, 7.0 Hz, 2H), 7.32
(tt, J=9.3, 2.4 Hz, 1H), 7.17 (d, J=9.1 Hz, 1H), 4.84 (dd, J=12.9,
7.3 Hz, 1H), 2.11-1.91 (m, 1H), 1.94-1.62 (m, 1H), 0.81 (t, J=7.3
Hz, 3H). ES/MS 467.3 (M+H.sup.+);
[0691]
(S)-2,4-diamino-6-(1-(3-(3,5-difluorophenyl)-5-methyl-4-oxo-3,4-dih-
ydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound
18a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.92 (s, 1H), 7.80-7.66
(m, 1H), 7.61-7.40 (m, 2H), 7.37-7.18 (m, 2H), 7.14 (d, J=9.0 Hz,
1H), 5.02-4.80 (m, 1H), 2.82-2.64 (s, 3H), 1.38 (s, 3H). ES/MS
449.2 (M+H.sup.+);
[0692]
(S)-2,4-diamino-6-(1-(3-(3,5-difluorophenyl)-5-methyl-4-oxo-3,4-dih-
ydroquinazolin-2-yl)propylamino)pyrimidine-5-carbonitrile (Compound
19a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.87 (s, 3H), 7.75-7.66
(m, 1H), 7.50 (dd, J=24.2, 8.6 Hz, 3H), 7.38-7.24 (m, 2H),
7.24-7.06 (m, 2H), 4.80 (dd, J=13.1, 7.5 Hz, 1H), 2.90-2.57 (m,
3H), 2.11-1.86 (m, 1H), 1.77 (dt, J=29.5, 11.4 Hz, 1H), 0.82 (m,
3H). ES/MS 463.2 (M+H.sup.+);
[0693]
(S)-2,4-diamino-6-(1-(5-chloro-3-(3-cyano-5-fluorophenyl)-4-oxo-3,4-
-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 20a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.12-7.97 (m,
1H), 7.96-7.76 (m, 4H), 7.73 (ddd, J=8.1, 2.4, 1.1 Hz, 1H),
7.67-7.61 (m, 1H), 5.08-4.78 (m, 1H), 1.40 (d, J=6.6 Hz, 3H). ES/MS
476.1 (M+H.sup.+);
[0694]
(S)-2,4-diamino-6-(1-(3-(3,5-difluorophenyl)-5,8-difluoro-4-oxo-3,4-
-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 21a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.83 (d, J=9.9
Hz, 1H), 7.56-7.26 (m, 4H), 7.17 (d, J=9.0 Hz, 1H), 5.13-4.84 (m,
1H), 1.41 (d, J=6.6 Hz, 3H). ES/MS 471.2 (M+H.sup.+);
[0695]
(S)-2,4-diamino-6-(1-(8-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-
-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 22a): .sup.1H
NMR (400 MHz, DMSO) .delta. 8.08 (dd, J=16.8, 7.2 Hz, 2H),
7.68-7.48 (m, 4H), 7.45 (s, 3H), 5.07-4.84 (m, 1H), 1.38 (d, J=6.5
Hz, 3H). ES/MS 432.9 (M+H.sup.+);
[0696]
(S)-2,4-diamino-6-(1-(5-methyl-4-oxo-3-phenyl-3,4-dihydroquinazolin-
-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 23a): .sup.1H
NMR (400 MHz, DMSO) .delta. 7.92 (s, 1H), 7.80-7.66 (m, 1H),
7.61-7.40 (m, 2H), 7.37-7.18 (m, 4H), 7.14 (d, J=9.0 Hz, 1H),
5.02-4.80 (m, 1H), 2.82-2.64 (s, 3H), 1.38 (s, 3H). ES/MS 413.1
(M+H.sup.+);
[0697]
(S)-2,4-diamino-6-(1-(3-(3-cyano-5-fluorophenyl)-5-methyl-4-oxo-3,4-
-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 24a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.17-7.80 (m,
4H), 7.76 (t, J=7.7 Hz, 1H), 7.66-7.55 (m, 1H), 7.38 (d, J=7.4 Hz,
1H), 5.03-4.81 (m, 1H), 2.76 (d, J=14.7 Hz, 3H), 1.42 (t, J=9.7 Hz,
3H). ES/MS 456.3 (M+H.sup.+);
[0698]
(S)-2,4-diamino-6-(1-(3-(3,5-difluorophenyl)-8-fluoro-5-methyl-4-ox-
o-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 25a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.66 (dd,
J=10.0, 8.3 Hz, 4H), 7.48 (d, J=9.2 Hz, 1H), 7.40-7.28 (m, 2H),
7.15 (d, J=9.3 Hz, 2H), 6.15 (ddd, J=6.4, 5.8, 3.6 Hz, 1H),
5.13-4.84 (m, 1H), 2.68 (d, J=7.0 Hz, 3H), 1.41 (d, J=6.6 Hz, 3H).
ES/MS 467.2 (M+H.sup.+);
[0699]
(S)-2,4-diamino-6-(1-(3-(3,5-difluorophenyl)-6-fluoro-4-oxo-3,4-dih-
ydroquinazolin-2-yl)propylamino)pyrimidine-5-carbonitrile (Compound
26a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.66 (dd, J=10.0, 8.3 Hz,
4H), 7.48 (d, J=9.2 Hz, 1H), 7.40-7.28 (m, 2H), 7.15 (d, J=9.3 Hz,
2H), 6.15 (ddd, J=6.4, 5.8, 3.6 Hz, 1H), 5.13-4.84 (m, 1H), 2.68
(d, J=7.0 Hz, 3H), 1.41 (d, J=6.6 Hz, 3H). ES/MS 467.4
(M+H.sup.+);
[0700]
(S)-2,4-diamino-6-(1-(3-(3,5-difluorophenyl)-5,8-difluoro-4-oxo-3,4-
-dihydroquinazolin-2-yl)propylamino)pyrimidine-5-carbonitrile
(Compound 27a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.02-7.77 (m,
1H), 7.65-7.25 (m, 4H), 7.20 (d, J=9.4 Hz, 1H), 4.80 (dd, J=12.9,
7.5 Hz, 1H), 2.08-1.67 (m, 2H), 0.88-0.65 (m, 3H). ES/MS 485.1
(M+H.sup.+);
[0701]
(S)-2,4-diamino-6-(1-(3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquina-
zolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 28a):
.sup.1H NMR (400 MHz, DMSO) .delta. 8.32-8.10 (m, 1H), 7.91 (ddd,
J=23.8, 12.7, 9.1 Hz, 1H), 7.76 (dd, J=14.1, 6.5 Hz, 1H), 7.68-7.56
(m, 1H), 7.50 (d, J=9.2 Hz, 1H), 7.32 (tt, J=9.3, 2.4 Hz, 1H), 7.18
(d, J=9.1 Hz, 1H), 5.08-4.94 (m, 1H), 1.54-1.31 (m, 3H). ES/MS
435.1 (M+H.sup.+);
[0702]
(S)-2,4-diamino-6-(1-(3-(3,5-difluorophenyl)-5,6-difluoro-4-oxo-3,4-
-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 29a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.01 (dd,
J=18.7, 9.1 Hz, 1H), 7.63 (dd, J=8.9, 3.5 Hz, 1H), 7.48 (d, J=8.5
Hz, 1H), 7.33 (dd, J=10.5, 8.2 Hz, 1H), 7.17 (d, J=8.4 Hz, 1H),
5.04-4.88 (m, 1H), 1.37 (t, J=20.2 Hz, 3H). ES/MS 471.2
(M+H.sup.+);
[0703]
(S)-2,4-diamino-6-(1-(3-(3,5-difluorophenyl)-5,6-difluoro-4-oxo-3,4-
-dihydroquinazolin-2-yl)propylamino)pyrimidine-5-carbonitrile
(Compound 30a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.00 (dd,
J=18.4, 9.1 Hz, 1H), 7.61 (dd, J=8.6, 3.5 Hz, 1H), 7.49 (d, J=8.4
Hz, 1H), 7.35 (t, J=9.3 Hz, 1H), 7.21 (d, J=8.6 Hz, 1H), 4.78 (d,
J=5.6 Hz, 1H), 1.98 (dd, J=13.1, 6.5 Hz, 1H), 1.96-1.70 (m, 1H),
0.81 (t, J=7.3 Hz, 3H). ES/MS 485.3 (M+H.sup.+);
[0704]
(S)-2,4-diamino-6-(1-(3-(3-cyano-5-fluorophenyl)-8-fluoro-5-methyl--
4-oxo-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 31a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.16-7.84 (m,
2H), 7.76-7.54 (m, 2H), 7.38 (s, 2H), 4.97 (m, 1H), 2.68 (s, 3H),
1.41 (d, J=6.5 Hz, 3H). ES/MS 474.3 (M+H.sup.+);
[0705]
(S)-2,4-diamino-6-(1-(3-(3-cyano-5-fluorophenyl)-5-fluoro-4-oxo-3,4-
-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 32a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.12-7.77 (m,
3H), 7.63 (dd, J=23.6, 9.0 Hz, 2H), 7.45-7.19 (m, 1H), 5.04-4.62
(m, 1H), 1.39 (d, J=6.5 Hz, 3H). ES/MS 460.4 (M+H.sup.+);
[0706]
(S)-2,4-diamino-6-(1-(5-fluoro-3-(3-fluoro-5-(trifluoromethyl)pheny-
l)-4-oxo-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 33a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.02-7.85 (m,
1H), 7.77-7.62 (m, 1H), 7.65-7.45 (m, 2H), 7.37 (dd, J=18.2, 7.5
Hz, 2H), 5.27-4.66 (m, 1H), 1.38 (dd, J=13.9, 6.6 Hz, 3H). ES/MS
503.6 (M+H.sup.+);
[0707]
(S)-2,4-diamino-6-(1-(3-(3,5-difluorophenyl)-4-oxo-8-(trifluorometh-
yl)-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 34a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.43 (d, J=8.1
Hz, 1H), 8.30 (d, J=7.7 Hz, 1H), 7.75 (t, J=7.8 Hz, 2H), 7.54 (d,
J=9.9 Hz, 1H), 7.32 (t, J=9.3 Hz, 1H), 7.14 (d, J=9.6 Hz, 1H), 6.75
(d, J=8.6 Hz, 4H), 6.25-5.95 (m, 1H), 5.24-4.98 (m, 1H), 1.43 (d,
J=6.6 Hz, 3H). ES/MS 503.3 (M+H.sup.+);
[0708]
(S)-2,4-diamino-6-(1-(3-(3,5-difluorophenyl)-5-fluoro-8-methyl-4-ox-
o-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 35a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.77 (dd,
J=8.5, 5.5 Hz, 1H), 7.49 (d, J=9.1 Hz, 1H), 7.31 (ddd, J=19.3,
10.1, 7.6 Hz, 2H), 7.19 (d, J=8.6 Hz, 1H), 5.16-4.76 (m, 1H), 2.57
(s, 3H), 1.41 (d, J=6.6 Hz, 3H). ES/MS 467.2 (M+H.sup.+).
[0709]
(S)-2,4-diamino-6-(1-(3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroquina-
zolin-2-yl)propylamino)pyrimidine-5-carbonitrile (Compound 36a):
.sup.1H NMR (400 MHz, DMSO) .delta. 8.22-8.07 (m, 1H), 7.99-7.84
(m, 1H), 7.73 (d, J=7.6 Hz, 1H), 7.64-7.43 (m, 2H), 7.39-7.25 (m,
1H), 7.20 (d, J=8.5 Hz, 1H), 4.83 (dd, J=12.9, 7.4 Hz, 1H),
2.10-1.89 (m, 1H), 1.89-1.61 (m, 1H), 0.85-0.69 (m, 3H). ES/MS
449.3 (M+H.sup.+);
[0710]
(S)-2,4-diamino-6-(1-(3-(3,5-difluorophenyl)-5-fluoro-8-methyl-4-ox-
o-3,4-dihydroquinazolin-2-yl)propylamino)pyrimidine-5-carbonitrile
(Compound 37a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.93-7.64 (m,
2H), 7.49 (d, J=9.0 Hz, 1H), 7.36-6.85 (m, 4H), 6.34-5.98 (m, 1H),
4.90 (dd, J=13.5, 6.6 Hz, 1H), 2.55 (s, 3H), 2.15-1.93 (m, 1H),
1.77 (dt, J=13.9, 6.9 Hz, 1H), 0.84 (t, J=7.2 Hz, 3H). ES/MS 481.1
(M+H.sup.+);
[0711]
(S)-2,4-diamino-6-(1-(3-(3-cyanophenyl)-5-fluoro-4-oxo-3,4-dihydroq-
uinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 38a):
.sup.1H NMR (400 MHz, DMSO) .delta. 8.13 (s, 1H), 7.99-7.73 (m,
3H), 7.70 (d, J=7.8 Hz, 1H), 7.65-7.52 (m, 2H), 7.46-7.22 (m, 2H),
4.87 (dd, J=14.3, 7.7 Hz, 1H), 1.36 (d, J=6.5 Hz, 3H). ES/MS 442.4
(M+H.sup.+);
[0712]
(S)-2,4-diamino-6-(1-(8-methyl-4-oxo-3-(3-(trifluoromethyl)phenyl)--
3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 39a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.08 (t, J=25.4
Hz, 1H), 8.04-7.82 (m, 2H), 7.85-7.62 (m, 3H), 7.59-7.31 (m, 1H),
5.16-4.76 (m, 1H), 2.72-2.59 (m, 3H), 1.53-1.33 (m, 3H). ES/MS
481.2 (M+H.sup.+);
[0713]
(S)-2,4-diamino-6-(1-(5-fluoro-4-oxo-3-(3-(trifluoromethyl)phenyl)--
3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 40a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.08 (s, 1H),
8.02-7.77 (m, 3H), 7.76-7.55 (m, 3H), 5.13-4.68 (m, 1H), 1.37 (dd,
J=18.9, 6.6 Hz, 3H). ES/MS 485.4 (M+H.sup.+);
[0714]
(S)-2,4-diamino-6-(1-(5-chloro-3-(3,5-dichlorophenyl)-4-oxo-3,4-dih-
ydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound
41a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.90 (s, 1H), 7.86-7.73
(m, 4H), 7.73-7.65 (m, 2H), 7.65-7.53 (m, 2H), 7.37 (t, J=1.8 Hz,
1H), 4.95 (dd, J=13.7, 6.7 Hz, 1H), 1.37 (d, J=6.6 Hz, 3H). ES/MS
501.5 (M+H.sup.+);
[0715]
(S)-2,4-diamino-6-(1-(3-(3,5-dichlorophenyl)-5-fluoro-4-oxo-3,4-dih-
ydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound
42a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.86 (td, J=8.2, 5.6 Hz,
1H), 7.77-7.67 (m, 1H), 7.61-7.46 (m, 2H), 7.35 (dd, J=17.2, 6.3
Hz, 2H), 5.12-4.72 (m, 1H), 1.37 (d, J=6.6 Hz, 3H). ES/MS 486.3
(M+H.sup.+);
[0716]
(S)-2,4-diamino-6-(1-(5-chloro-3-(3-chloro-5-fluorophenyl)-4-oxo-3,-
4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 43a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.01-7.74 (m,
1H), 7.74-7.54 (m, 1H), 7.55-7.18 (m, 4H), 5.06-4.74 (m, 1H), 1.36
(t, J=6.1 Hz, 3H). ES/MS 486.1 (M+H.sup.+);
[0717]
(S)-2,4-diamino-6-(1-(3-(3-chloro-5-fluorophenyl)-5-fluoro-4-oxo-3,-
4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 44a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.93 (dd,
J=22.1, 13.3 Hz, 1H), 7.87-7.74 (m, 1H), 7.69 (ddd, J=14.1, 8.2,
1.2 Hz, 2H), 7.60 (m, 3H), 5.09-4.81 (m, 1H), 1.47-1.26 (m, 3H).
ES/MS 468.1 (M+H.sup.+);
[0718]
(S)-2,4-diamino-6-(1-(5-chloro-3-(3-fluoro-5-(trifluoromethyl)pheny-
l)-4-oxo-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 45a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.93 (dd,
J=22.1, 13.3 Hz, 1H), 7.87-7.74 (m, 1H), 7.69 (ddd, J=14.1, 8.2,
1.2 Hz, 2H), 7.60 (m, 3H), 5.09-4.81 (m, 1H), 1.47-1.26 (m, 3H).
ES/MS 518.1 (M+H.sup.+);
[0719]
(S)-2,4-diamino-6-(1-(5-fluoro-4-oxo-3-(3-(trifluoromethyl)phenyl)--
3,4-dihydroquinazolin-2-yl)propylamino)pyrimidine-5-carbonitrile
(Compound 46a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.95-7.63 (m,
4H), 7.52 (dd, J=24.6, 8.1 Hz, 1H), 7.32 (dd, J=18.9, 10.7 Hz, 2H),
4.92-4.40 (m, 1H), 2.14-1.86 (m, 1H), 1.89-1.54 (m, 1H), 0.89-0.45
(m, 3H). ES/MS 498.2 (M+H.sup.+);
[0720]
(S)-2,4-diamino-6-(1-(5-chloro-4-oxo-3-(3-(trifluoromethyl)phenyl)--
3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 47a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.01 (d, J=38.7
Hz, 1H), 7.91-7.75 (m, 3H), 7.75-7.63 (m, 4H), 7.63-7.52 (m, 2H),
5.02-4.74 (m, 1H), 1.43-1.19 (m, 3H). ES/MS 500.1 (M+H.sup.+);
[0721]
(S)-2,4-diamino-6-(1-(5-chloro-3-(3-cyano-5-fluorophenyl)-8-fluoro--
4-oxo-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 48a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.00 (dd,
J=25.2, 16.0 Hz, 1H), 7.85 (dd, J=26.3, 17.5 Hz, 2H), 7.73-7.56 (m,
2H), 5.11-4.81 (m, 1H), 1.40 (d, J=6.6 Hz, 3H). ES/MS 494.1
(M+H.sup.+);
[0722]
(S)-2,4-diamino-6-(1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazolin-
-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 49a): .sup.1H
NMR (400 MHz, DMSO) .delta. 7.78 (t, J=8.0 Hz, 1H), 7.63 (dd,
J=8.2, 1.2 Hz, 1H), 7.57 (dd, J=7.8, 1.2 Hz, 1H), 7.57-7.45 (m,
5H), 6.79 (d, J=7.0 Hz, 1H), 6.55 (br s, 1H), 6.25 (br s, 1H), 4.72
(dq, J=6.45, 6.45 Hz, 1H), 1.29 (d, J=6.8 Hz, 3H). ES/MS 433.1
(M+H.sup.+);
[0723]
(S)-2,4-diamino-6-(1-(5,8-dichloro-4-oxo-3-phenyl-3,4-dihydroquinaz-
olin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 50a):
.sup.1H NMR (400 MHz, DMSO) .delta. 7.98 (d, J=8.6 Hz, 1H), 7.58
(d, J=8.4 Hz, 1H), 7.55-7.38 (m, 5H), 7.9-6.9 (very broad, 3H),
4.91 (dq, J=6.85, 6.85 Hz, 1H), 1.34 (d, J=6.65 Hz, 3H). ES/MS
468.1 (M+H.sup.+);
[0724]
(S)-2,4-diamino-6-(1-(5-chloro-3-(3,5-dimethoxyphenyl)-4-oxo-3,4-di-
hydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound
51a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.77 (t, J=7.8 Hz, 1H),
7.64 (d, J=8.0 Hz, 1H), 7.57 (d, J=7.8 Hz, 1H), 6.73 (m, 1H), 6.55
(m, 1H), 6.47 (m, 1H), 5.03 (m, 1H), 3.73 (s, 3H), 3.68 (s, 3H),
1.37 (d, J=6.6 Hz, 3H). ES/MS 493.1 (M+H.sup.+);
[0725]
(S)-2,4-diamino-6-(1-(5-(difluoromethyl)-3-(3,5-difluorophenyl)-4-o-
xo-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 52a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.04-7.75 (m,
5H), 7.72-7.45 (m, 3H), 7.42-7.10 (m, 4H), 5.03-4.97 (m, 1H), 1.40
(d, J=7.7 Hz, 3H). ES/MS 485.1 (M+H.sup.+);
[0726]
(S)-2,4-diamino-6-(1-(5-(difluoromethyl)-3-(3,5-difluorophenyl)-4-o-
xo-3,4-dihydroquinazolin-2-yl)propylamino)pyrimidine-5-carbonitrile
(Compound 53a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.04-7.74 (m,
5H), 7.72-7.37 (m, 4H) 7.36-7.05 (m, 3H), 4.87-4.79 (m, 1H),
2.06-1.95 (m, 1H), 1.84-1.76 (m, 1H), 0.80 (t, J=7.4 Hz, 3H). ES/MS
499.1 (M+H.sup.+);
[0727]
(S)-2,4-diamino-6-(1-(3-(3-(difluoromethyl)-5-fluorophenyl)-5-fluor-
o-4-oxo-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 54a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.05-7.33 (m,
9H), 7.29-6.81 (m, 3H), 5.05-4.86 (m, 1H), 1.43-1.34 (m, 3H). ES/MS
485.1 (M+H.sup.+);
[0728]
(S)-2,4-diamino-6-(1-(5-chloro-3-(3-(difluoromethyl)-5-fluorophenyl-
)-4-oxo-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 55a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.93-7.57 (m,
6H), 7.55-7.30 (m, 3H), 7.26-6.92 (m, 3H), 5.05-4.87 (m, 1H),
1.44-1.36 (m, 3H). ES/MS 501.1 (M+H.sup.+);
[0729]
(S)-2,4-diamino-6-(1-(8-(difluoromethyl)-4-oxo-3-phenyl-3,4-dihydro-
quinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound
56a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.31 (d, J=7.8 Hz, 1H),
8.16 (d, J=7.0 Hz, 1H), 7.91-7.05 (m, 12H), 5.03-4.93 (m, 1H), 1.37
(d, J=6.7 Hz, 3H). ES/MS 449.1 (M+H.sup.+);
[0730]
(S)-2,4-diamino-6-(1-(8-(difluoromethyl)-3-(3,5-difluorophenyl)-4-o-
xo-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 57a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.33 (d, J=7.4
Hz, 1H), 8.19 (d, J=7.4 Hz, 1H), 7.95-7.05 (m, 10H), 5.12-5.03 (m,
1H), 1.44 (d, J=6.7 Hz, 3H). ES/MS 485.1 (M+H.sup.+);
[0731]
(S)-2,4-diamino-6-(1-(8-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-
-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 58a): .sup.1H
NMR (400 MHz, DMSO) .delta. 8.08-7.90 (m, 2H), 7.86-7.70 (m, 3H),
7.65-7.50 (m, 4H), 7.47-7.20 (m, 4H), 5.01-4.92 (m, 1H), 1.38 (d,
J=6.6 Hz, 3H). ES/MS 417.1 (M+H.sup.+);
[0732]
(S)-2,4-diamino-6-(1-(5,8-difluoro-4-oxo-3-phenyl-3,4-dihydroquinaz-
olin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 59a):
.sup.1H NMR (400 MHz, DMSO) .delta. 7.92-7.72 (m, 2H), 7.70-7.50
(m, 4H), 7.48-7.11 (m, 6H), 4.93-4.85 (m, 1H), 1.36 (d, J=6.7 Hz,
3H). ES/MS 435.1 (M+H.sup.+);
[0733]
(S)-2,4-diamino-6-(1-(8-fluoro-5-methyl-4-oxo-3-phenyl-3,4-dihydroq-
uinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 60a):
.sup.1H NMR (400 MHz, DMSO) .delta. 7.91 (br s, 1H), 7.78 (br s,
2H), 7.63 (t, J=9.0 Hz, 1H), 7.57-7.47 (m, 3H), 7.46-7.37 (m, 3H),
7.37-7.24 (m, 2H), 4.95-4.86 (m, 1H), 2.51 (s, 3H), 1.36 (d, J=6.2
Hz, 3H). ES/MS 431.1 (M+H.sup.+);
[0734]
(S)-2,4-diamino-6-(1-(5-fluoro-8-methyl-4-oxo-3-phenyl-3,4-dihydroq-
uinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 61a):
.sup.1H NMR (400 MHz, DMSO) .delta. 7.87-7.60 (m, 4H), 7.58-7.42
(m, 6H), 7.40-7.11 (m, 2H), 4.95-4.87 (m, 2H), 2.57 (s, 3H), 1.35
(d, J=6.7 Hz, 3H). ES/MS 431.1 (M+H.sup.+);
[0735]
(S)-2,4-diamino-6-(1-(5-(difluoromethyl)-4-oxo-3-phenyl-3,4-dihydro-
quinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound
62a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.09-7.65 (m, 7H),
7.62-7.13 (m, 7H), 4.99-4.90 (m, 1H), 1.38 (d, J=6.7 Hz, 3H). ES/MS
449.1 (M+H.sup.+);
[0736]
(S)-2,4-diamino-6-(1-(3-(3-cyanophenyl)-5-(difluoromethyl)-4-oxo-3,-
4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 63a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.19-8.01 (m,
3H), 8.00-7.83 (m, 6H), 7.81-7.60 (m, 4H), 5.03-4.90 (m, 1H), 1.41
(d, J=6.7 Hz, 3H). ES/MS 474.1 (M+H.sup.+);
[0737]
(S)-2,4-diamino-6-(1-(3-(3-cyanophenyl)-8-fluoro-5-methyl-4-oxo-3,4-
-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 64a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.15-8.13 (m,
1H), 7.97-7.76 (m, 4H), 7.75-7.59 (m, 4H), 7.40-7.10 (m, 2H),
4.96-4.85 (m, 1H), 2.68 (s, 3H), 1.39 (d, J=6.7 Hz, 3H). ES/MS
456.1 (M+H.sup.+);
[0738]
(S)-2,4-diamino-6-(1-(3-(3-(difluoromethyl)-5-fluorophenyl)-5-fluor-
o-4-oxo-3,4-dihydroquinazolin-2-yl)propylamino)pyrimidine-5-carbonitrile
(Compound 65a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.92-7.31 (m,
9H), 7.27-6.81 (m, 3H), 4.86-4.66 (m, 1H), 2.08-1.86 (m, 1H),
1.85-1.73 (m, 1H), 0.85-0.72 (m, 3H). ES/MS 499.1 (M+H.sup.+);
[0739]
(S)-2,4-diamino-6-(1-(5-chloro-3-(3-(difluoromethyl)-5-fluorophenyl-
)-4-oxo-3,4-dihydroquinazolin-2-yl)propylamino)pyrimidine-5-carbonitrile
(Compound 66a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.87-7.40 (m,
9H), 7.32-6.81 (m, 3H), 4.86-4.63 (m, 1H), 1.44-1.36 (m, 3H),
2.08-1.86 (m, 1H), 1.85-1.73 (m, 1H), 0.85-0.72 (m, 3H). ES/MS
515.1 (M+H.sup.+);
[0740]
(S)-2,4-diamino-6-((1-(8-chloro-3-(3,5-difluorophenyl)-5-fluoro-4-o-
xo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 67a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.10 (m, 1H),
7.79, 7.68 (2 bs, 3H), 7.48 (m, 1H), 7.42 (m, 1H), 7.35 (m, 1H),
7.13 (m, 1H), 5.06 (m, 1H), 1.44 (d, 3H). ES/MS: 487.1
(M+H.sup.+);
[0741]
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-8-methoxy-4-oxo-3,4-d-
ihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 68a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.96 (bs, 1H),
7.75 (bs, 1H), 7.70 (m, 1H), 7.49 (m, 3H), 7.33 (m, 1H), 7.16 (m,
1H), 5.02 (m, 1H), 3.97 (s, 3H), 2.02 (m, 1H), 1.42 (d, 3H). ES/MS
465.1 (M+H.sup.+);
[0742]
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-6,8-difluoro-4-oxo-3,-
4-dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile
(Compound 69a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.97 (m, 1H),
7.73 (m, 1H), 7.66 (bs, 2H), 7.51 (m, 1H), 7.35 (m, 1H), 7.18 (m,
1H), 4.85 (m, 1H), 2.02 (m, 1H), 1.84 (m, 1H), 0.83 (t, 3H). ES/MS
485.1 (M+H.sup.+);
[0743]
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-6,8-difluoro-4-oxo-3,-
4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 70a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.98 (m, 1H),
7.78 (bs, 1H), 7.73 (m, 1H), 7.62 (bs, 1H), 7.50 (m, 1H), 7.34 (m,
1H), 7.15 (m, 1H), 5.03 (m, 1H), 1.42 (d, 3H). ES/MS calcd. For
C.sub.21H.sub.14F.sub.4N.sub.8O: 470.1. found m/z=471.1
(M+H.sup.+).
[0744]
(S)-2,4-diamino-6-((1-(8-chloro-3-(3,5-difluorophenyl)-4-oxo-3,4-di-
hydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 71a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.11 (m, 2H),
7.83 (bs, 1H), 7.67 (bs, 1H), 7.59 (t, 1H), 7.51 (m, 1H), 7.34 (m,
1H), 7.12 (m, 1H), 5.09 (m, 1H), 1.45 (d, 3H). ES/MS 469.1
(M+H.sup.+);
[0745]
(S)-2,4-diamino-6-((1-(8-chloro-3-(3,5-difluorophenyl)-4-oxo-3,4-di-
hydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile
(Compound 72a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.10 (m, 2H),
7.75 (bs, 2H), 7.59 (t, 1H), 7.51 (m, 1H), 7.33 (m, 2H), 7.12 (m,
1H), 4.98 (m, 1H), 2.08 (m, 1H), 1.83 (m, 1H), 0.89 (t, 3H). ES/MS
483.1 (M+H.sup.+);
[0746]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3,5-difluorophenyl)-8-methyl-4-o-
xo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 73a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.78 (bs, 1H),
7.73 (bs, 1H), 7.72 (dd, 1H), 7.49 (m, 2H), 7.36 (m, 1H), 7.18 (m,
1H), 5.03 (m, 1H), 2.58 (s, 3H), 1.42 (d, 3H). ES/MS 483.1
(M+H.sup.+);
[0747]
(S)-2,4-diamino-6-((1-(5,8-dichloro-3-(3,5-difluorophenyl)-4-oxo-3,-
4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 74a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.04 (d, 1H),
7.76 (bs, 1H), 7.66 (bs, 1H), 7.63 (d, 1H), 7.49 (m, 1H), 7.35 (m,
1H), 7.14 (m, 1H), 5.05 (m, 1H), 1.43 (d, 3H). ES/MS 503.0
(M+H.sup.+);
[0748]
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-8-methyl-4-oxo-3,4-di-
hydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 75a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.99 (m, 1H),
7.89 (bs, 1H), 7.79 (m, 1H), 7.78 (bs, 1H), 7.49 (m, 2H), 7.36 (m,
1H), 7.18 (m, 1H), 5.06 (m, 1H), 2.64 (s, 3H), 1.44 (d, 3H). ES/MS
449.1 (M+H.sup.+);
[0749]
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-8-methyl-4-oxo-3,4-di-
hydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile
(Compound 76a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.98 (m, 1H),
7.79 (bs, 2H), 7.78 (m, 1H), 7.73 (bs, 2H), 7.49 (m, 2H), 7.36 (m,
1H), 7.19 (m, 1H), 4.95 (m, 1H), 2.63 (s, 3H), 2.06 (m, 1H), 1.80
(m, 1H), 0.86 (t, 3H). ES/MS 463.1 (M+H.sup.+);
[0750]
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-5-fluoro-4-oxo-3,4-di-
hydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile
(Compound 77a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.89 (m, 2H),
7.88 (bs, 2H), 7.56 (dd, 1H), 7.51 (m, 1H), 7.36 (m, 2H), 7.20 (m,
1H), 4.81 (m, 1H), 2.00 (m, 1H), 1.84 (m, 1H), 0.82 (t, 3H). ES/MS
calcd. For C.sub.22H.sub.17F.sub.3N.sub.8O: 466.2. found m/z=467.2
(M+H.sup.+).
[0751]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3,5-difluorophenyl)-4-oxo-3,4-di-
hydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile
(Compound 78a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.82 (t, 1H),
7.82 (bs, 2H), 7.69 (dd, 1H), 7.63 (dd, 1H), 7.51 (m, 1H), 7.35 (m,
1H), 7.20 (m, 1H), 4.80 (m, 1H), 2.00 (m, 1H), 1.83 (m, 1H), 0.81
(t, 3H). ES/MS 483.1 (M+H.sup.+);
[0752]
(S)-2,4-diamino-6-(1-(3-(3,5-difluorophenyl)-6,7-difluoro-4-oxo-3,4-
-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 79a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.10-8.05 (m,
1H), 7.88-7.84 (m, 2H), 7.70 (s, 1H), 7.48-7.46 (d, J=8.8, 1H),
7.33-7.28 (m, 1H), 7.12-7.10 (d, J=8.4, 1H), 4.85 (dd, J=13.6, 6.4
Hz, 1H), 1. (d, J=6.4 Hz, 3H). ES/MS 471.1 (M+H.sup.+);
[0753]
2,4-diamino-6-((3-(3,5-difluorophenyl)-6,7-difluoro-4-oxo-3,4-dihyd-
roquinazolin-2-yl)methylamino)pyrimidine-5-carbonitrile (Compound
80);
[0754]
(S)-2,4-diamino-6-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-
-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound 81a): .sup.1H
NMR (400 MHz, DMSO) .delta. 7.90-7.85 (m, 2H), 7.75 (s, 1H),
7.63-7.58 (m, 1H), 7.56 (s, 1H), 7.54-7.52 (m, 2H), 7.46-7.39 (m,
3H), 4.89 (dd, J=13.6, 6.4 Hz 1H), 1.38 (d, J=6.4 Hz, 3H). ES/MS
417.2 (M+H.sup.+);
[0755]
(S)-2,4-diamino-6-(1-(3-(3-cyanophenyl)-5-fluoro-8-methyl-4-oxo-3,4-
-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 82a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.15 (s, 1H),
7.97-785 (m, 3H), 7.80-7.63 (m, 4H), 7.31-7.25 (m, 1H), 4.96-4.90
(m, 1H), 2.58 (s, 3H), 1.40 (t, J=5.2 Hz, 3H). ES/MS 456.2
(M+H.sup.+);
[0756]
(S)-2,4-diamino-6-(1-(3-(3-cyano-5-fluorophenyl)-5-fluoro-8-methyl--
4-oxo-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 83a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.06-8.00 (m,
2H), 7.96-7.91 (m, 2H), 7.84-7.75 (m, 2H), 7.65-7.62 (m, 1H), 4.85
(dd, J=13.0, 6.4 Hz, 1H), 2.58 (s, 3H), 1.44 (d, J=6.8 Hz, 3H).
ES/MS 474.2 (M+H.sup.+);
[0757]
2,4-diamino-6-((8-chloro-3-(3-cyanophenyl)-4-oxo-3,4-dihydroquinazo-
lin-2-yl)methylamino)pyrimidine-5-carbonitrile (Compound 84);
[0758]
(S)-2,4-diamino-6-(1-(6-chloro-3-(3,5-difluorophenyl)-5-fluoro-4-ox-
o-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 85a);
[0759]
(S)-2,4-diamino-6-(1-(6-chloro-3-(3,5-difluorophenyl)-5-fluoro-4-ox-
o-3,4-dihydroquinazolin-2-yl)propylamino)pyrimidine-5-carbonitrile
(Compound 86a);
[0760]
(S)-5-(5-chloro-2-(1-(2,6-diamino-5-cyanopyrimidin-4-ylamino)ethyl)-
-4-oxoquinazolin-3(4H)-yl)isophthalonitrile (Compound 87a);
[0761]
(S)-2,4-diamino-6-(1-(3-(3,5-bis(trifluoromethyl)phenyl)-5-fluoro-4-
-oxo-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 88a);
[0762]
(S)-2,4-diamino-6-(1-(8-chloro-3-(3,5-difluorophenyl)-6-fluoro-4-ox-
o-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 89a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.19 (dd,
J=8.5, 2.9 Hz, 1H), 7.85 (dd, J=8.1, 2.9 Hz, 1H), 7.48 (d, J=9.0
Hz, 1H), 7.35-7.28 (m, 1H), 7.10 (d, J=8.9 Hz, 1H), 5.11-4.99 (m,
1H), 1.43 (d, J=6.5 Hz, 3H). ES/MS 487.5 (M+H.sup.+);
[0763]
(S)-2,4-diamino-6-(1-(5-chloro-3-(3,5-difluorophenyl)-4-oxo-3,4-dih-
ydroquinazolin-2-yl)ethylamino)pyrimidine-5-carboxamide (Compound
90a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.84 (d, J=6.8 Hz, 1H),
7.84-7.76 (m, 1H), 7.65 (d, J=1.2 Hz, 1H), 7.62 (dd, J=3.8, 1.2 Hz,
1H), 7.60 (d, J=1.2 Hz, 1H), 7.49 (m, 5H), 7.38 (d, J=8.9 Hz, 1H),
4.91-4.68 (m, 1H), 1.34 (d, J=6.6 Hz, 3H). (M+H.sup.+);
[0764]
(S)-2-(1-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-3-(3,5-di-
fluorophenyl)-4-oxo-3,4-dihydroquinazoline-5-carboxamide (Compound
91a). .sup.1H NMR (400 MHz, DMSO) .delta. 7.85 (dd, J=8.1, 7.4 Hz,
1H), 7.72 (dd, J=8.2, 1.2 Hz, 1H), 7.50 (br. S, 1H), 7.43 (br. D,
J=9.0 Hz, 1H), 7.39 (dd, J=7.3, 1.2 Hz, 1H), 7.95-6.84 (m, 4H),
7.36-7.27 (m, 2H), 7.13 (br. D, J=8.5 Hz, 1H), 5.06-4.96 (m, 1H),
1.40 (d, J=6.6 Hz, 3H). ES/MS 478.1 (M+H.sup.+).
[0765]
(S)-2-(1-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-p-
henyl-3,4-dihydroquinazoline-5-carboxamide (Compound 92a). .sup.1H
NMR (400 MHz, DMSO) .delta. 7.83 (dd, J=8.1, 7.4 Hz, 1H), 7.69 (dd,
J=8.2, 1.2 Hz, 1H), 8.01-7.04 (br. M, 4H), 7.58-7.39 (m, 5H), 7.36
(dd, J=7.3, 1.2 Hz, 1H), 7.27 (br. S, 2H), 4.96-4.83 (m, 1H), 1.33
(d, J=6.7 Hz, 3H). ES/MS 442.1 (M+H.sup.+).
[0766]
(S)-2,4-diamino-6-(1-(5-chloro-3-(3-(difluoromethyl)-5-fluorophenyl-
)-4-oxo-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carboxamide
(Compound 93a): .sup.1H NMR (400 MHz, DMSO) .delta. 11.00 (s, 1H),
9.65 (s, 1H), 7.76-7.67 (m, 3H), 7.60-7.27 (m, 5H), 7.25-6.90 (m,
4H), 4.70-4.63 (m, 1H), 1.31 (d, J=7.0 Hz, 3H). ES/MS 519.1
(M+H.sup.+);
[0767]
(S)-5-chloro-2-(1-(2,6-diamino-5-(methylsulfonyl)pyrimidin-4-ylamin-
o)ethyl)-3-(3,5-difluorophenyl)quinazolin-4(3H)-one (Compound
94a);
[0768]
(S)-2,4-diamino-6-(1-(5-(methylsulfonyl)-4-oxo-3-phenyl-3,4-dihydro-
quinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound
95a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.33 (dd, J=7.1 and 2.0
Hz, 1H), 8.13-8.06 (m, 2H), 8.02-7.62 (m, 4H), 7.59-7.41 (m, 6H),
5.01-4.93 (m, 1H), 3.51 (s, 3H), 1.38 (d, J=6.6 Hz, 3H). ES/MS
477.1 (M+H.sup.+);
[0769]
(S)-2,4-diamino-6-(1-(3-(3,5-difluorophenyl)-5-(methylsulfonyl)-4-o-
xo-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 96a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.37-8.31 (m,
1H), 8.14-8.07 (m, 2H), 7.95-7.55 (m, 4H), 7.52 (d, J=8.6 Hz, 1H),
7.40-7.25 (m, 2H), 7.15 (d, J=9.0 Hz, 1H), 5.09-5.01 (m, 1H), 3.50
(s, 3H), 1.42 (d, J=6.2 Hz, 3H). ES/MS 513.1 (M+H.sup.+);
[0770]
(S)-2,4-diamino-6-(1-(3-(3-(difluoromethyl)phenyl)-5-fluoro-4-oxo-3-
,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 97a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.12-7.45 (m,
9H), 7.42-6.79 (m, 4H), 5.00-4.82 (m, 1H), 1.39-1.30 (m, 3H). ES/MS
467.1 (M+H.sup.+);
[0771]
(S)-2,4-diamino-6-(1-(3-(3-(difluoromethyl)-5-fluorophenyl)-5-(meth-
ylsulfonyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbo-
nitrile (Compound 98a): .sup.1H NMR (400 MHz, DMSO) .delta.
8.36-8.31 (m, 1H), 8.14-8.07 (m, 2H), 8.05-7.55 (m, 4H), 7.50-6.32
(m, 5H), 5.14-4.97 (m, 1H), 3.50 (s, 3H), 1.44-1.37 (m, 3H). ES/MS
545.1 (M+H.sup.+);
[0772]
(S)-2,4-diamino-6-(1-(5-(difluoromethyl)-3-(3-(difluoromethyl)-5-fl-
uorophenyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbo-
nitrile (Compound 99a): .sup.1H NMR (400 MHz, DMSO) .delta.
8.07-7.87 (m, 4H), 7.82-7.30 (m, 6H), 7.25-6.78 (m, 3H), 5.08-4.93
(m, 1H), 1.43-1.36 (m, 3H). ES/MS 517.1 (M+H.sup.+);
[0773]
(S)-2,4-diamino-6-(1-(5-chloro-3-(3-(difluoromethyl)phenyl)-4-oxo-3-
,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carboxamide
(Compound 100a): .sup.1H NMR (400 MHz, DMSO) .delta. 11.10 (br s,
1H), 8.95-8.71 (m, 1H), 7.84-7.35 (m, 12H), 7.26-6.83 (m, 1H),
4.77-4.87 (m, 1H), 1.32-1.22 (m, 3H). ES/MS 501.1 (M+H.sup.+);
[0774]
(S)-2-(1-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-3-(3,5-di-
fluorophenyl)-4-oxo-3,4-dihydroquinazoline-8-carbonitrile (Compound
101a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.48-8.42 (m, 2H), 7.87
(bs, 1H), 7.77-7.73 (m, 1H), 7.74 (bs, 1H), 7.51-7.49 (m, 1H),
7.35-7.29 (m, 1H), 7.08-7.05 (m, 1H), 5.15 (m, 1H), 1.48 (d, J=6.4
Hz, 3H). ES/MS 460.1 (M+H.sup.+);
[0775]
(S)-2,4-diamino-6-((1-(8-chloro-3-(3,5-difluorophenyl)-5-fluoro-4-o-
xo-3,4-dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile
(Compound 102a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.11-8.08 (m,
1H), 7.86-7.60 (2 bs, 3H), 7.51-7.48 (m, 1H), 7.44-7.39 (m, 1H),
7.36-7.32 (m, 1H), 7.13-7.11 (m, 1H), 4.94 (m, 1H), 2.06 (m, 1H),
1.82 (m, 1H), 0.88 (t, 3H). ES/MS 501.1 (M+H.sup.+);
[0776]
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-8-ethyl-4-oxo-3,4-dih-
ydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound
103a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.00 (dd, J=7.6, 1.2 Hz,
1H), 7.84 (bs, 1H), 7.78 (dd, J=7.6, 1.6 Hz, 1H), 7.77 (bs 1H),
7.54-7.50 (m, 1H), 7.37-7.32 (m, 1H), 7.21-7.18 (m, 1H), 5.06 (m,
1H), 3.10 (m, 2H), 1.43 (d, J=6.8 Hz, 3H), 1.30 (t, J=7.2 Hz, 3H).
ES/MS 463.2 (M+H.sup.+);
[0777]
(S)-5-chloro-2-(1-((2,6-diamino-5-chloropyrimidin-4-yl)amino)ethyl)-
-3-phenylquinazolin-4(3H)-one (Compound 104a): .sup.1H NMR (400
MHz, DMSO) .delta. 7.80 (t, J=8.0, 1H), 7.72 (bs, 1H), 7.69 (d,
J=1.2 Hz, 1H), 7.69 (bs, 1H), 7.67 (d, J=1.2 Hz, 1H), 7.61 (d,
J=1.2 Hz, 1H), 7.59 (d, J=1.2 Hz, 1H), 7.54-7.52 (m, 2H), 7.48 (bs,
2H), 7.43-7.40 (m, 3H), 7.31 (bs, 1H), 4.85 (m, 1H), 1.36 (d, J=6.8
Hz, 3H). ES/MS 442.1 (M+H.sup.+);
[0778]
(S)-2-(1-((2,6-diamino-5-chloropyrimidin-4-yl)amino)propyl)-3-(3,5--
difluorophenyl)-5-fluoroquinazolin-4(3H)-one (Compound 105a):
.sup.1H NMR (400 MHz, DMSO) .delta. 7.92-7.86 (m, 2H), 7.74 (d, J=8
Hz, 1H), 7.58-7.56 (m, 2H), 7.54-7.50 (m, 2H), 7.40-7.31 (m, 2H),
7.01-6.93 (m, 1H), 4.77 (m, 1H), 2.02 (m, 1H), 1.84 (m, 1H), 0.84
(t, 3H). ES/MS 476.1 (M+H.sup.+);
[0779]
(S)-2,4-diamino-6-(1-(5-chloro-3-(3-(difluoromethyl)phenyl)-4-oxo-3-
,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 106a);
[0780]
(S)-2,4-diamino-6-(1-(5-chloro-3-(3-isopropylphenyl)-4-oxo-3,4-dihy-
droquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound
107a);
[0781]
(S)-2,4-diamino-6-(1-(5-chloro-3-(3-fluorophenyl)-4-oxo-3,4-dihydro-
quinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile (Compound
108a);
[0782]
(S)-2,4-diamino-6-(1-(5-chloro-3-(3-methoxy-2-methylphenyl)-4-oxo-3-
,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compounds 109a-1 and 109a-2); and
[0783]
(S)-2,4-diamino-6-(1-(5-chloro-3-(5-fluoro-3-methoxy-2-methylphenyl-
)-4-oxo-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compounds 110a-1 and 110a-2).
[0784]
(S)-2,4-diamino-6-((1-(5-methoxy-4-oxo-3-phenyl-3,4-dihydroquinazol-
in-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 111a).
.sup.1H NMR (400 MHz, DMSO) .delta. 8.05-7.54 (br. M, 4H), 7.75 (t,
J=8.2 Hz, 1H), 7.53-7.35 (m, 5H), 7.21 (dd, J=8.1, 0.8 Hz, 1H),
7.09-7.03 (m, 1H), 4.89-4.77 (m, 1H), 3.82 (s, 3H), 1.31 (d, J=6.6
Hz, 1H). ES/MS 429.2 (M+H.sup.+).
[0785]
(S)-2-(1-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-3-(3,5-di-
fluorophenyl)-4-oxo-3,4-dihydroquinazoline-5-carbonitrile (Compound
112a). .sup.1H NMR (400 MHz, DMSO) .delta. 8.11 (dd, J=6.5, 2.3 Hz,
1H), 8.09-7.99 (m, 2H), 7.95-7.52 (br. M, 4H), 7.52-7.46 (m, 1H),
7.36 (tt, J=9.3, 2.4 Hz, 1H), 7.20 (dd, J=9.1, 0.8 Hz, 1H),
5.03-4.91 (m, 1H), 1.40 (d, J=6.6 Hz, 3H). ES/MS 460.1
(M+H.sup.+).
[0786]
(S)-3-(3-cyano-5-fluorophenyl)-2-(1-((2,6-diamino-5-cyanopyrimidin--
4-yl)amino)ethyl)-4-oxo-3,4-dihydroquinazoline-5-carbonitrile
(Compound 113a). .sup.1H NMR (400 MHz, DMSO) .delta. 8.15-8.10 (m,
1H), 8.10-7.99 (m, 3H), 7.98-7.90 (m, 1H), 7.72-7.63 (m, 1H),
7.57-6.81 (br. M, 4H), 5.01-4.90 (m, 1H), 1.39 (d, J=6.6 Hz, 3H).
ES/MS 467.1 (M+H.sup.+).
[0787]
(S)-2,4-diamino-6-((1-(3-(3-chloro-5-(difluoromethyl)phenyl)-5-fluo-
ro-4-oxo-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 114a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.96-7.78 (m,
3H), 7.65-7.50 (m, 4H), 7.36-7.31 (m, 2H), 7.21-6.77 (m, 3H),
4.96-4.90 (m, 1H), 1.38-1.33 (m, 3H). ES/MS 501.1 (M+H.sup.+);
[0788]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-chloro-5-(difluoromethyl)pheny-
l)-4-oxo-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 115a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.96-7.75 (m,
3H), 7.72-7.64 (m, 2H), 7.63-7.50 (m, 4H), 7.21-6.78 (m, 3H),
4.97-4.87 (m, 1H), 1.39-1.31 (m, 3H). ES/MS 517.1 (M+H.sup.+);
[0789]
(S)-2,4-diamino-6-((1-(3-(3-(difluoromethyl)phenyl)-5-(methylsulfon-
yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 116a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.36-8.31 (m,
1H), 8.18-8.05 (m, 2H), 8.00-7.40 (m, 7H), 7.35-6.83 (m, 3H),
5.08-4.92 (m, 1H), 3.51-3.48 (m, 3H), 1.44-1.35 (m, 3H). ES/MS
527.1 (M+H.sup.+);
[0790]
(S)-2,4-diamino-6-((1-(3-(3-fluorophenyl)-5-(methylsulfonyl)-4-oxo--
3,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 117a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.36-8.32 (m,
1H), 8.13-8.05 (m, 2H), 8.00-7.65 (m, 3H), 7.63-7.42 (m, 3H),
7.40-7.20 (m, 3H), 5.06-4.96 (m, 1H), 3.50 (s, 3H), 1.41 (d, J=6.7
Hz, 3H). ES/MS 495.1 (M+H.sup.+);
[0791]
(S)-2,4-diamino-6-((1-(3-(3,5-bis(difluoromethyl)phenyl)-5-fluoro-4-
-oxo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 118a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.10-7.86 (m,
3H), 7.84-7.66 (m, 3H), 7.60 (d, J=8.2 Hz, 1H), 7.45-6.89 (m, 6H),
5.03-4.94 (m, 1H), 1.39 (d, J=6.7 Hz, 3H). ES/MS 517.1
(M+H.sup.+);
[0792]
(S)-2,4-diamino-6-((1-(3-(3,5-bis(difluoromethyl)phenyl)-5-chloro-4-
-oxo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 119a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.08-7.95 (m,
1H), 8.04 (s, 1H), 7.90-7.66 (m, 6H), 7.64 (dd, J=5.1 and 1.2 Hz,
1H), 7.33-6.90 (m, 4H), 5.02-4.94 (m, 1H), 1.39 (d, J=6.7 Hz, 3H).
ES/MS 533.1 (M+H.sup.+);
[0793]
(S)-2,4-diamino-6-(1-(5-chloro-3-(3-(difluoroethyl)phenyl)-4-oxo-3,-
4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 120a). .sup.1H NMR (400 MHz, DMSO) .delta. 7.87-7.72 (m,
2H), 7.72-7.64 (m, 1H), 7.62-7.46 (m, 4H), 5.04-4.83 (m, 1H),
5.04-4.70 (m, 1H), 1.93 (m, 4H), 1.42-1.22 (m, 3H).
[0794]
(S)-2,4-diamino-6-(1-(3-(3-(difluoromethyl)phenyl)-5-fluoro-4-oxo-3-
,4-dihydroquinazolin-2-yl)ethylamino)pyrimidine-5-carbonitrile
(Compound 121a). .sup.1H NMR (400 MHz, DMSO) .delta. 7.84 (m, 2H),
7.58 (m, 4H), 7.38-7.12 (m, 1H), 5.14-4.61 (m, 2H), 1.93 (dt,
J=34.0, 18.8 Hz, 4H), 1.34 (dd, J=13.7, 6.5 Hz, 3H). ES/MS 467.1
(M+H.sup.+).
[0795]
(S)-2-(1-(2,6-diamino-5-cyanopyrimidin-4-ylamino)ethyl)-4-oxo-3-phe-
nyl-3,4-dihydroquinazoline-8-carbonitrile (Compound 122a).
[0796]
(S)-2-(1-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-8-fluoro--
4-oxo-3-phenyl-3,4-dihydroquinazoline-5-carbonitrile (Compound
124a). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.10 (dd, J=8.4,
4.5 Hz, 1H), 7.93 (dd, J=9.6, 8.4 Hz, 1H), 7.84-7.50 (br. m, 4H),
7.49-7.37 (m, 3H), 7.35-6.90 (br. m, 2H), 4.92-4.80 (m, 1H), 1.32
(d, J=6.6 Hz, 3H). ES/MS 442.1 (M+H.sup.+).
[0797]
(S)-2-(1-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-3-(3,5-di-
fluorophenyl)-8-fluoro-4-oxo-3,4-dihydroquinazoline-5-carbonitrile
(Compound 125a). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.14
(dd, J=8.4, 4.5 Hz, 1H), 7.97 (dd, J=9.6, 8.5 Hz, 1H), 7.78-6.87
(br. m, 4H), 7.50-7.42 (m, 1H), 7.34 (tt, J=9.3, 2.4 Hz, 1H),
7.21-7.13 (m, 1H), 5.01-4.87 (m, 1H), 1.37 (d, J=6.5 Hz, 3H). ES/MS
478.1 (M+H.sup.+).
[0798]
(S)-5-chloro-2-(1-((2,6-diamino-5-chloropyrimidin-4-yl)amino)ethyl)-
-8-fluoro-3-phenylquinazolin-4(3H)-one (Compound 127a). .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 7.82-7.70 (m, 2H), 7.61 (dd, J=8.8,
4.5 Hz, 1H), 7.58-7.48 (m, 4H), 7.44-7.37 (m, 4H), 4.95-4.80 (m,
1H), 1.38 (d, J=6.6 Hz, 3H). ES/MS 460.1 (M+H.sup.+).
[0799]
(S)-2,4-diamino-6-((1-(5-bromo-4-oxo-3-phenyl-3,4-dihydroquinazolin-
-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 129a).
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.75 (dd, J=6.6, 2.5
Hz, 1H), 7.70-7.59 (m, 2H), 7.57-7.34 (m, 5H), 6.77 (d, J=7.0 Hz,
1H), 6.53 (s, 2H), 6.23 (s, 2H), 4.69 (h, J=6.6 Hz, 1H), 1.26 (d,
J=6.7 Hz, 3H). ES/MS 477.1 (M+H.sup.+).
[0800]
(S)-2,4-diamino-6-((1-(5-bromo-3-(3-fluorophenyl)-4-oxo-3,4-dihydro-
quinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound
130a). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.80 (dt, J=5.1,
3.0 Hz, 1H), 7.73-7.64 (m, 2H), 7.63-7.48 (m, 1H), 7.48-7.35 (m,
1H), 7.35-7.23 (m, 1H), 6.83 (td, J=7.7, 6.8, 4.1 Hz, 1H), 6.54 (s,
2H), 6.25 (d, J=18.2 Hz, 2H), 4.85-4.67 (m, 1H), 1.39-1.27 (m, 3H).
ES/MS 495.1 (M+H.sup.+).
[0801]
(S)-2-(1-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-3-(3-fluo-
rophenyl)-4-oxo-3,4-dihydroquinazoline-5-carbonitrile (Compound
131a). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.12-8.05 (m,
1H), 8.04-7.95 (m, 2H), 7.64-7.51 (m, 1H), 7.51-7.39 (1, 2H),
7.39-7.26 (m, 1H), 6.84 (dd, J=6.8, 4.8 Hz, 1H), 6.55 (s, 2H), 6.26
(d, J=17.5 Hz, 2H), 4.87-4.72 (m, 1H), 1.41-1.28 (m, 3H). ES/MS
442.1 (M+H.sup.+).
[0802]
(S)-2,4-diamino-6-((3,3,3-trifluoro-1-(6-fluoro-4-oxo-3-phenyl-3,4--
dihydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile
(Compound 132a). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
7.94-6.50 (m, 12H), 5.23 (t, J=8.0 Hz, 1H), 3.53 (brs, 2H)
3.19-2.68 (m, 2H). ES/MS 485.2 (M+H).sup.+.
[0803]
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-6-fluoro-4-oxo-3,4-di-
hydroquinazolin-2-yl)-3,3,3-trifluoropropyl)amino)pyrimidine-5-carbonitril-
e (Compound 133a). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
8.37-6.70 (m, 9H), 6.58-6.33 (m, 1H), 6.30-6.12 (m, 1H), 5.27 (td,
J=7.9, 4.4 Hz, 1H), 3.68 (d, J=11.1 Hz, 1H), 3.22-2.87 (m, 2H).
ES/MS 521.2 (M+H).sup.+.
[0804]
(R)-2,4-diamino-6-((1-(5-chloro-3-(3,5-difluorophenyl)-4-oxo-3,4-di-
hydroquinazolin-2-yl)-2-methoxyethyl)amino)pyrimidine-5-carbonitrile
(Compound 135a). 1H NMR (400 MHz, DMSO-d6) .delta. 8.12-7.01 (m,
12H), 5.13 (p, J=6.3 Hz, 1H), 3.88 (dt, J=10.6, 5.4 Hz, 1H), 3.66
(dt, J=9.7, 6.0 Hz, 1H), 3.21 (s, 3H). ES/MS 499.3 (M+H).sup.+;
[0805]
(S)-2,4-diamino-6-((1-(3-(3,5-bis(difluoromethyl)phenyl)-5-fluoro-4-
-oxo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 136): .sup.1H NMR (400 MHz, DMSO) .delta. 8.12-7.96 (m,
3H), 7.90 (td, J=8.2, 5.5 Hz, 1H), 7.85-7.65 (m, 3H), 7.60 (dd,
J=8.3, 1.0 Hz, 1H), 7.47-6.88 (m, 5H), 4.98 (p, J=6.6 Hz, 1H), 1.39
(d, J=6.6 Hz, 3H). ES/MS 517.1 (M+H.sup.+);
[0806]
(S)-2,4-diamino-6-((1-(3-(3,5-bis(difluoromethyl)phenyl)-5-chloro-4-
-oxo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 137): .sup.1H NMR (400 MHz, DMSO) .delta. 8.11-7.93 (m,
2H), 7.90-7.67 (m, 5H), 7.64 (dd, J=7.8, 1.2 Hz, 1H), 7.37-6.88 (m,
3H), 5.02-4.93 (m, 1H), 1.39 (d, J=6.6 Hz, 3H). ES/MS 533.1
(M+H.sup.+);
[0807]
(S)-2-(1-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-3-(3-(dif-
luoromethyl)-5-fluorophenyl)-4-oxo-3,4-dihydroquinazoline-5-carbonitrile
(Compound 138a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.18-7.98 (m,
5H), 7.91-7.31 (m, 5H), 7.28-6.80 (m, 2H), 5.10-4.90 (m, 1H),
1.44-1.36 (m, 3H). ES/MS 492.1 (M+H.sup.+);
[0808]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3,5-difluorophenyl)-6-fluoro-4-o-
xo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 140a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.01-7.72 (m,
7H), 7.49 (dm, J=8.8 Hz, 1H), 7.34 (tt, J=9.4, 2.4 Hz, 1H),
7.19-7.12 (m, 1H), 4.98 (p, J=6.7 Hz, 1H), 1.40 (d, J=6.6 Hz, 3H).
ES/MS 487.1 (M+H.sup.+);
[0809]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-(difluoromethyl)-5-fluoropheny-
l)-6-fluoro-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carb-
onitrile (Compound 141a): .sup.1H NMR (400 MHz, DMSO) .delta.
8.00-7.95 (m, 2H), 7.85-7.51 (m, 4H), 7.51-7.38 (m, 3H), 7.26-6.81
(m, 2H), 5.05-4.88 (m, 1H), 1.44-1.35 (m, 3H). ES/MS 519.1
(M+H.sup.+);
[0810]
(S)-2,4-diamino-6-((1-(3-(2-fluorophenyl)-5-(methylsulfonyl)-4-oxo--
3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 142a-1): .sup.1H NMR (400 MHz, DMSO) .delta. 8.36-8.30
(m, 1H), 8.15-8.06 (m, 3H), 7.71-7.45 (m, 3H), 7.42-7.25 (m, 3H),
7.23-7.05 (m, 2H), 5.30-5.22 (m, 1H), 3.49 (s, 3H), 1.43 (d, J=6.5
Hz, 3H). ES/MS 495.1 (M+H.sup.+);
[0811]
(S)-2,4-diamino-6-((1-(3-(2-fluorophenyl)-5-(methylsulfonyl)-4-oxo--
3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 142a-2): .sup.1H NMR (400 MHz, DMSO) .delta. 8.33 (dt,
J=7.4, 1.4 Hz, 1H), 8.14-8.04 (m, 3H), 7.87 (br s, 2H), 7.71-7.39
(m, 4H), 7.36-7.10 (m, 2H), 5.01-4.94 (m, 1H), 3.49 (s, 3H), 1.35
(d, J=6.5 Hz, 3H). ES/MS 495.1 (M+H.sup.+);
[0812]
(S)-2,4-diamino-6-((1-(5-chloro-3-(2,6-difluorophenyl)-4-oxo-3,4-di-
hydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 145a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.37 (br s,
1H), 7.88 (td, J=8.0, 1.0 Hz, 1H), 7.79-7.61 (m, 4H), 7.50-7.38 (m,
1H), 7.28 (t, J=8.9 Hz, 1H), 7.19-7.05 (m, 3H), 5.27-5.18 (m, 1H),
1.43 (d, J=6.5 Hz, 3H). ES/MS 469.1 (M+H.sup.+);
[0813]
(S)-2,4-diamino-6-((1-(3-(2,6-difluorophenyl)-5-(methylsulfonyl)-4--
oxo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 146a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.38-8.30 (m,
1H), 8.18-8.13 (m, 2H), 7.51-7.41 (m, 2H), 7.30 (t, J=9.0 Hz, 1H),
7.12-7.07 (m, 2H), 5.34-5.25 (m, 1H), 3.48 (s, 3H), 1.45 (d, J=6.5
Hz, 3H). ES/MS 513.1 (M+H.sup.+);
[0814]
(S)-2,4-diamino-6-((1-(5,8-difluoro-3-(3-fluorophenyl)-4-oxo-3,4-di-
hydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 148a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.93-7.61 (m,
5H), 7.57-7.41 (m, 2H), 7.41-7.29 (m, 2H), 7.27-7.20 (m, 2H),
4.96-4.82 (m, 1H), 1.38-1.32 (d, J=6.5 Hz, 3H). ES/MS 453.1
(M+H.sup.+);
[0815]
(S)-2,4-diamino-6-((1-(3-(3-cyanophenyl)-5,8-difluoro-4-oxo-3,4-dih-
ydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound
149a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.11-8.08 (m, 1H), 7.91
(ddd, J=8.0, 2.0, 1.2 Hz, 1H), 7.87-7.74 (m, 4H), 7.73-7.66 (m,
2H), 7.62-7.56 (m, 1H), 7.40-7.33 (m, 2H), 4.90-4.80 (m, 1H), 1.34
(d, J=6.5 Hz, 3H). ES/MS 460.1 (M+H.sup.+);
[0816]
(S)-2,4-diamino-6-((1-(5,8-difluoro-4-oxo-3-phenyl-3,4-dihydroquina-
zolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile (Compound 150a):
.sup.1H NMR (400 MHz, DMSO) .delta. 7.75 (td, J=9.5, 4.2 Hz, 1H),
7.68-7.35 (m, 7H), 7.32 (ddd, J=10.6, 9.1, 3.6 Hz, 1H), 7.11 (br s,
3H), 4.68 (td, J=7.7, 4.5 Hz, 1H), 1.90-1.81 (m, 1H), 1.80-1.69 (m,
1H), 0.66 (t, J=7.3 Hz, 3H). ES/MS 449.1 (M+H.sup.+);
[0817]
(S)-2,4-diamino-6-((1-(5,8-difluoro-3-(3-fluorophenyl)-4-oxo-3,4-di-
hydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile
(Compound 151a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.81-7.72 (m,
2H), 7.60-7.40 (m, 4H), 7.40-7.19 (m, 5H), 4.75-4.64 (m, 1H),
1.96-1.82 (m, 1H), 1.83-1.70 (m, 1H), 0.72 (m, 3H). ES/MS 467.1
(M+H.sup.+);
[0818]
(S)-2,4-diamino-6-((1-(3-(3-cyanophenyl)-5,8-difluoro-4-oxo-3,4-dih-
ydroquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile
(Compound 152): .sup.1H NMR (400 MHz, DMSO) .delta. 8.11 (t, J=1.8
Hz, 1H), 7.94-7.58 (m, 5H), 7.50-7.20 (m, 4H), 4.70-4.62 (m, 2H),
1.95-1.86 (m, 1H), 1.82-1.73 (m, 1H), 0.79-0.69 (m, 3H). ES/MS
474.1 (M+H.sup.+);
[0819]
(S)-2-(1-((2,6-diamino-5-chloropyrimidin-4-yl)amino)ethyl)-3-(3-flu-
orophenyl)-5-(methylsulfonyl)quinazolin-4(3H)-one (Compound 153a):
.sup.1H NMR (400 MHz, DMSO) .delta. 8.37-8.32 (m, 1H), 8.13-8.09
(m, 2H), 7.75 (d, J=7.1 Hz, 1H), 7.64-7.32 (m, 6H), 7.32-7.20 (m,
2H), 5.04-4.95 (m, 1H), 3.51 (s, 3H), 1.45-1.41 (m, 3H). ES/MS
504.1 (M+H.sup.+);
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-8-iodo-4-oxo-3,4-dihydroqui-
nazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
[0820]
(S)-2,4-diamino-6-((1-(8-iodo-4-oxo-3-phenyl-3,4-dihydroquinazolin--
2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
[0821]
(S)-2,4-diamino-6-((1-(6-fluoro-3-(3-fluorophenyl)-8-iodo-4-oxo-3,4-
-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
[0822]
(S)-2,4-diamino-6-((1-(6-fluoro-3-phenyl-8-iodo-4-oxo-3,4-dihydroqu-
inazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
[0823]
(S)-2,4-diamino-6-((1-(6-iodo-4-oxo-3-phenyl-3,4-dihydroquinazolin--
2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
[0824]
(S)-2,4-diamino-6-((1-(3-(3-(difluoromethyl)phenyl)-8-iodo-4-oxo-3,-
4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
[0825]
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-6-fluoro-8-iodo-4-oxo-
-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile;
(S)-2,4-diamino-6-((1-(5-chloro-3-(3,5-difluorophenyl)-4-oxo-3,4-dihydroq-
uinazolin-2-yl)-3-methylbutyl)amino)pyrimidine-5-carbonitrile
(Compound 163a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.98 (t, J=6.4
Hz, 1H), 7.75 (bs, 1H), 7.63 (dd, J=1.2, 8.0 Hz, 1H), 7.61 (dd,
J=1.2, 8.0 Hz, 1H), 7.56-7.52 (m, 1H), 7.46-7.40 (m, 2H), 4.78 (m,
1H), 1.82 (m, 1H), 1.64 (m, 1H), 1.52 (m, 1H), 0.82 (d, J=6.8 Hz,
3H), 0.50 (d, J=6.4 Hz, 3H). ES/MS 511.2 (M+H.sup.+);
[0826]
2,4-diamino-6-(((1S,2S)-1-(5-chloro-3-(3,5-difluorophenyl)-4-oxo-3,-
4-dihydroquinazolin-2-yl)-2-methylbutyl)amino)pyrimidine-5-carbonitrile
(Compound 164a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.98 (bs, 1H),
7.89 (t, J=8.0 Hz, 1H), 7.77 (dd, J=1.2, 8.0 Hz, 1H), 7.70 (dd,
J=1.2, 7.6 Hz, 1H), 7.51-7.48 (m, 1H), 7.39-7.33 (m, 1H), 7.13-7.10
(m, 1H), 4.91 (m, 1H), 2.28 (m, 1H), 1.56 (m, 1H), 1.02 (m, 1H),
0.95-0.82 (m, 6H). ES/MS 511.2 (M+H.sup.+);
[0827]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3,5-difluorophenyl)-4-oxo-3,4-di-
hydroquinazolin-2-yl)-3,3,3-trifluoropropyl)amino)pyrimidine-5-carbonitril-
e (Compound 165a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.89 (bs,
1H), 7.83 (t, J=8.0 Hz, 1H), 7.70 (dd, J=1.2, 8.0 Hz, 1H), 7.65
(dd, J=1.2, 8.0 Hz, 1H), 7.51-7.48 (m, 1H), 7.39-7.34 (m, 1H),
7.31-7.29 (m, 1H), 5.22 (m, 1H), 3.10-3.00 (m, 2H). ES/MS 537.1
(M+H.sup.+);
[0828]
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-5-fluoro-4-oxo-3,4-di-
hydroquinazolin-2-yl)-3,3,3-trifluoropropyl)amino)pyrimidine-5-carbonitril-
e (Compound 166a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.96 (bs,
1H), 7.90 (ddd, 1H), 7.58 (d, J=8.0 Hz, 1H), 7.50 (m, 1H),
7.42-7.34 (m, 2H), 7.29 (m, 1H), 5.24 (m, 1H), 3.17-3.02 (m, 2H).
ES/MS 521.1 (M+H.sup.+);
[0829]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-cyanophenyl)-4-oxo-3,4-dihydro-
quinazolin-2-yl)-3-methylbutyl)amino)pyrimidine-5-carbonitrile
(Compound 167a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.22 (t, J=1.6
Hz, 1H), 8.08 (t, J=1.6 Hz, 1H), 8.02-7.93 (m, 3H), 7.84-7.77 (m,
4H), 7.66-7.59 (m, 5H), 4.70 (m, 2H), 1.80 (m, 2H), 1.47 (m, 4H),
0.79 (m, 4H), 0.44 (d, J=6.4 Hz, 3H), 0.32 (d, J=6.0 Hz, 3H). ES/MS
500.1 (M+H.sup.+);
[0830]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-fluorophenyl)-4-oxo-3,4-dihydr-
oquinazolin-2-yl)-3-methylbutyl)amino)pyrimidine-5-carbonitrile
(Compound 168a): .sup.1H NMR (400 MHz, DMSO) .delta. 7.80-7.76 (m,
1H), 7.68-7.51 (m, 5H), 7.45-7.36 (m, 1H), 4.70 (m, 1H), 1.81 (m,
1.5H), 1.50 (m, 4H), 1.26 (m, 0.5H), 0.79 (m, 2H), 0.44 (d, J=6.0
Hz, 1H), 0.32 (d, J=6.0 Hz, 1H). ES/MS 493.1 (M+H.sup.+);
[0831]
(S)-2,4-diamino-6-((1-(3-(3,5-difluorophenyl)-5-fluoro-4-oxo-3,4-di-
hydroquinazolin-2-yl)butyl)amino)pyrimidine-5-carbonitrile
(Compound 175a). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.86
(td, J=8.2, 5.4 Hz, 1H), 7.66 (s, 1H), 7.52 (t, J=8.7 Hz, 1H),
7.43-7.03 (m, 3H), 4.81 (q, J=6.9 Hz, 1H), 1.83 (q, J=7.5 Hz, 2H),
1.20 (ddt, J=43.6, 13.8, 6.8 Hz, 2H), 0.70 (t, J=7.3 Hz, 3H). ES/MS
481.3 (M+H.sup.+).
[0832]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-cyanophenyl)-6-fluoro-4-oxo-3,-
4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 176a), .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.09
(t, J=1.9 Hz, 1H), 8.06-7.80 (m, 3H), 7.82-7.50 (m, 3H), 6.99-6.64
(m, 1H), 6.49 (d, J=5.9 Hz, 1H), 6.21 (d, J=17.0 Hz, 1H), 4.73 (h,
J=6.6 Hz, 1H), 1.29 (d, J=6.6 Hz, 3H). ES/MS 476.9 (M+H.sup.+).
[0833]
(S)-2,4-diamino-6-((1-(6-fluoro-3-(3-fluorophenyl)-4-oxo-3,4-dihydr-
oquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile (Compound
178a). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.87-7.64 (m,
2H), 7.55 (tdd, J=10.1, 5.0, 2.4 Hz, 1H), 7.48-7.15 (m, 2H), 6.67
(dd, J=17.8, 7.5 Hz, 1H), 6.53 (d, J=4.8 Hz, 2H), 6.20 (s, 2H),
4.69-4.46 (m, 1H), 1.92-1.58 (m, 2H), 0.67 (dt, J=10.0, 7.3 Hz,
3H). ES/MS 449.3 (M+H.sup.+).
[0834]
(S)-2,4-diamino-6-((1-(5-fluoro-3-(3-fluorophenyl)-4-oxo-3,4-dihydr-
oquinazolin-2-yl)propyl)amino)pyrimidine-5-carbonitrile (Compound
179a). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.05-7.57 (m,
3H), 7.61-7.39 (m, 3H), 7.39-6.85 (m, 4H), 4.71 (tt, J=12.7, 5.9
Hz, 1H), 2.04-1.63 (m, 2H), 0.84-0.52 (m, 3H). ES/MS 449.4
(M+H.sup.+).
[0835]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-cyanophenyl)-8-fluoro-4-oxo-3,-
4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 181a). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.10
(t, J=1.7 Hz, 1H), 7.98-7.45 (m, 10H), 4.97-4.69 (m, 1H), 1.34 (d,
J=6.5 Hz, 3H). ES/MS 476.7 (M+H.sup.+).
[0836]
(S)-2,4-diamino-6-((1-(5-fluoro-3-(3-fluorophenyl)-4-oxo-3,4-dihydr-
oquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound
182a): .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.85 (tdd,
J=8.2, 5.5, 1.0 Hz, 2H), 7.73 (bs, 2H), 7.58-7.18 (m, 5H), 4.89
(dt, J=11.5, 6.7 Hz, 1H), 1.34 (dd, J=6.6, 2.6 Hz, 3H). ES/MS 435.1
(M+H.sup.+).
[0837]
(S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazoli-
n-2-yl)ethyl)amino)pyrimidine-5-carboxamide (Compound 183a).
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.4 (bs, 2H), 8.98 (d,
J=6.9 Hz, 1H), 7.85-7.75 (m, 1H), 7.69-7.45 (m, 8H), 4.78 (p, J=6.6
Hz, 1H), 1.30 (d, J=6.7 Hz, 3H). ES/MS 451.1 (M+H.sup.+);
[0838]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-methoxy-4-methylphenyl)-4-oxo--
3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 184a). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.80
(td, J=8.0, 1.4 Hz, 1H), 7.74-7.56 (m, 2H), 7.28-7.11 (m, 1H),
6.99-6.86 (m, 1H), 6.80-6.71 (m, 1H), 5.10-5.01 (m, 1H), 3.79 (s,
1.2H), 3.73 (s, 1.8H), 2.27-2.11 (2 s, 3H), 1.41-1.34 (m, 3H).
ES/MS 478.1 (M+H.sup.+).
[0839]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-methoxyphenyl)-4-oxo-3,4-dihyd-
roquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound
185a). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.82-6.85 (m,
7H), 5.01-4.90 (m, 1H), 3.74 (s, 3H), 1.35 (d, J=6.6 Hz, 3H). ES/MS
463.1 (M+H.sup.+).
[0840]
(S)-2,4-diamino-6-((1-(5-chloro-3-(4-fluoro-3-methoxyphenyl)-4-oxo--
3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 186a). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.05
(bs, 2H), 7.97-6.7 (m, 6H), 5.05 (m, 1H), 3.84 (s, 3H), 1.44-1.37
(m, 3H). ES/MS 481.1 (M+H.sup.+).
[0841]
(S)-2,4-diamino-6-((1-(5-chloro-3-(5-methoxy-2-methylphenyl)-4-oxo--
3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 187a-1). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
7.86-7.76 (m, 1H), 7.69 (dd, J=8.2, 1.2 Hz, 1H), 7.61 (dd, J=7.8,
1.2 Hz, 1H), 7.24-7.17 (m, 1H), 7.12 (d, J=2.7 Hz, 1H), 6.91 (dd,
J=8.5, 2.7 Hz, 1H), 5.04 (p, J=6.6 Hz, 1H), 3.76 (s, 3H), 1.95 (s,
3H), 1.37 (d, J=6.5 Hz, 3H). ES/MS 477.1 (M+H.sup.+).
[0842]
(S)-2,4-diamino-6-((1-(5-chloro-3-(5-methoxy-2-methylphenyl)-4-oxo--
3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 187a-2). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
7.86-7.80 (m, 1H), 7.71 (dd, J=8.2, 1.2 Hz, 1H), 7.63 (dd, J=7.8,
1.2 Hz, 1H), 7.32-7.25 (m, 1H), 6.95-6.83 (m, 2H), 4.87 (p, J=6.7
Hz, 1H), 3.66 (s, 3H), 1.98-1.92 (m, 3H), 1.46-1.29 (m, 3H). ES/MS
477.1 (M+H.sup.+).
[0843]
(S)-2,4-diamino-6-((1-(5-chloro-3-(5-(difluoromethyl)-2-methylpheny-
l)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 188a-1). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.79
(dt, J=10.8, 8.0 Hz, 1H), 7.73-7.51 (m, 3H), 7.41-7.28 (m, 2H),
7.05 (t, J=56.4 Hz, 1H), 5.16 (dd, J=8.5, 6.0 Hz, 1H), 2.08 (s,
3H), 1.35 (d, J=6.5 Hz, 3H). ES/MS 497.1 (M+H.sup.+).
[0844]
(S)-2,4-diamino-6-((1-(5-chloro-3-(5-(difluoromethyl)-2-methylpheny-
l)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 188a-2). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.08
(bs, 1H), 7.86-7.77 (m, 1H), 7.72 (dd, J=8.2, 1.2 Hz, 1H), 7.62
(dd, J=7.8, 1.2 Hz, 1H), 7.52 (d, J=7.3 Hz, 1H), 7.44 (d, J=6.8 Hz,
2H), 6.85 (t, J=56.0 Hz, 1H), 4.77 (p, J=6.6 Hz, 1H), 2.08 (s, 3H),
1.36 (d, J=6.6 Hz, 3H). ES/MS 497.1 (M+H.sup.+).
[0845]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-(difluoromethyl)-2-methylpheny-
l)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 189a-1). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.33
(bs, 1H), 7.91-7.48 (m, 3H), 7.48-7.37 (m, 2H), 7.04 (t, J=54.7 Hz,
1H), 5.28 (dt, J=13.1, 6.7 Hz, 1H), 2.08 (s, 3H), 1.38 (d, J=6.5
Hz, 3H). ES/MS 497.1 (M+H.sup.+).
[0846]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-(difluoromethyl)-2-methylpheny-
l)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 189a-2). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.98
(bs, 1H), 7.86-7.31 (m, 6H), 7.16 (t, J=54.8 Hz, 1H), 4.80 (p,
J=6.6 Hz, 1H), 2.09 (s, 3H), 1.29 (d, J=6.6 Hz, 3H). ES/MS 497.1
(M+H.sup.+).
[0847]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-(difluoromethyl)-5-methoxyphen-
yl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 190a). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.82
(td, J=8.0, 3.0 Hz, 1H), 7.70 (ddd, J=8.1, 6.9, 1.2 Hz, 1H), 7.62
(ddd, J=7.8, 2.9, 1.2 Hz, 1H), 7.38 (m, 2H), 7.15-7.02 (m, 1H),
6.83 (t, J=55.8 Hz, 1H), 5.17-4.92 (m, 1H), 3.82 (s, 0.5H), 3.77
(s, 0.5H), 1.41 (d, J=6.5 Hz, 1.5H), 1.38 (d, J=6.6 Hz, 1.5H).
ES/MS 513.1 (M+H.sup.+).
[0848]
(S)-2,4-diamino-6-((1-(5-chloro-3-(2,5-dimethylphenyl)-4-oxo-3,4-di-
hydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 191a-1). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.78
(t, J=8.0 Hz, 1H), 7.65 (dd, J=8.3, 1.2 Hz, 1H), 7.56 (dd, J=7.8,
1.1 Hz, 1H), 7.21-7.06 (m, 3H), 6.71 (d, J=8.5 Hz, 1H), 6.51 (s,
2H), 6.12 (s, 2H), 4.98 (dq, J=9.1, 6.5 Hz, 1H), 2.30 (s, 3H), 1.95
(s, 3H), 1.30 (d, J=6.5 Hz, 3H). ES/MS 461.1 (M+H.sup.+).
[0849]
(S)-2,4-diamino-6-((1-(5-chloro-3-(2,5-dimethylphenyl)-4-oxo-3,4-di-
hydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 191a-2). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.93
(bs, 1H), 7.79 (td, J=8.0, 0.9 Hz, 1H), 7.69 (dt, J=8.2, 1.1 Hz,
1H), 7.59 (dt, J=7.9, 1.1 Hz, 1H), 7.20 (d, J=8.3 Hz, 1H), 7.03 (d,
J=6.1 Hz, 2H), 4.81 (p, J=6.6 Hz, 1H), 2.13 (s, 3H), 1.96 (s, 3H),
1.33 (d, J=6.6 Hz, 3H). ES/MS 461.1 (M+H.sup.+).
[0850]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-fluoro-5-methoxyphenyl)-4-oxo--
3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 192a). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 7.78
(t, J=8.0 Hz, 1H), 7.65 (ddd, J=8.2, 3.4, 1.2 Hz, 1H), 7.58 (dd,
J=7.8, 1.1 Hz, 1H), 7.11-7.03 (m, 1H), 6.82 (m, 2H), 4.99 (d, J=6.9
Hz, 1H), 3.75 (s, 1.5H), 3.69 (s, 1.5H), 1.36 (m, 3H). ES/MS 481.1
(M+H.sup.+).
[0851]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-fluoro-5-(trifluoromethoxy)phe-
nyl)-4-oxo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitril-
e (Compound 193a). .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
7.85-7.75 (m, 1H), 7.72-7.56 (m, 4H), 7.50-7.34 (m, 1H), 7.26 (bs,
2H), 4.90 (dt, J=45.4, 6.8 Hz, 1H), 1.36 (m, 3H). ES/MS 535.1
(M+H.sup.+).
[0852]
(S)-5-chloro-2-(1-((2,6-diamino-5-fluoropyrimidin-4-yl)amino)ethyl)-
-3-phenylquinazolin-4(3H)-one (Compound 194a).sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 8.18 (bs, 1H), 7.84-7.75 (m, 1H), 7.66 (dd,
J=8.2, 1.2 Hz, 1H), 7.60 (dd, J=7.8, 1.2 Hz, 1H), 7.56-7.51 (m,
2H), 7.50-7.40 (m, 3H), 7.37 (bs, 2H), 7.12 (bs, 1H), 4.72 (t,
J=6.8 Hz, 1H), 1.36 (d, J=6.7 Hz, 3H). ES/MS 426.1 (M+H.sup.+).
[0853]
(S)-8-chloro-3-(1-((2,6-diamino-5-chloropyrimidin-4-yl)amino)ethyl)-
-2-phenylisoquinolin-1(2H)-one (Compound 195a): 1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.54 (brs, 1H), 7.77-7.42 (m, 6H), 7.40-7.30
(m, 4H), 7.24 (brs, 2H), 6.76 (s, 1H), 4.78 (p, J=6.9 Hz, 1H), 1.33
(d, J=6.8 Hz, 3H). ES/MS 442.1 (M+H.sup.+).
[0854]
(S)-2,4-diamino-6-((1-(8-chloro-1-oxo-2-phenyl-1,2-dihydroisoquinol-
in-3-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 196a):
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 8.01 (s, 1H), 7.82-7.31
(m, 13 zH), 6.78 (s, 1H), 4.79 (p, J=6.5 Hz, 1H), 1.32 (d, J=6.7
Hz, 3H). ES/MS 432.1 (M+H.sup.+).
[0855]
(S)-2,4-diamino-6-((1-(5-chloro-4-oxo-3-phenyl-3,4-dihydroquinazoli-
n-2-yl)-2-methylpropyl)amino)pyrimidine-5-carbonitrile (Compound
197a).
[0856]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3,5-difluorophenyl)-4-oxo-3,4-di-
hydroquinazolin-2-yl)-2-methylpropyl)amino)pyrimidine-5-carbonitrile
(Compound 198a).
[0857]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-fluoro-2-methylphenyl)-4-oxo-3-
,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 199a-1).
[0858]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-fluoro-2-methylphenyl)-4-oxo-3-
,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 199a-2).
[0859]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3,5-difluoro-2-methylphenyl)-4-o-
xo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 200a-1).
[0860]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3,5-difluoro-2-methylphenyl)-4-o-
xo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 200a-2).
[0861]
(S)-2,4-diamino-6-((1-(5-chloro-3-(5-fluoro-2-methylphenyl)-4-oxo-3-
,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 201a-1).
[0862]
(S)-2,4-diamino-6-((1-(5-chloro-3-(5-fluoro-2-methylphenyl)-4-oxo-3-
,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 201a-2).
[0863]
(S)-2,4-diamino-6-((1-(5-chloro-3-(2,3-dimethylphenyl)-4-oxo-3,4-di-
hydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 202a-1).
[0864]
(S)-2,4-diamino-6-((1-(5-chloro-3-(2,3-dimethylphenyl)-4-oxo-3,4-di-
hydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 202a-2).
[0865]
(S)-2,4-diamino-6-((1-(5-chloro-3-(4-fluoro-2,3-dimethylphenyl)-4-o-
xo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 203a-2).
[0866]
(S)-2,4-diamino-6-((1-(5-chloro-3-(4-fluoro-2,3-dimethylphenyl)-4-o-
xo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 203a-2).
[0867]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3,4-difluoro-2-methylphenyl)-4-o-
xo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 204a-1).
[0868]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3,4-difluoro-2-methylphenyl)-4-o-
xo-3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
(Compound 204a-2).
[0869]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-fluoro-5-methoxyphenyl)-4-oxo--
3,4-dihydroquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
carbonitrile (Compound 205a).
[0870]
(S)-2,4-diamino-6-((1-(5-chloro-3-(3-methoxyphenyl)-4-oxo-3,4-dihyd-
roquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile
carbonitrile (Compound 206a).
Example 4b
Preparation of a Compound of Formula (I)
[0871] A. Preparation of a Compound of Formula (I) in which n=2,
R.sup.1a is F, R.sup.1b.dbd.CN, m=1, R2=F, R3 is methyl, and
R.sup.4 is cyano (Compound 154a)
##STR00240##
[0872] To a solution of
(S)-2,4-diamino-6-((1-(6-fluoro-3-(3-fluorophenyl)-8-iodo-4-oxo-3,4-dihyd-
roquinazolin-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (560 mg,
1.0 mmol) in NMP (4 mL) was added cuprous cyanide (2.0 mmol, 180
mg) and tetrakis(triphenylphosphine)Pd(0) (0.10 mmol, 120 mg). The
mixture was irradiated in microwave reactor at 150.degree. C. for
one hour. Purification by flash chromatography (40 g flash silica,
30% EtOAc/Hexanes to 20% MeOH/EtOAc), followed by HPLC eluting with
5%-95% water/acetonitrile (0.1% v/v trifluoroacetic acid) provided
(S)-2-(1-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-6-fluoro-3-(3-f-
luorophenyl)-4-oxo-3,4-dihydroquinazoline-8-carbonitrile as a white
solid. .sup.1H NMR (400 MHz, DMSO) .delta. 8.55 (dd, J=2.8, 8.4 Hz,
1H), 8.20 (dd, J=3.2, 8.0 Hz, 1H), 7.88-7.17 (m, 5H), 5.07 (m, 1H),
1.44 (d, J=6.8 Hz, 3H). ES/MS 460.1 (M+H.sup.+);
B. Preparation of a Compound of Formula (I), varying R.sup.1,
R.sup.2, and R.sup.3; and a compound of Formula (J), varying
R.sup.1, R.sup.2, R.sup.3 and R.sup.4
[0873]
(S)-2-(1-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-3-(3,5-di-
fluorophenyl)-4-oxo-3,4-dihydroquinazoline-8-carbonitrile (Compound
101a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.48-8.42 (m, 2H), 7.87
(bs, 1H), 7.77-7.73 (m, 1H), 7.74 (bs, 1H), 7.51-7.49 (m, 1H),
7.35-7.29 (m, 1H), 7.08-7.05 (m, 1H), 5.15 (m, 1H), 1.48 (d, J=6.4
Hz, 3H). ES/MS 460.1 (M+H.sup.+);
[0874]
(S)-2-(1-(2,6-diamino-5-cyanopyrimidin-4-ylamino)ethyl)-4-oxo-3-phe-
nyl-3,4-dihydroquinazoline-8-carbonitrile (Compound 122a).
[0875]
(S)-2-(1-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-6-fluoro--
4-oxo-3-phenyl-3,4-dihydroquinazoline-8-carbonitrile (Compound
155a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.53 (dd, J=2.8, 8.4 Hz,
1H), 8.19 (dd, J=2.8, 8.0 Hz, 1H), 7.92-7.34 (m, 6H), 5.03 (m, 1H),
1.42 (d, J=6.4 Hz, 3H). ES/MS 442.1 (M+H.sup.+);
[0876]
(S)-2,4-diamino-6-((1-(8-methoxy-4-oxo-3-phenyl-3,4-dihydroquinazol-
in-2-yl)ethyl)amino)pyrimidine-5-carbonitrile (Compound 156a):
.sup.1H NMR (400 MHz, DMSO) .delta. 7.70 (d, J=1.6 Hz, 1H), 7.68
(d, J=1.6 Hz, 1H), 7.54-7.38 (m, 6H), 4.93 (m, 1H), 3.96 (s, 1H),
1.36 (d, J=6.8 Hz, 3H). ES/MS 429.2 (M+H.sup.+);
[0877]
(S)-2-(1-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-4-oxo-3-p-
henyl-3,4-dihydroquinazoline-6-carbonitrile (Compound 159a):
.sup.1H NMR (400 MHz, DMSO) .delta. 8.56 (dd, J=0.4, 2.0 Hz, 1H),
8.25 (dd, J=2.4, 8.8 Hz, 1H), 7.86 (dd, J=0.8, 8.8 Hz, 1H), 7.83
(bs, 2H), 7.66 (bs, 2H) 7.58-7.41 (m, 5H), 4.91 (m, 1H), 1.36 (d,
J=6.8 Hz 1H). ES/MS 424.1 (M+H.sup.+);
[0878]
(S)-2-(1-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-3-(3-(dif-
luoromethyl)phenyl)-4-oxo-3,4-dihydroquinazoline-8-carbonitrile
(Compound 160a): .sup.1H NMR (400 MHz, DMSO) .delta. 8.47-8.41 (m,
2H), 8.04 (bs, 2H), 7.87 (bs, 2H), 7.83-7.48 (m, 5H), 5.10 (m, 1H),
3.30 (t, J=6.8 Hz, 1H), 2.18 (t, J=8.0 Hz, 1H), 1.91 (m, 1H), 1.45
(m, 3H). ES/MS 474.1 (M+H.sup.+);
[0879]
(S)-2-(1-((2,6-diamino-5-cyanopyrimidin-4-yl)amino)ethyl)-3-(3,5-di-
fluorophenyl)-6-fluoro-4-oxo-3,4-dihydroquinazoline-8-carbonitrile
(Compound 161a).
Biological Examples
[0880] Activity testing was conducted in the Examples below using
methods described herein and those well known in the art.
Example B1
Characterization of Compounds of Formula (I)
[0881] This Example compares the biological activity of the
compounds of formula (I) and Compounds V, X, Y and Z having the
following structures:
##STR00241##
[0882] Enzymatic activity of PI3K isoforms was measured to compare
the PI3K isoform selectivity of the compounds tested, including
selectivity to PI3K.delta.. A cellular assay measuring basophil
activation was used to assess the potency of the compounds tested.
Hepatocyte stability was also measured to assess the potential
half-life of the tested compounds in human subjects. Each of these
biological experiments are described in further detail below.
[0883] Enzymatic Activity of PI3K Isoforms
[0884] Enzymatic activity of the class I PI3K isoforms in the
presence of the compounds of Table 1 above and compounds X, Y and Z
was measured using a time-resolved fluorescence resonance energy
transfer (TR-FRET) assay.
[0885] The TR-FRET assay was used to monitor formation of the
product 3,4,5-inositol triphosphate molecule (PIP3) as it competed
with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin
homology domain protein. An increase in phosphatidylinositide
3-phosphate product results in a decrease in TR-FRET signal as the
labeled fluorophore is displaced from the GRP-1 protein binding
site.
[0886] Class I PI3K isoforms were expressed and purified as
heterodimeric recombinant proteins. All assay reagents and buffers
for the TR-FRET assay were purchased from Millipore. PI3K isoforms
were assayed under initial rate conditions in the presence of 25 mM
Hepes (pH 7.4), and 2.times.Km ATP (100-300 .mu.M), 10 .mu.M PIP2,
5% glycerol, 5 mM MgCl2, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM
dithiothreitol, 1% (v/v) DMSO at the following concentrations for
each isoform: PI3K .alpha., .beta., and .delta. at 50 picomolar
(pM) and PI3K.gamma. at 2 nanomolar (nM). After an assay reaction
time of 30 minutes at 25.degree. C., reactions were terminated with
a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM
Europium labeled GRP-1 detector protein before reading TR-FRET on
an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 .mu.s
delay and 500 .mu.s read window).
[0887] Data are normalized based on a positive (1 uM wortmanin) and
negative (DMSO) controls. The .alpha., .beta., .delta., and .gamma.
IC.sub.50 values were calculated from the fit of the dose-response
curves to a four-parameter equation. IC.sub.50 are reported in
units of nM. These assays generally produced results within 3-fold
of the reported mean.
[0888] IC.sub.50 values were obtained for all PI3K isoforms
(.alpha., .beta., .delta., and .gamma.), and Table 2 summarizes the
IC.sub.50 data collected for PI3K.delta. in this Example B1.
[0889] Activity on Basophils
[0890] Effect on basophil activation was measured in human whole
blood using the Flow2 CAST.RTM. kit (Buhlmann Laboratories AG,
Baselstrasse, Switzerland) following the protocol provided by the
manufacturer with minor modifications. Human whole blood was
collected into K.sub.2-EDTA venipuncture tubes. Whole blood samples
were treated with either DMSO (0.3% final) or a serial dilution of
compounds in DMSO for 60 minutes at 37.degree. C. Basophils were
then activated either with anti-FccRI mAb or with fMLP. To activate
basophils using the anti-FccRI mAb; 50 .mu.l of whole blood was
mixed with 110 .mu.l of stimulation buffer (B-BAT-STB) and 20 .mu.l
of anti-FccRI (B-BAT-STCON). To activate basophils with fMLP; 50
.mu.l of whole blood was mixed with 80 .mu.l of stimulation buffer
(B-BAT-STB) and 50 .mu.l of fMLP (B--CCR-FMLP). Stimulation buffer
was used as a negative control. 20 .mu.l of the staining reagent
(combination of anti-human CD63-FITC and anti-human CCR3-PE mAbs)
was then added to each tube. The tubes were mixed gently and
incubated for 25 min at 37.degree. C. Subsequently, erythrocytes
were lysed and fixed by the addition of 2 ml of lysing solution
(B-BAT-LYR) for 10 min at room temperature. Cells were pelleted by
centrifugation at 1200 rpm for 10 min at room temperature in a
swing-out rotor. Supernatant was aspirated and cell pellet
resuspended in 400 .mu.l of wash buffer. Flow cytometric analysis
of the basophil activation was performed on a FC500MPL flow
cytometer (Beckman Coulter Inc., Fullerton, Calif.). CCR3-staining
and side scatter were applied to gate at least 200 basophils that
expressed a high density of CCR3. The percent CD63 positive cells
within the gated basophil population were determined in different
treatment groups and normalized to the vehicle control (0.3% DMSO)
with anti-FcERI mAb of fMLP stimulus as 100%. Final compound
concentration was adjusted to correct for dilution effect of added
reagents. The EC.sub.50 values were calculated from the analysis of
the dose-response curves to a four-parameter equation. All
EC.sub.50 values represent geometric mean values and are reported
in units of nM. Table 2 below summarizes the EC.sub.50 data
collected from this Example B1.
[0891] Hepatocyte Stability
[0892] This assay was used to evaluate the metabolic stability of
test articles (TA) following incubation in cryopreserved
hepatocytes by monitoring parent drug disappearance via LC/MC. The
TA with 1% final DMSO concentration was incubated with 1 million
hepatocytes/ml at 2 .mu.M substrate in duplicate. The incubation
was carried out at 37.degree. C. with 5% CO.sub.2 and saturating
humidity. Samples were taken at 0, 1, 2, and 4 hours to monitor the
disappearance of TA and a half-life (t.sub.1/2) was determined.
Table 2 below summarizes the t.sub.1/2 values (e.g.
t.sub.1/2.sup.a) collected from this Example B1.
[0893] Alternatively, assay reagents and/or conditions can be
modified in determining the inhibitory activities to PI3K isomers.
In additional studies, similar assay using TA and 0.01% final DMSO
concentration were incubated with 1 million hepatocytes/mL at 1
.mu.M substrate in duplicate. The incubation was carried out at
37.degree. C. with 5% CO.sub.2 and saturating humidity. Samples
were taken at 0, 1, 3, and 6 hours to monitor the disappearance of
TA and a half-life (t.sub.1/2) was determined. Table 2 below
summarizes the t.sub.1/2 values (e.g. t.sub.1/2.sup.b) collected
from this Example B1.
[0894] The symbols used in Table 2 below are as follows:
[0895] ####=<1 nM *=<1 h
[0896] ###=>1 nM AND <10 nM **=>1 AND <3 h
[0897] ##=>10 nM AND <50 nM ***=>3 AND <6 h
[0898] #=>50 nM ****=>6 AND <10 h [0899] *****=>10
h
TABLE-US-00002 [0899] TABLE 2 human human Compound IC.sub.50
EC.sub.50 hepatocyte t1/2.sup.b hepatocyte t1/2.sup.a 1a #### ####
** **** 2a #### ### 3a ### ## 4a #### ### **** 5a #### ### ** 6a
#### # 7a ### #### 8a #### ### *** 9a ### ### 10a ### ### *** *****
11a ### ### **** ***** 12a ### ### ***** 13a ## ### ***** 14a ###
### 15a #### #### *** 16a ### ### *** ***** 17a ### #### **** *****
18a #### #### *** 19a #### ### *** 20a ### ### **** 21a ### ### ***
**** 22a ### ### ***** 23a #### #### 24a ### ### **** 25a #### ####
** 26a ## ### ***** 27a ## ### ** ***** 28a ## ### ***** 29a ## ###
***** 30a ## 31a ### ### **** 32a ## 33a # 34a # 35a ### ### ****
36a ## ### ***** ***** 37a ## ## *** **** 38a ## ### ***** *****
39a ## 40a ### ### **** 41a ### ## *** 42a ## ### ** ***** 43a ###
### *** 44a ## ## ** ***** 45a ### # 46a ## 47a ### ### *** 48a ##
# ***** 49a #### #### *** ***** 50a #### #### **** 51a ### ### ***
52a ### ### **** ***** 53a ### ## ***** 54a ## ### *** ***** 55a
#### ### **** 56a ## ### **** 57a ## 58a ### ### 59a #### ### 60a
#### #### 61a ### #### *** ***** 62a #### #### 63a ### ### *****
64a #### ### 65a ## 66a ### ### *** 67a ### ### ** ***** 68a # 69a
## 70a ## ### 71a ### ### ** ***** 72a ## # **** 73a ### #### ***
74a ### #### *** 75a ### ## ***** 76a ## # ***** 77a ### ### **
***** 78a ### ### **** 79a ## 80 # 81a ### #### 82a ## # **** 83a
## 84 # 85a # 86a # 87a # 88a # 89a ### ### **** ***** 90a ### ###
*** 91a ## ## ***** 92a ### # 94a # 95a ### ## 96a ### ## 97a ###
### *** ***** 98a ## # *** 99a ### ## **** 100a ### ### ** 101a ###
### *** ***** 102a ## ### **** 103a ## 104a #### ### *** 105a #
106a #### ### ** ***** 107a ### ### * 108a #### ### *** *****
109a-1 ## 109a-2 #### ### ** 110a-1 # 110a-2 ### 111a ## # 112a ###
### ***** 113a # 114a # 115a ### ## 116a ### # 117a ### ## 118a #
119a ### ## 120a ### ### ** 121a ### ### *** 122a ### ### *****
***** 124a ### ### 125a ## ## 127a ### ### ** 129a #### #### 130a
#### 131a ### ### 132a # 133a # 135a ### ### ** 136a # 137a ### ##
138a ## 140a ### ### *** 141a ## ## 142a-1 ### ## 142a-2 ### ##
145a ### ### **** 146a ### # 148a ### #### 149a ## ### **** 150a
### ### *** 151a ### ### *** 152a ## ### *** 153a ### ## 154a ###
### ***** 155a ### ## ***** 156a # ## 159a # 160a ### ### *** 161a
## ## 162a # 163a ### # ** 164a ### # 165a # 166a # 167a ## # 168a
### # 175a ### ### **** 176a ## ### ***** 178a ### ### ***** 179a
### ### **** 181a ### #### **** 182a ### ### ***** 183a #### ##
**** 184a ## # 185a #### #### ** 186a ### ## 187a-1 ### ## 187a-2
### ### 188a-1 ### ## 188a-2 #### #### ** 189a-1 ## # 189a-2 ####
### 190a ### ## ** 191a-1 ### ## 191a-2 ### ### 192a ### #### **
193a ### ### ** 194a # # 195a #### ### 196a #### #### 197a #### ###
*** 198a ### ### 199a-1 #### #### 199a-2 ### # 200a-1 ## ## 200a-2
## ### 201a-1 #### #### 201a-2 ### ### **** 202a-1 #### ### 202a-2
## # 203a-1 ### # 203a-2 # ## 204a-1 ## 204a-2 ### 205a ### #### **
206a #### #### X ### ### ** Y #### ## * Z ### ## ** t1/2a: the t1/2
values for TA with 1% final DMSO t1/2b: the t1/2 values for TA with
0.01% final DMSO
[0900] The results from this Example B1 demonstrate that certain
compounds of formula (I) have greater activities in the cellular
assay and/or greater stability in human hepatocytes (i.e. longer
half-life), for instance, than compounds X, Y, V, and Z. Table 3
below shows the t.sub.1/2 and EC.sub.50 values of Compounds 1a,
49a, 182, X, Y, V, and Z.
TABLE-US-00003 TABLE 3 Com- Com- Com- Com- Com- pound 1a pound 49a
pound X pound Y pound Z t.sub.1/2.sup.a .sup. >9 hours >10
hours <1 hour <2 hours <3 hours t.sub.1/2.sup.b .sup.
>1 hour .sup. >4 hours <2 <2 hours <2 EC.sub.50
<0.5 nM <0.5 nM >5 nM >15 nM >10 nM Com- Com- pound
182 pound V t.sub.1/2.sup.a t.sub.1/2.sup.b >20 hour <1 hour
EC.sub.50 <2 nM >4 nM t1/2a: the t1/2 values for TA with 1%
final DMSO t1/2b: the t1/2 values for TA with 0.01% final DMSO.
* * * * *